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1 Introduction  
 
1.1 Adenylyl cyclases: function, classification and evolution 
Adenylyl cyclases are responsible for the synthesis of cAMP (adenosine 3´,5´-cyclic 
monophosphate) from adenosine triphosphate (ATP). Although they represent low 
abundance proteins in the cell, they produce a universal signalling molecule which 
mediates with high amplification diverse physiological processes in organisms as 
phylogenetically diverse as Escherichia coli and Homo sapiens. Transcription in bacteria 
and development in fungi and parasites are cAMP-regulated. In eukaryotes cellular 
functions like energy homeostasis, reproduction, brain function and cell differentiation 
are influenced by cAMP too. Cyclic AMP functions as a second messenger to relay 
extracellular signals to intracellular effectors such as protein kinase A. Regulation of 
intracellular concentrations of cyclic AMP are controlled primarily through modulation of 
AC activity and phosphodiesterases. The family of eukaryotic ACs consists of several 
membrane bound ACs and a single soluble AC with orthologs of the latter in rat, 
Dictyostelium and bacteria but absent from the genomes of D. melanogaster, C. 
elegans, A. thaliana and S. cereviciae (Roelofs and Van Haastert, 2002).  
Cyclases (ACs and GCs) have been classified according to their amino acid sequence 
similarities rather than their substrate specificities. The class I type comprises ACs which 
produce cAMP as a consequence of its phosphorylation and are found in E. coli, 
Salmonella, Pasteurella, Haemophilus and Vibrio as single copy genes (Danchin, 1993).     
The second class of ACs comprises those which are calmodulin-activated, secreted 
toxins like the enzymes produced by the pathogenic organisms Bordetella pertussis 
(Ladant and Ullman, 1999) and Bacillus anthracis (Baillie and Read, 2001). [For class III 
ACs see below] 
The fourth and fifth classes of ACs may be represented by cyclases with thermostable 
properties from Aeromonas hydrophila and from the ruminal anaerobe Prevotella 
ruminicola, respectively (Danchin, 1993).  
The class III of nucleotide cyclases truly represents a conserved cyclase catalytic fold 
which are found in prokaryotes and in eukaryotes (Danchin, 1993). Recently, after 
analysis of amino acid sequence profiles, a division of the class III in to four subclasses, 
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class IIIa to IIId was suggested. This subclassification is partly based on length 
differences of an “arm” region. This region was thought to be essential for dimerization 
(Tesmer et al., 1997) and comprises the sequence between a conserved glycine and the 
downstream adenine-specifying residue (D1018 in AC type II from rat) (Linder and 
Schultz, 2003). The arm region contains 14 residues in subclass a (mammalian ACs, 
mycobacterial Rv1625c), 15 residues in subclass b in conjunction with a highly 
characteristic D to T/S switch in a substrate defining position (Anabaena cya B1, 
mammalian soluble AC), 7 to 11 amino acids in subclass c (mycobacterial Rv1264, 
Rv0386, Streptomyces coelicolor AC acc. num. P40135) and 13-14 residues in subclass 
d (U. maydis AC acc. num. A55481, L. donovani cyaA acc. num. Q27675) in which also 
a special motif surrounding the substrate-defining lysine is highly conserved (Linder and 
Schultz, 2003). From an analysis based on the available genome sequence from over 
80 bacteria and other pathogenic organisms, it is becoming clear that the majority of 
cells have at least one cyclase belonging to class III cyclases and that the other classes 
of cyclases are more restricted in their occurrence. That demonstrates the versatility of 
the class III catalytic domain which apparently can be incorporated as a distinct 
functional domain into a larger polypeptide in conjunction with other protein domains 
with diverse physiological functions. Furthermore, it appears that the same class III fold 
can adapt to utilize ATP or GTP as a substrate, given the sequence similarity between 
mammalian ACs and GCs (Shenoy et al., 2002). From recent phylogenetic studies it has 
been concluded that within the family of ACs, soluble ACs were poorly conserved during 
evolution, whereas membrane-bound ACs have expanded to form the subgroups of 
prevailing ACs and GCs (Roelofs and Van Haastert, 2002). 
Most class III cyclases, from bacteria to higher vertebrates, are constructed in a modular 
fashion as evident from their rather large size. The variability in the block-building of 
cyclases makes possible a fine regulation of their activity (Linder and Schultz, 2003) 
[see figure 1.1]. 
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Fig. 1.1: Adenylyl and guanylyl cyclases (catalytic domain class III) are modular proteins. 
Drawn are the mammalian AC model (Tang and Hurley, 1998), the predicted topology for 
M. tuberculosis AC Rv1625c (Guo et al., 2001), Rv1264 (Linder et al., 2002), Rv0386, 
Plasmodium falciparum AC (Weber, 2003) and Anabaena CyaB1 (Kanacher, 2003). 
Predicted topology is also shown for mammalian GC’s (isoforms A to G), soluble GC, sea 
urchin GC and for Paramecium GC (Linder et al., 2000). FSK=forskolin; IC=ion channel; 
AAA=AAA-ATPase; HTH=helix-turn-helix; R-GGP=regulator GAFA-GAFB-PAS; PtA=P-
type ATPase; H=heme; NO=nitric oxide; R=receptor; K=kinase. The formation of 
homodimers is represented through identical colored catalytic domains, heterodimers 
show catalytic domains with different color intensity. 
 
Evolutionarily, it has been shown that the ‘palm’ domain of the prokaryotic DNA 
polymerases I shares a common fold with the class III AC catalytic core, obviously both 
enzymes catalyse a phosphoryl transfer by a similar two-metal-ion mechanism 
suggesting a common ancestor. (Artymiuk et al., 1997 ; Tesmer et al., 1999). 
Interestingly, the catalytic domain of the γ-proteobacterial ACs (typified by E. coli CyaA) 
has similarity to the polymerase β-type nucleotidyl transferase superfamily, too. That 
emphasizes the general trend that cyclase signal transduction components evolved from 
enzymes involved in nucleotide processing (Aravind and Koonin, 1999).  
In this work, an AC of Mycobacterium tuberculosis (Rv0386) with an N-terminal 
AC domain (class IIIc) and an attached C-terminal transcription factor domain is 
presented. Because here basically the AC function was studied, the meaning of 
combining a signal-transducing enzyme with a component of the basic nucleic acid 
processing is still an open question, the answer of which could be very useful for 
understanding evolution and maybe new regulatory mechanisms of ACs.  
 
1.2 Mammalian adenylyl cyclases  
Cyclic AMP is produced in mammals by nine isoforms of membrane-bound ACs 
and one soluble AC. The nine cloned ACs have a similar structure, with two hydrophobic 
domains comprising six predicted transmembrane helices each, and two cytoplasmic 
domains (Fig. 1.1). The cytosolic domains are similar to each other (roughly 30% 
identity), to the sequences within both bacterial and yeast ACs and even to those within 
GCs. Both together are responsible for catalytic activity (Taussig and Gilman, 1995; 
Sunahara et al., 1996). The nine isoforms share several regulatory features like 
activation by the α subunit of the heterotrimeric G protein Gs, activation by the diterpene 
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forskolin (with exception of type IX) and inhibition by a class of adenosine analogs 
known as P-site inhibitors. Individual forms can also be regulated by other G protein 
subunits, Ca2+-calmodulin, Ca2+ or phosphorylation (Sunahara et al., 1996; Tesmer et 
al., 1997). 
The cytosolic domains are called C1 and C2 and are subdivided into C1a, C1b, 
and C2a, C2b respectively, where C1a and C2a contain all of the catalytic apparatus. 
These C1a and C2a domains heterodimerize with each other in solution but can also 
form homodimers or even chimeric heterodimers if derived from different isoforms (Tang 
and Gilman, 1995; Yan et al., 1996; Whisnant et al., 1996). The structure of the type II 
AC C2 region revealed a wreathlike dimer arrangement which is likely to exist in other 
enzymes including many similar ACs and GCs. In this arrangement the interface of C1a 
and C2a domains accommodate the catalytic site and the forskolin regulatory site. 
Recombinant C1 and C2 domains are capable of carrying out catalysis when they are 
mixed and activated by forskolin (Zhang et al., 1997; Tang and Hurley, 1998). The two 
metal ions required for catalysis bind to specific residues found in the C1 region, the 
nucleotide binding pocket and other catalytic residues are contributed primarily by the 
C2 region. Similarly, forskolin binds to a site on the C1-C2 heterodimer through 
hydrophobic interactions with residues of both, C1 and C2 domains contributing 
(Dessauer et al., 1997; Tesmer et al., 1997; Zhang et al., 1997). 
From crystallographic and mutational studies those amino acid residues were 
determined which participate in catalysis in mammalian ACs (Tesmer et al., 1997, 1999; 
Zhang et al., 1997). For definition of substrate specificity all important amino acids are 
contributed from the C2 region, they are D1018 (AC type II from rat) which recognizes 
the exocyclic amine and K938 which recognizes the unprotonated N1 of adenine. Both 
residues are capable to discriminate against O6 and N2, and the protonated N1 of 
guanine (Tesmer et al., 1997; Sunahara et al., 1998). The amino acids responsible for 
metal coordination are D396 and D440 (in canine AC type V). One Mg2+ ion binds 
together with ATP, while the second one acts kinetically as a free ion (Tesmer et al., 
1997). Residues N1025 and R1029 (in rat AC type II) stabilize the transition state by 
stabilizing the negative charge on the pyrophosphate leaving group (Yan et al., 1997; 
Hurley, 1998). For binding forskolin, amino acids T410 and S942 (in rat AC type II) are 
implicated (Tesmer et al., 1997).  
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In the present work, the possibility of formation of active heterodimeric chimeras 
between mammalian C1 or C2 monomers and inactive mutated monomers from M. 
tuberculosis (Rv1625c, catalytic domain) was studied. The possibility of creating a non-
existing forskolin-binding site by mutation of the mycobacterial catalytic domain was 
examined. Chimeras between mammalian and Paramecium GC monomers, as well as 
between mycobacterial AC and Paramecium GC monomers were also studied.  
Table 1.1 shows the amino acid residues that are essential for catalysis classified 
according to the catalytic function they realize. The mammalian AC amino acid positions 
are compared with respect to their equivalent positions in Rv1625c and Rv0386 of M. 
tuberculosis, as well as in Paramecium GC. 
 
 Purine binding Metal binding Transition-state 
stabilization 
Forskolin binding 
Mammalian AC 
K938 
ACII 
C2 rat 
D1018 
ACII 
C2 rat 
D396 
ACV 
C1dog 
D440 
ACV 
C1dog 
N1025 
ACII 
C2 rat 
R1029 
ACII 
C2 rat 
T410 
ACII 
C1 rat 
S942 
ACII 
C2 rat 
M. tuberculosis 
Rv1625c K296 D365 D256 D300 N372 R376 N372 D300 
M. tuberculosis 
Rv0386 Q57 N106 D16 D61 N113 R117 N113 D61 
Paramecium 
GC 
E1681 
(C1) 
S1748 
(C1) 
D2233 
(C2) 
D2277 
(C2) 
N1755 
(C1) 
R1759 
(C1) 
L2356 
(C2) 
K1685 
(C1) 
 
Table 1.1: Summary of the canonical amino acid residues responsible for catalysis in 
mammalian ACs (Tesmer et al., 1997, 1999; Zhang et al., 1997) in comparison with their 
equivalent residues in Rv1625c (Guo et al., 2001) and Rv0386 (present work) of M. 
tuberculosis and with Paramecium GC (Linder et al., 2000). Residues of the 
mycobacterial and Paramecium cyclases which are positional but not functional 
equivalent to those of mammalian ACs are in italics.  
 
1.3 Adenylyl cyclases of Mycobacterium tuberculosis 
The complete sequence of Mycobacterium tuberculosis H37Rv was published in 
1998 with the annotation of only five genes (Rv1625c, Rv1318c, Rv1319c, Rv1320c and 
Rv1264) as putative ACs (Cole et al., 1998). Later on, using computational methods 15 
putative ACs were detected (McCue et al., 2000). M. tuberculosis encodes several more 
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putative nucleotide cyclases than other prokaryotic species with the presence of 
predicted cytoplasmic (9), receptor-type membrane bound (1) and integral membrane 
(5) cyclases. Two of them (Rv1625c and Rv2435c) are classified as class a ACs 
together with the mammalian ACs (Cole et al., 1998; McCue et al., 2000).  
To date, nine gene products of M. tuberculosis, Rv1625c and Rv1264 (Guo et al., 
2001; Reddy et al., 2001; Linder et al., 2002), Rv0386 (present work), Rv1318c, 
Rv1319c, Rv1320c, Rv3645, Rv2212 and Rv1900c (Hammer, Zeibig, Motaal, Wetterer; 
unpublished) have been shown to possess AC activity. 
The gene Rv1625c encodes a six-transmembrane-helices membrane-anchored 
AC with a single C-terminal catalytic domain, representing exactly one-half of a 
mammalian AC (Tang and Hurley, 1998). Certainly, by alignment of the mycobacterial 
catalytic domain with C1 from canine type V and C2 from rat type II ACs, considerable 
sequence identities were found. The most important is the conservation of each of the 
amino acids that have been identified crystallographically as participating in catalysis. A 
soluble enzymatically active catalytic domain from Rv1625c was constructed, expressed 
in E. coli and characterized. The dimerization was substantiated with construction of 
linked monomers. Mutations of the amino acid residues indispensable for catalysis by 
the mammalian heterodimers inactivated the mycobacterial cyclase. Finally, it was 
possible to reconstitute productive heterodimers from inactive mutant monomers. These 
molecular and biochemical properties of Rv1625c made it likely that this cyclase is an 
evolutionary precursor of the mammalian AC family (Guo et al., 2001). 
The gene product Rv1264, predicted to be composed of a C-terminal AC catalytic 
domain and a novel N-terminal protein domain, could also be expressed in E. coli 
(Linder et al., 2002). Rv1264 has the same modular composition as ACs from 
Streptomyces and Brevibacterium liquefaciens (Peters et al., 1991; Danchin et al., 
1993). The catalytic domain expressed alone displayed high AC activity, 
homodimerization was demonstrated and the catalysis depended on the same amino 
acids previously identified as critical in mammalian ACs. Because of the notably lower 
AC activity of the holoenzyme, an autoinhibitory function of the N-terminal domain was 
suggested (Linder et al., 2002).  
Until today, several anti-mycobacterial agents interfering with the synthesis and 
assembly of components of the mycobacterial cell wall have controlled a lot of infection 
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cases. But the control of global tuberculosis has so far failed and the number of 
multidrug-resistant isolates is rising. Therefore, it is required to advance our understand 
of the complex biology of tuberculosis infection. The completed genome project is a 
major step toward this goal (Young, 2001). 
From the genome sequence it is obvious that M. tuberculosis is equipped with a 
range of transcriptional regulators. These could confer a high capacity for adaptation as 
shown in several studies where a change in the pattern of gene expression occurred 
after transfer from laboratory conditions to the macrophage intracellular environment 
(Young, 2001). Also, the large number of putative cyclases in M. tuberculosis could point 
to the development of the ability to sense and respond to many intracellular and 
extracellular signals through this second messenger system (McCue et al., 2000). It is 
unknown if cyclase activity is necessary for pathogenesis, but it has been reported that 
macrophages with ingested mycobacteria increase cAMP levels which may inhibit the 
phagosome-lysosome fusion (Lowrie et al., 1975; McCue et al., 2000).   
A recent computational study of genomic sequence comparison placed the gene 
Rv0386 between 19 genes in the genome of M. tuberculosis that may have been 
acquired by horizontal gene transfer from eukaryotes (Gamieldien et al., 2002), an event 
that could have conferred survival advantages to an ancient mycobacterium before 
becoming a pathogen of eukayotes (McCue et al., 2000). On the basis of studies of the 
mycobacterial AC Rv1625c, in this thesis the enzyme Rv0386 was basically studied as 
an AC without paying much attention to its putative feature as a transcription factor. 
Investigation of this enzyme was of particular interest because of its deviation from the 
canonical amino acid residues participating in catalysis, specifically those involved in the 
definition of substrate specificity. The possibility of an AC catalysis by a novel 
mechanism lead to attempts of crystallization.  
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2 Materials 
2.1 Chemicals and materials 
Amersham Pharmacia Biotech, Freiburg: ECL Plus Western Blot Detection System, 
Hyperfilm ECL, Thermo Sequenase Fluorescent Labeled Primer Cycle 
Sequencing Kit with 7-deaza-dGTP, Formamide, [2,8-3H]-cAMP, [8-3H]-cGMP 
AppliChem, Darmstadt: HEPES, Acrylamide 4K-Solution 30% 
Appligene, Heidelberg: Taq DNA-Polymerase with 10X reaction buffer 
Bayer, Leverkusen: Aprotinin 
BioGenes, Berlin: Specific antibodies anti-KD0386 and anti-DB0386 
BIOLOG-Life Science Institute, Bremen: (Rp)-ATP-α-S 
BIO-RAD, München: BIO-RAD Protein-Assay Dye Reagent Concentrate 
Biozym Diagnostik, Hess. Oldendorf: Sequagel XR, Sequagel Complete Buffer 
Reagent, Chill-Out 14 Liquid Wax von MJ Research  
Canberra PACKARD, Taunusstein: Ultima Gold XR LSC Cocktail 
Dianova, Hamburg: Goat anti-mouse antibodies horseradish peroxidase conjugated, 
Goat anti-rabbit antibodies horseradish peroxidase conjugated 
Fluka, Basel: Trypsin inhibitor from lima beans, TLCK, TPCK, SDS, PMSF, PEG 5000 
monomethyl ether, PEG 6000, Nonidet P 40 
Hampton Research, CA (USA): Reagent Kits Crystal Screen, Crystal Screen 2 and 
Crystal Screen Lite for the crystallization screen for proteins and other molecules, 
PEG 400, PEG 3350, PEG 8000 
Hartmann Analytik, Braunschweig: [α-32P]-ATP and [α-32P]-GTP 
ICN Biomedicals, Eschwege: [α-32P]-ATP 
Macherey-Nagel, Düren: Nucleotrap 
Merck, Darmstadt: Imidazole, Glycin, sodium citrate, potassium-sodium tartrate, 
sodium acetate, sodium chloride, PEG 4000 
Millipore, Bedford (USA): Centricon YM-10 Centrifugal Filter Devices (MWCO 10000) 
MWG-Biotech, Ebersberg: Oligonucleotides 
New England Biolabs, Schwalbach/Taunus: Restriction Endonucleases, BSA, T4-
Polynucleotide Kinase, 10X Kinase buffer 
Pall Corporation, Michigan (USA): Nanosep 10K OMEGA centrifugal devices  
  10 
Peqlab, Erlangen: Agarose, peqGOLD Protein Marker 
Promega, Madison (USA): Wizard MiniPreps Plasmid Purification Kit 
Qiagen, Hilden: Ni2+-NTA-Agarose, pQE-Expression vectors, E. coli M15 [pREP4], 
Purified mouse monoclonal RGS⋅His antibody (BSA-free) 
Roche (Boehringer), Mannheim: Restriction endonucleases, Klenow-Polymerase, 
Alkaline Phosphatase, Rapid DNA Ligation Kit, dNTP’s, ATP, GTP, CTP, 
Complete Protease Inhibitor Cocktail Tablets 
Sartorius, Göttingen: Cellulose Acetate Filter with pore size 0.2 µm, Polycarbonate 
Filter Holder 
SERVA Electrophoresis, Heidelberg: Coomasie-Brilliant-blue G250, VISKING Dialysis 
Tubing 8/32 and 27/32 with MWCO 12000-14000. 
Sigma, Deissenhofen: Glycerol, MOPS, TRIS, EDTA, Xgal, IPTG, Ponceau S, Tween 
20, TEMED, PMSF, BSA, ITP, UTP, αβ-CH2-ADP, Cordycepin 5’-triphosphate, 
2’3’ GMP, 2’ GMP, 8-Br-cGMP, monobutyryl cAMP, dibutyryl cAMP, 2’d3’-AMP 
Spectrum Medical Instruments, Los Angeles (USA): Spectrapor Membrane Tubing 
MWCO 3500 
Stratagene, Heidelberg: Plasmid pBluescript II SK (-), E. coli XL1-Blue MRF’ 
 
2.2 Equipment 
Amersham Pharmacia Biotech, Freiburg: ÄKTATM FPLC with Fraction Collector Frac-
950, Pump P-920, Monitor UPC-900, Valve INV-907, Mixer M-925 and Software 
Unicorn Version 4.00, general accessories for FPLC and Anion Exchange 
Column MonoQ HR 5/5. 
Biometra, Göttingen: TRIO-Thermoblock thermocycler 
BIO-RAD, München: Trans-Blot SD Semi Dry Transfer Cell 
Branson, Danbury, USA: Sonifier B-12, Ultrasound Bath Bransonic B12 
Carl Zeiss, Göttingen: Microscope Axioskop 40/40 FL with fixed Polarisator with 
Lambda plate and Canon PowerShot G2 high quality digital camera with 4.0 M pixel 
CCD sensor and 3X optical zoom. 
Eberhard-Karls-Universität, Tübingen: Gel electrophoresis chambers 
Eppendorf, Hamburg: Thermostat 3401, Table Centrifuges 5410 & 5414, Cooling 
centrifuge 5402, BioPhotometer  
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Hampton Research, CA (USA): VDX 24 well polystyrene pre-greased plates, 22 mm 
siliconized glass cover slides (squares) 
Heraeus, Osterode: Megafuge 1.0 R (BS 4402/A) 
Idaho Technologies, Idaho Falls (USA): Air Thermo Cycler 1605 
Kontron-Hermle, Gosheim: Centrikon H401 & ZK401, Rotors A6.14 (SS34) and  
A8.24 (GSA) 
Macherey-Nagel, Düren: Porablot PDVF-Blotting membrane (0.25 x 3 m) 
Millipore, Eschborn: Water purification system MilliQ UF Plus 
MWG-Biotech, Ebersberg: LI-COR DNA sequencer model 4000 
Sartorius, Göttingen: Balance BP 2100 S, Analytic balance handy 
Savant, Farmingdale (USA): Vacuum centrifuge speed vac concentrator SVC100H 
Schleicher & Schuell, Dassel: Whatmanpaper 3MM, Protran BA 83 Cellulosenitrate 
0.2 µm  (200 x 200 mm) Nucleic acid and protein transfer media  
SLM Instruments, Urbana (USA): French Pressure Cell Press FA-078-E1, Manual Fill 
20K Cell FA-073 (7.6 cm diam., 40 ml sample capacity) 
Stratagene, Austin (USA): UV Stratalinker 2400  
 
2.3 Buffers and solutions 
2.3.1 Molecular biology 
 All solutions, buffers and culture media for molecular biology methods were 
sterilized 20 min at 120°C and 1 bar. pH was measured at room temperature.   
 
Buffers for DNA 
 
10X TAE     
 400 mM Tris/acetate pH 8.0 
   10 mM Na2EDTA 
  
 
 
10X Klenow buffer  
 200 mM Tris/HCl pH 7.5 
   60 mM MgCl2 
   10 mM DTT 
 1 mg/ml  BSA 
 
 
TE-buffer 
 10 mM Tris/HCl pH 7.5 
   1 mM Na2EDTA 
 
 
10X TBE 
1000 mM Tris 
   890 mM Boric acid 
     25 mM Na2EDTA
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4X Loading sample buffer (agarose gel) 
          0.05 % Bromphenolblue 
          0.05 % Xylenecyanol 
          50.0 % Glycerol 
 
Loading sample buffer (sequencing gel) 
 95 %   Formamide 
 20 mM Na2EDTA 
 0.05 % Bromphenolblue 
 0.05 %  Xylenecyanol 
 
10X CM buffer  
 100 mM CaCl2 
 100 mM MgCl2 
 
10X Dephosphorylation buffer 
 500 mM Tris/HCl pH 8.5 
     1 mM Na2EDTA
 
Bacterial culture media 
 
LB-broth 
    1 %  Bacto Tryptone 
 0.5 %  Yeast extract 
    1 %  NaCl 
 
LB-agar 
 1.5 %  Agar in LB-broth 
 
LB-Amp-agar 
 100 µg Ampicilin / ml LB-agar 
 
 
2.3.2 Protein chemistry 
 
Protein purification with Ni-NTA-agarose 
 
Pellet wash buffer 
 50 mM  Tris/HCl pH 8.0 
  1  mM EDTA 
 
 
Cell Lysis buffer 
 50 mM Tris/HCl pH 8.0 
 10 mM β-mercaptoethanol 
 50 mM NaCl 
Wash buffer A 
   50 mM Tris/HCl pH 8.0 
   10 mM β-mercaptoethanol 
     2 mM MgCl2 
 400 mM NaCl 
     5 mM  Imidazole 
 
Wash buffer B 
   50 mM Tris/HCl pH 8.0 
   10 mM β-mercaptoethanol 
    2  mM MgCl2 
 400 mM NaCl 
   15 mM Imidazole 
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Wash buffer C 
   50 mM Tris/HCl pH 8.0 
   10 mM β-mercaptoethanol 
     2 mM MgCl2 
   10 mM NaCl 
   15 mM  Imidazole 
 
Elution buffer 
   50 mM  Tris/HCl pH 8.0 
   10 mM β-mercaptoethanol 
     2 mM MgCl2 
   10 mM NaCl 
150 mM  Imidazole
 
Glycerol dialysis buffer 
 10 mM NaCl 
 50 mM Tris/HCl pH 7.5 
  2  mM β-mercaptoethanol 
 20 %  Glycerol 
 
Phosphate dialysis buffer 
50 mM Na2HPO4/NaH2PO4 
buffer (pH 7.5) 
 10 %  Glycerol 
 
 
 
Equilibration mixture for Ni-NTA-agarose 
      5 ml Cell lysis buffer 
  225 mM NaCl 
 13.5 mM Imidazole pH 8.0 
   4.5 mM MgCl2 
 
 
Membrane Suspension Buffer 
   50 mM Tris/HCl pH 8.0 
   15 mM β-Mercaptoethanol 
 250 mM NaCl 
    20   % Glycerol 
      2   % CHAPS
High Saline Buffer 
    50 mM Tris/HCl pH 8.0 
    10 mM β-Mercaptoethanol 
      2 mM MgCl2 
      5 mM Imidazole pH 8.0 
  250 mM NaCl 
     20   % Glycerol 
       2   %  CHAPS 
 
Low Saline Buffer 
    50 mM Tris/HCl pH 8.0 
    10 mM β-Mercaptoethanol 
      2 mM MgCl2 
    15 mM Imidazole pH 8.0 
    10 mM NaCl 
     20   % Glycerol 
       2   %  CHAPS 
Elution Buffer with Detergent 
    50 mM Tris/HCl pH 8.0 
    10 mM β-Mercaptoethanol 
      2 mM MgCl2 
  300 mM Imidazole pH 8.0 
    10 mM NaCl 
     20   % Glycerol 
       2   %  CHAPS 
 
Tosyl-L-phenylalanin-chlormethylketon 
(TPCK) 
 2.2 mg/ml in Ethanol (Stock) 
 
Nα-Tosyl-L-lysin-chlormethylketon-
hydrochlorid (TLCK) 
 2.2 mg/ml in 1 mM HCl (Stock) 
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Phenylmethansulfonylchlorid (PMSF) 
2.2 mg/ml in Isopropanol  (Stock) 
Lima bean Trypsin Inhibitor 
 3.2 mg/ml in H2O (Stock)
Aprotinin 
 2.8 mg/ml in NaCl 0.9% (Stock) 
 
 
 
SDS-Polyacrylamide gel electrophoresis 
 
Resolving Gel buffer 
 1.5 M  Tris/HCl pH 8.8 
 0.4 %  SDS 
 
Stacking Gel buffer 
 500 mM Tris/HCl pH 6.8 
   0.4 % SDS 
10X Running buffer 
 250 mM Tris 
 1.92 M Glycin 
      1 % SDS 
 
Staining solution 
 0.2 %  Coomassie Brilliant  
Blue G-250 
 10  %  Acetic acid 
 40  %  Methanol 
 
4X Sample buffer 
 130 mM  Tris/HCl pH 6.8 
    10 % SDS 
    10 % β-mercaptoethanol 
    20 % Glycerol 
 0.06 % Bromphenolblue 
 
Destaining solution 
 10 %  Acetic acid 
 30 %  Ethanol 
 
 
 
Protein marker 
 0.1 mg/ml BSA (66 kDa) 
 0.1 mg/ml Ovoalbumine (45 kDa) 
 0.1 mg/ml GAPDH (36 kDa) 
0.1 mg/ml Chymotrypsinogen A (25 kDa) 
0.1 mg/ml Trypsin inhibitor (20.1 kDa) 
0.1 mg/ml Cytochrom C (12.5 kDa) 
       30   % 4X sample loading buffer 
 
 
 
Western blot 
 
TBS buffer (Tris buffer saline) pH 7.6 
   20 mM Tris 
 150 mM NaCl 
 
M-TBS 
5 % Milk powder non-fat     
in TBS 
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Towbin-Blot-buffer 
   25 mM Tris 
 192 mM Glycin 
   20  % Methanol 
 
TBS-T 
 0.1 %  Tween 20 in TBS 
 
 
 
Ponceau S Staining Solution 
 0.1 % (w/v) Ponceau S 
   in 5% (v/v) acetic acid  
 
 
Cyclase enzyme test 
 
Creatine kinase 
       4 U /2.5 µl         Creatine kinase in  
             10 mM Tris/HCl pH 7.5  
 
Creatine phosphate 
120 mM in 10 mM Tris/HCl 
pH 7.5 
 
 
 
 
ATP or GTP Stock solution 
10 mM adjusted to pH 7.2-
7.5 with NaOH 
 
cAMP or cGMP Stock solutions 
 40 mM in H2O  (adjust pH to 
   7.5 with Tris buffer)
 
10X AC-Start Solution 
  0.75 to 10 mM ATP with 
   2.5-4x106 Bq/ml 
   [α-32P]-ATP 
 
 
 
10X GC-Start Solution 
  0.75 to 10 mM GTP with 
   2.5-4x106 Bq/ml 
   [α-32P]-GTP 
 
 
2X AC-Cocktail 
 43.5 % Glycerol 
100 mM Tris-HCl pH 7.5 or      
MOPS pH 7.5 
     4 mM cAMP with 
2-4x103 Bq/ml 
   [2,8-3H]-cAMP 
     0.46 mg/2ml Creatine kinase 
     6 mM Creatine phosphate 
      2 to 5   mM MnCl2 or 
      5 to 10 mM MgCl2 
 
 
 
2X GC-Cocktail 
 43.5 % Glycerol 
 100 mM MOPS pH 7.5 
     4 mM cGMP with 
2-4x103 Bq/ml 
   [8-3H]-cGMP 
         5   mM MnCl2 or 
            10 mM MgCl2 
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Adenylyl cyclase stop buffer (pH 7) 
 3 mM  cAMP 
 3 mM  ATP 
 1.5 %  SDS 
 
Guanylyl cyclase stop buffer 
 1.5   % SDS    
 
Forskolin solution 
 10 mM Forskolin in DMSO 
 
 
 
Crystallization buffers 
Self-produced crystallization buffers were made using deionized purified water (MilliQ) 
and were filtrated through 0.2 µm size pore filters applying vacuum to a filter holder 
device. 
 
2.4 Oligonucleotides  
Restriction sites are underlined, mutations are in bold and mutations together with 
restriction sites are bold and underlined. 
 
Name Sense Sequence (5’→ 3’) Position Comments 
Sequencing primers for plasmids 
T7 s GTA ATA CGA CTC ACT ATA 
GGG C 
625-646 T7 pBluescript II 
SK(-) 
T3 as AAT TAA CCC TCA CTA AAG 
GG 
772-791 T3 pBluescriptII 
SK(-) 
U –pQE-IR s GAA TTC ATT AAA GAG 
GAG AAA 
88-108 universal pQE30 
R –pQE-IR as CAT TAC TGG ATC TAT CAA 
CAG G 
212-233 reverse pQE30 
Cloning primers of Rv1625c mutants 
myktub kat-s s AAA GGA TCC GAT ACT 
GCG CGT GCG GAG GCG 
604-631 BamHI 
Primer from Dr. 
Guo. 
myktub 372A-1   as CAT CCG GCT AGC GAC 
AGC GAC CGC GTC GCC 
1102-1131 NheI  
myktub 372A-2 s GTC AAT GTC GCT AGC 
CGG ATG GAA TCC 
1111-1137 NheI  
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myktub 1-as        as AAA GAG CTC TCA GAC 
CCC TGC CGT GCG 
1314-1338 SacI 
Primer from Dr. 
Guo. 
myktub 372T-1 as CAT CCG GCT AGC GAC 
AGT GAC CGC GTC GCC 
1102-1131 NheI  
myktub 300S-1 as AAC CAT GTA ACT CGA 
GCC GCT GAC CTT GAT 
883-912 XhoI  
myktub 300S-2 s GTC AGC GGC TCG AGT 
TAC ATG GTT GTC 
889-916 XhoI  
Cloning primers of Rv0386 holoenzyme and AC catalytic domain 
myco0386/B-C-
Hforw 
s AAA GGA TCC ATG AGC 
AAG TTG CTG CCA CGG 
GGC ACA GTG ACA TTG 
CTG TTG GCC GAC GTC 
GAG GGT TCC ACC 
1-63 BamHI  
myco0386/B-C-
H-rev 
as AAA AGC TTT CAA TCG ATA 
CGC AAT TCG GGA TG 
505-534 HindIII 
myco0386/C-
Cforw 
s CGT ATC GAT TTC CCG 
CCG CTG 
517-537 ClaI  
myco0386/C-
Crev 
as GCC ATC GAT GAT CTC 
GTC AAG 
1192-1212 ClaI  
myco0386/C-
Sforw 
s ACG CTT GAC GAG ATC 
ATC GAT GGC 
1189-1212 ClaI  
myco0386/C-
Srev 
as CAG GGC CTT GTC GGC 
CAA TGC CCG 
1855-1878 SfiI  
myco0386/S-
Sforw 
s CGG GCA TTG GCC GAC 
AAG GCC CTG  
1855-1878 SfiI  
myco0386/S-
Srev 
as GGC GGC CAA CGC GGC 
CGT GGT CAA C 
2460-2484 SfiI  
myco0386/S-
Hforw 
 
s TTG ACC ACG GCC GCG 
TTG GCC GCC 
2461-2484 SfiI  
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myco0386/S-
Hrev 
as AAA AGC TTT CAG GTA 
CGG CGG GCG GCC GC 
3238-3258 HindIII 
Cloning primers of Rv0386 mutants 
myco0386/ 
Q57Krev 
as ACC CTC ACC CTT CTC 
GAC AGG CCT TAC GCC 
151-180 StuI  
myco0386/ 
Q57Kforw 
s GGC GTA AGG CCT GTC 
GAG AAG GGT GAG GGT  
 
151-180 StuI 
myco0386/ 
Q57Arev 
as ACC CTC ACC CGC CTC 
GAC AGG CCT TAC GCC  
151-180 StuI  
myco0386/ 
Q57Aforw 
s GGC GTA AGG CCT GTC 
GAG GCG GGT GAG GGT 
151-180 StuI  
myco0386/ 
N106Drev 
as GTT GAT GGT GGG CCC 
GGC ATA GTC GCC TTC 
GTC 
307-339 ApaI  
myco0386/ 
N106Dforw 
s GAC GAA GGC GAC TAT 
GCC GGG CCC ACC ATC 
AAC  
307-339 ApaI  
myco0386/ 
N106Arev 
as GTT GAT GGT GGG CCC 
GGC ATA GGC GCC TTC 
GTC 
307-339 ApaI  
myco0386/ 
N106Aforw 
s GAC GAA GGC GCC TAT 
GCC GGG CCC ACC ATC 
AAC  
307-339 ApaI  
myco0386/ 
QKNDforw 
s AAG TGG CCG CCG CGT 
TAG ATC TGC AGC GAG CG 
220-249 Bgl II 
myco0386/ 
QKNDrev 
as AAC CGC GCT CGC TGC 
AGA TCT AAC GCG GCG GC 
222-252 Bgl II 
myco0386/ 
N106Sforw 
s GAC GAA GGC TCA TAT 
GCC GGT CCG ACC  
 
307-333 NdeI  
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myco0386/ 
N106Srev 
as GGT CGG ACC GGC ATA 
TGA GCC TTC GTC  
307-333 NdeI  
Primers for transcription factor-, ATPase- and DNA-binding domains of Rv0386 
NHis/TF/ 
Rv0386forw 
s AAA GGA TCC TGT CAT 
CCC GAA TTG CGT ATC 
502-522 BamHI 
NHis/DBDom/ 
Rv0386 
s AAA GGA TCC GCA TGG 
GCC GAA GGT GCC GCG  
 
2980-3000 BamHI 
NHis/AADom/ 
Rv0386re 
as AAA AAG CTT GTG GCG 
CAT CGT CTC GCA  
1501-1518 HindIII 
Primer for N-terminally elongated adenylyl cyclase domain 
CDC1551ac-
forw 
s AAA GGA TCC ATG CGA 
CTG AGT GGA GCG GGG 
ATG AGC AAG TTG CTG 
CCA CGG GGC ACA  
1-27 BamHI and 
addition of 
MRLSGAG  
myco0386/cata/
C-His 
as AAA AGA TCT ATC GAT 
ACG CAA TTC GGG ATG 
505-525 Bgl II  
Primer for C-terminally His-tagged catalytic domain 
myco0386/cata/C-His (see above) 
 
2.5 Plasmids 
 
 
 
 
 
 
 
 
 
 
Source: Stratagene 
Apa I 
Dra II 
Xho I 
Hinc II 
Sal I 
Cla I 
Hind III 
Eco RV 
Eco RI 
Pst I 
Sma I 
Bam HI 
Xba I 
Not I 
Eag I 
Sac II 
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Source: Qiagen 
Source: Qiagen 
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3 Methods 
 
3.1 Polymerase chain reaction (PCR) 
The polymerase chain reaction was carried out with specific primers to amplify DNA 
fragments from plasmid or genomic DNA and for introduction of endonuclease restriction 
sites and point mutations.  The annealing temperature was calculated with the formula: 
    ( ) ( ) 442 −×+×= GCATTa              
(AT) and (GC) represent the number of A+T and G+C respectively in the primer 
sequence. If the annealing temperatures for each primer were different the lower one 
was employed. 
The reaction was run in 50 µl with a thermocycler with heatable lids to avoid volume and 
concentration changes through evaporation and condensation. The samples contained 
max. 1 ng plasmid or 800 ng genomic DNA, 5-10% DMSO, 200 µM dNTPs, 1 pmol/µl 
primers, 1U Taq-DNA-Polymerase and 1X of the corresponding reaction buffer. The 
temperature program applied is shown in Table 3.1. 
 
Denaturation 95°C 5 min 
Denaturation 95°C 1 min 
Primer annealing Ta 1 min 
20
 - 
40
 
cy
cl
es
  
Extension 72°C 1 min 
Fill up  72°C 10 min 
 
Table 3.1: Program used for polymerase chain reaction. 
 
3.2 Isolation and purification of DNA 
3.2.1 General 
Plasmid DNA was isolated from bacterial cultures through a small-scale purification 
method, known as miniprep. The standard protocol of the Wizard Plus Minipreps DNA 
Purification System (PROMEGA) was carried out using 1-3 ml of O/N bacterial culture 
(12-16h by 37°C) and a vacuum manifold giving a yield of 1-10 ng DNA. DNA was 
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eluted with sterile water. The purified plasmid could be used directly for DNA sequencing 
and restriction digestion. 
DNA fragments separated through electrophoresis were excised from the agarose gel 
with the help of a scalpel and extracted with the help of the Macherey-Nagel Nucleotrap-
Gelextractions-Kit following the protocol of the manufacturers.   
If a change in the buffer conditions was necessary in order to process the DNA samples, 
they were desalted following the corresponding protocol of the Nucleotrap-
Gelextractions-Kit (Macherey-Nagel).  
 
3.2.2 Agarose electrophoresis 
To determine yield and purity of an isolated DNA or PCR reaction, to check digestion by 
a restriction enzyme and to determine the size of DNA molecules, agarose 
electrophoresis was carried out. Agarose was dissolved in TAE-buffer and melted in a 
microwave oven. The solution was poured into a mould in which a well-forming comb 
was fitted. The agarose content was choosen according to the expected size (bp) of 
DNA-fragments: 
    ≥ 2000 bp           0.8 - 1   % 
       500 – 2000 bp           1 – 1.8  % 
    ≤  500  bp                  2    % 
 
TAE-buffer was used for electrophoresis, agarose gels were submerged in a horizontal 
electrophoresis apparatus. The DNA samples were mixed with loading sample buffer. 
Electrophoresis was performed at 80-100 V for 0.5-1 h at room temperature. The size 
markers EcoR I/Hind III-digested λ-DNA (λ-Marker: 21226, 5184, 4973, 4277, 3530, 
2027, 1904, 1584, 1330, 983, 831, 564, 125 bp) and MspI/SspI-digested pBluescript II 
SK(-)-Vector (π-Marker: 489, 404, 312, 270, 242/241, 215, 190, 157, 147, 110, 67, 57, 
34, 26 bp) were co-electrophoresed with DNA samples. For detection of the DNA, gels 
were submerged in a ethidium bromide bath (0.01 mg/ml) for 1-2 min. The gel was run 
10 additional min and DNA fragments visualized on a UV light box (302 nm) and 
photographed. 
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3.2.3 Photometric determination of DNA concentration  
Nucleic acid content was measured at 260 nm. An OD of 1 corresponds to 50 µg/ml for 
double-stranded DNA. The ratio OD260/OD280 was calculated to estimate purity. An OD 
ratio of >1.8 was desirable.  
 
3.3 Enzymatic Methods 
3.3.1 General molecular biology methods 
Restriction enzyme digestions were performed by incubating double-stranded DNA 
molecules with the appropriate amount of restriction enzyme at the optimal temperature 
required and in the corresponding buffer as recommended by the supplier. In the case of 
simultaneous digestion with 2 or more enzymes, the more compatible buffer or the One-
Phor-All-buffer was used. If no possible compatibility was found, digestions were 
performed sequentially with a desalting step in-between. 
 
3.3.2 Generation of blunt ends  
After PCR or a restriction digest, the Klenow-fragment of the DNA-Polymerase I was 
used. For blunting, maximally 500 ng DNA, 1 µl of 10X Klenow-buffer and 0.8 µl of 
Klenow-Polymerase (1 U/µl) in a 10 µl reaction volume were mixed. The reaction 
mixture was incubated for 10 min at 37°C. Then 1 µl of dNTPs (25 mM) was added and 
the incubation continued for 30 min. The sample was heated to 70°C for 10 min for 
inactivation. 
 
3.3.3   5’-Phosphorylation of PCR products 
This was necessary for blunt end ligation.  The reaction was composed of 1-2 µg DNA 
or of the Klenow-treated DNA solution, 1 mM ATP, 10 U T4-Polynucleotide Kinase and 
1X T4-PNK-buffer in 15 µl (37 °C, 1 h).  
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3.3.4   5’-Dephosphorylation of plasmid vectors 
To suppress circularization of plasmid DNA, the 5‘-phosphates from both ends were 
removed with calf alkaline phosphatase. 500 ng DNA, 1 U/pmol of enzyme and 1X 
dephosphorylation buffer were mixed in 10 µl and incubated at 37°C for 1 h.  
 
3.3.5   Ligation of DNA fragments 
DNA fragments were ligated with the Rapid DNA Ligation Kit according to the 
instructions of the manufacturer. The molar ratio of vector to DNA insert should be 1:3 
for one insert and 1:1:1 in the case of two inserts. 
 
3.4 Transformation of recombinant DNA 
3.4.1 Competent cells of E. coli 
From a new plate of XL1-blue MRF-, BL21 (DE3) [pREP4], BL21 STAR (DE3) [pREP4] 
or BL21 Rosetta (DE3) [pREP4] cells, a single colony was picked and grown up in 5 ml 
LB broth (37°C, O/N). 1 ml was transferred into 50 ml LB and grown at 37°C to 0.3-0.4 
OD600 (approx. 2-3 h). The culture was cooled on ice (10 min) and transferred to Falcon 
tubes. Cells were recovered at 2500 x g (15-20 minutes, 4°C). Pellets were suspended 
in 10 ml of ice cold CaCl2 (0.1 M) and centrifuged (2500 x g, 15 min, 4°C). This step was 
repeated with addition of 20 % glycerol. The suspended pellets were standing on ice for 
2 hours, aliquoted (100 µl) and stored at –80°C.  
 
3.4.2 Rapid transformation 
One aliquot of competent cells was thawed on ice. 100 ng plasmid DNA (max.) was 
added and mixed. After 5-15 min on ice the mixture was spread on LB agar plates 
containing the appropriate antibiotic and incubated at 37 °C O/N.  
 
3.4.3 Standard transformation 
The entire DNA ligation reaction (21 µl from a Rapid Ligation Kit protocol) was diluted in 
1X CM buffer to 50 µl. This was added to competent cells (100 µl), mixed gently and 
incubated on ice (30-45 min). Cells were then heat-shocked (1 to 2 min, 42°C) and 
incubated on ice (10 to 20 min). 400 µl of LB-broth were added and cells were incubated 
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at 37 °C for 45-60 min with agitation (210-230 rpm). 50 to 200 µl of the mixture were 
spread on LB agar plates with appropriate antibiotics. Plates were incubated in an 
inverted position for 12-16 h at 37 °C. For transformation with pBluescript II SK (-) vector 
it was possible to make a blue-white screen by spreading 40 µl of IPTG 0.1 M and 40 µl 
of X-Gal (2 %) over the LB agar plate prior to plating. Bacteria carrying recombinant 
DNA formed white colonies, those carrying plasmids without insert formed blue colonies. 
 
3.4.4 Glycerol stock cultures 
1-3 ml of a O/N bacterial culture was centrifuged (2 min, 10,000 x g). The pellet was 
suspended in 750 µl of a mixture of LB-broth/Glycerol  4:1, storage at –80 °C.  
 
3.5 DNA Sequencing  
Miniprep DNA was sequenced using sequenase and 7-deaza-dGTP (the latter to 
prevent band compression caused by DNA secondary structure). The Thermo 
Sequenase Primer Cycle Sequencing Kit was used. The DNA/Primer-Mix varied in its 
composition and volume depending on the type of vector used. DMSO was added to 
avoid primer-dimer formation. Primers used were fluorescent-labeled: for pBluescript T3 
and T7 primers (Ta= 56°C), and for pQE30 U-pQE-IR800 and R-pQE-IR800 primers 
(Ta= 54 °C) were used.  
 
DNA fragment cloned in pBluescript DNA fragment cloned in pQE30 
DNA 1-2 pmol 
(∼130 ng/kb) 
(8 µl) 
DNA 1-2 pmol 
(∼130 ng/kb) 
(10 µl) 
Primer [2 pmol/µl] 1.5  µl Primer [4 pmol/µl] 2 µl 
DMSO 0.7 µl DMSO 0.7 µl 
Final volume (with H2O) 21 µl Final volume 18 µl 
 
Table 3.2: Components of the DNA/Primer-Mix used for DNA sequencing depended on the 
vector used for cloning. 
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4 - 5 µl of DNA/Primer-Mix were added to 2 µl of G, A, T or C-reagent mix of the 
corresponding kit following the instructions of the supplier. Each reaction was overlayed 
with one drop chill-out-wax and run in a Thermocycler using the following program: 
 
Step Temperature Time Cycles 
First denaturation 95 °C 2 min 1 
Denaturation 95 °C 20 s 
Annealing Ta of the primers used 20 s 
Extension 70 °C 20 s 
25-30 
Termination 4 °C ∞ 1 
 
Table 3.3: Program used for DNA sequencing. 
 
At the end of the reaction 6 µl of Formamide loading dye of the kit were added. 1 µl of 
each sample was loaded onto a 6% polyacrylamide gel and electrophoresed with the 
help of a LI-COR Sequencing apparatus at 50 W (max. 1500 V or 37 mA, 50°C). 
Running buffer was TBE-buffer, DNA fragments were detected through Laser 
fluorescence at 800 nm. Data obtained was analyzed with the BaseImageIR V. 4.0 
Software.  
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3.6 Cloning  
All constructs were cloned in the MCS of pBluescriptII (SK-) as a first cloning step and 
for sequencing. Finally, they were cloned for expression into pQE30 or pQE60. As a 
result, all proteins had either an N-terminal MRGSH6GS or a C-terminal RSH6 extension. 
 
3.6.1 Mammalian and protozoan cyclases  
Clones of the mammalian and the Paramecium cyclases cytosolic regions were from 
Hoffmann (1999). 
 
3.6.2 M. tuberculosis Rv1625c 
3.6.2.1 Site-directed mutagenesis 
A DNA construct of Rv1625c (mycoAC204-443) with 5’-BamHI and 3’-SacI sites in pQE30 
was used as a template (Guo et al., 2001). Single amino acid mutations were introduced 
by site-directed mutagenesis using respective PCR. 
 
3.6.2.1.1 Mutants N372A and N372T 
Table 3.4 and Figure 3.1 outline the cloning steps used for mycoAC204-443 N372A and 
N372T, respectively. 
 
Mutant Fragment Primers Length of the PCR 
product (bp) 
1 myktub kat-s myktub 372A-1 534 N372A 
2 myktub 372A-2 myktub 1-as 237 
1 myktub kat-s myktub 372T-1 534 N372T 
2 myktub 372A-2 myktub 1-as 237 
  
Table 3.4: Primers used for cloning the mutants N372A and N372T. See sequence of the 
primers in chapter 2. 
 
Amplification conditions were: Ta= 52°C, 5 % DMSO, 20 cycles. Products were digested 
with BamHI/NheI to obtain fragment 1 and NheI/SacI for fragment 2 of both N372A and 
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N372T. The fragments were 5’ phosphorylated, purified by agarose gel electrophoresis 
and cloned into pQE30 plasmid digested with BamHI/SacI and dephosphorylated. 
Recombinants were isolated from E. coli XL-1 blue, and introduced into E. coli 
BL21(DE3)[pREP4] for protein expression with prior confirmation of the mutations by 
double-stranded sequencing.  
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Restriction sites and sequence changes used for the mutants N372A and 
N372T. Numbering of the bases corresponds to positions in the holoenzyme. The silent 
insertion of an NheI restriction site and the codon changes corresponding to the 
respective mutations are in bold. 
 
 
3.6.2.1.2 Mutant D300S 
For cloning the mutant D300S two PCR products were amplified. For fragment 1 (312 
bp) primers myktub kat-s and myktub 300S-1 with the insertion of a 5’-BamHI and a 3’-
XhoI restriction sites were used. Fragment 2 (456 bp) was obtained with myktub 300S-2 
and myktub 1-as with the insertion of a 5’-XhoI and a 3’-SacI site (figure 3.2). PCR 
conditions were: Ta= 52°C, 5 % DMSO, 20 cycles. PCR products were isolated, purified, 
digested with the respective enzymes and ligated to a dephoshorylated BamHI/SacI 
digested pQE30 vector. Recombinants were isolated from XL-1blue cells and introduced 
into BL21 cells for protein expression after sequencing. 
 
 
 
 
 
XYZ GCTAGC 
NheI BamHI SacI 
Stop 
610 1114 1120 1329 1338 
pQE30 
1114AAT1116 :   N372 
1114GCT1116 :   N372A 
1114ACT1116 :   N372T 
Fragment 1 Fragment 2 
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Figure 3.2 : Cloning of D300S in pQE30. Within the XhoI site the codon changes for the 
respective mutation were inserted by PCR (898TCG900 to 898GAC900). Numbering is 
according to the holoenzyme Rv1625c. 
 
3.6.3 Mycobacterium tuberculosis Rv0386 
3.6.3.1 Holoenzyme 
The M. tuberculosis genomic DNA was provided by Dr. Boettger (University of Zürich 
Medical School). The gene Rv0386 was obtained in 5 PCR reactions, i.e. in five different 
fragments which covered the entire ORF (3255 bp). For PCR conditions see Table 3.5. 
See appendix for Rv0386 DNA sequence (restriction sites used for cloning are outlined). 
 
PCR 
fragment Primers 
Length 
(bp) Tannealing (°C) Cycles % DMSO 
1 myco0386/B-C-Hforward myco0386/B-C-H-reverse 545 58 40 5 
2 myco0386/C-Cforward myco0386/C-Creverse 696 60 40 5 
3 myco0386/C-Sforward myco0386/C-Sreverse 690 62 40 5 
4 myco0386/S-Sforward myco0386/S-Sreverse 630 62 40 5 
5 myco0386/S-Hforward myco0386/S-Hreverse 806 70 40 5 
 
Table 3.5: Primers used and PCR conditions for cloning Rv0386.  
mycoAC204-443 
912 
BamHI 
pQE30 
610 
SacI 
XhoI Stop 
1338 897 
D300S mutant 
SacI 
Stop 
1338 
BamHI 
pQE30 
610 
primer 
sense 
primer
antisense
889 
primer 
sense 
primer 
antisense 
Fragment 1 Fragment 2 
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The primer myco0386/B-C-Hforward inserted a silent mutation at position 55 to eliminate 
a BamHI site. After PCR, the DNA products were purified by agarose gel 
electrophoresis, blunted, phosphorylated and ligated into different vectors (Table 3.6). 
 
PCR fragment Vector Expected direction 
1 pBSK(-), ClaI digested, dephosphorylated and blunted antisense 
2,3 and 4 pBSK(-), EcoRV digested, dephosphorylated and blunted sense 
5 pBSK(-), EcoRV digested, dephosphorylated and blunted antisense 
 
Table 3.6: Vectors used for cloning the DNA fragments obtained by PCR (see Figures 
3.3 and 3.4).  
  
The ligation products were transformed into XL-1 blue cells. The recombinant DNA was 
analyzed by restriction. The direction of the five PCR products within vectors was 
controlled through digestion with BamHI and HindIII. To search for clones with fragment 
I in antisense direction, an additional control digestion with only BamHI was carried out. 
Similarly, for fragment V a digest with only HindIII identified the clones with antisense 
direction. All clones were verified through sequencing (Figures 3.3 and 3.4). 
 
 
             BamHI             ClaI(521)             ClaI(1205)       SfiI(1870)        SfiI(2476)                         Stop HindIII 
         (-6)           I                  II            III                IV                       V        (3255)  
   
                GSMSKL...….IDFP....…....….IDGL..….….KALL.....….LAAG.....……..RRT-Stop-KL  
                                    1                        175                                      403                                625                            827                                             1085 
 
 
                      521bp             684bp           665bp          606bp               779bp 
 
 
Figure 3.3: Overview of the sequence of Rv0386 to be expressed. Note the five 
fragments. The restriction sites BamHI and HindIII were introduced through primers. ClaI 
and SfiI sites were from the original sequence. 
 
Figure 3.4: Steps used for cloning Rv0386. Levels above correspond to vector positions 
and levels below to Rv0386 positions.  
  31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fragment V Fragment I 
Fragment III 
Fragment IV 
HindIII SfiI HindIII BamHI 
SfiI ClaI 
SfiI SfiI 
∆EcoRV ClaI ∆EcoRV HindIII ∆ClaI ∆ClaI EcoRV KpnI 
pBluescript pBluescript 
Digestion 
ClaI / SfiI 
+ Step 1 
Digestion 
ClaI / KpnI 
Step 2 
Fragment V Fragment III Fragment IV pBluescript 
ClaI SfiI SfiI HindIII 
∆EcoRV KpnI 
Fragment I 
∆ClaI KpnI 
ClaI BamHI 
Fragment V Fragment III Fragment IV pBluescript 
ClaI SfiI SfiI HindIII 
∆EcoRV 
Fragment I 
KpnI 
BamHI 
Fragment II 
ClaI ClaI 
Digestion 
ClaI  
Step 3 
+ 
Digestion 
ClaI/KpnI  
Fragment V Fragment III Fragment IV 
pBluescript 
ClaI SfiI SfiI HindIII 
Fragment II 
ClaI 
Fragment I 
KpnI(657) 
BamHI 
BamHI(719) 
DraI(1912) DraI(1931) DraI(2623) 
XcmI(2472) XcmI(552) 
ClaI 
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657 
HindIII  
1396* 2342* 
Step 1: DNA fragment V in pBluescript (in antisense direction) was digested with SfiI 
(2h, 50°C) and subsequently with ClaI (O/N, 37°C). The product was dephosphorylated 
and used as a vector. Simultaneously, fragments IV and III in pBluescript were digested 
with SfiI and fragment 3 additionally with ClaI. Both products were phosphorylated to 
function as inserts. Vector and the two inserts were triple ligated and transformed in XL-
1 blue cells. Clones were first controlled by digestion with HindIII and ClaI. A second 
control digest was carried out with PstI (Figure 3.5). One of the correct clones was 
chosen. 
 
 
 
 
 
 
Fig. 3.5: Restriction sites used for controlling the insertion of fragment IV (SfiI/SfiI) in the 
correct direction between fragments III (ClaI/SfiI) and V (SfiI/HindIII). Names of the 
enzymes in bold correspond to restriction sites present in the holoenzyme sequence.  
*Numbering corresponds to positions in Rv0386. The other restriction sites and 
numberings correspond to pBluescript.  
 
Step 2: Fragment I cloned in pBluescript in antisense direction was digested with ClaI 
and KpnI (1h, 37°C). The product was the insert. Construct containing fragments III, IV 
and V cloned together in pBluescript (step 1) was digested with ClaI and KpnI and 
dephosphorylated to act as the vector (KpnI comes from pBluescript). Vector and insert 
were ligated and transformed in XL-1 blue cells. The obtained clones were controlled by 
digestion with BamHI and HindIII.  
 
Step 3: Fragments I/III/IV/V (in pBluescript) were digested with ClaI and then 
dephosphorylated to be the vector. Fragment II in pBluescript was digested with ClaI to 
serve as a insert. Vector and insert were ligated and transformed in XL-1 blue cells. 
Clones were analyzed by digestion with BamHI, XcmI and HindIII to verify the direction 
of fragment II.  
PstI ∆EcoRV ∆EcoRV 
711 697 697 
KpnI 
3261* 
ClaI 
1205* 
SfiI SfiI 
PstI PstI 
1870* 2476* 
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Step 4: The whole construct in pBluescript (in antisense direction) was digested with 
BamHI, HindIII and DraI to be the insert for the vector pQE30. DraI digests pBluescript 
into 3 fragments but does not cut the insert. This permitted the easy isolation of the 
insert from pBluescript because of the size difference. pQE30 was likewise digested with 
BamHI and HindIII and dephosphorylated. Insert and vector were ligated, transformed in 
XL-1 blue cells and clones were controlled by digestion with BamHI and HindIII. One of 
the correct clones was chosen for transformation into BL21 cells for expression and a 
glycerol stock culture was prepared. 
 
3.6.3.2 Adenylyl cyclase domain 
Fragment I used for cloning the holoenzyme (figure 3.4) was digested with BamHI and 
HindIII from pBluescript and ligated into pQE30 digested correspondingly. Finally, it was 
transformed in BL21 cells for expression.  
 
3.6.3.3 Putative AAA-ATPase domain 
Using the pQE30 cloned holoenzyme as a template, a PCR (Ta= 48°C, 10 % DMSO, 30 
cycles) with primers NHis/TF/Rv0386forw and NHis/AAADom/Rv0386rev was carried 
out. These primers inserted 5’-BamHI and 3’-HindIII sites. The DNA fragment between 
positions 502 and 1518 was amplified (Figure 3.6). The products were digested with 
BamHI and HindIII and phosphorylated. DNA of pQE30 was digested similarly and 
dephosphorylated. Insert and vector were ligated and transformed in XL-1 blue cells. 
Recombinant DNA from minipreps was sequenced to verify sequence fidelity. A correct 
clone was then transformed in BL21 cells and in BL21-STAR cells.  
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Fig. 3.6: Cloning steps of the AAA-ATPase domain of Rv0386 in expression vector 
pQE30. DNA from position 502 to 1518 was amplified. Numbering corresponds to 
positions in the holoenzyme sequence.  
 
 
3.6.3.4 Putative Transcription factor domain 
DNA between positions 502 and 1121 of Rv0386 was amplified by PCR (Ta= 54°C, 5 % 
DMSO, 30 cycles) with primers NHis/TF/Rv0386forw and myco0386/C-Crev (Figure 
3.7). The holoenzyme in pQE30 was used as a template. The primers introduced 5’-
BamHI and 3’-BglII restriction sites. PCR products were purified from agarose gel, 
blunted and phosphorylated. DNA of pBluescript was blunt digested with EcoRV and 
dephosphorylated. Insert and vector were ligated and transformed in XL-1 blue cells. 
Recombinant DNA of a correct clone was digested with BamHI and Bgl II and a 631 bp 
fragment was purified. The holoenzyme construct in pQE30 was digested with BamHI 
and BglII, dephosphorylated and used as a vector. With this step the fragment between 
positions –6 and 1121 of the holoenzyme sequence was removed and replaced with the 
631 bp fragment. The DNA of the obtained clones was analyzed by digestion with 
BamHI, Bgl II and HindIII (631, 2142 and 3460 bp fragments were expected). A correct 
clone was chosen for transformation into BL21 and BL21-STAR cells. 
 
 
 
 
 
 
1
BamHI 
Start ClaI ClaI Stop 
HindIII 
502 521 1205 1518 -6 3258 3261 
BamHI HindIII 
pQE30 
pQE30 
primer sense primer antisense 
AAA-ATPase
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Fig. 3.7: Cloning steps for the transcription factor domain of Rv0386 into vector pQE30. 
Numbering is according to the holoenzyme.  
 
 
3.6.3.5 Putative DNA-binding domain 
Amplification of fragment 2980 to 3261 was performed with primers 
NHis/DBDom/Rv0386 and myco0386/S-Hrev (Ta= 64°C, 5 % DMSO, 30 cycles). 5’-
BamHI and 3’-HindIII sites were introduced (Figure 3.8). Fragment V used for cloning 
the holoenzyme (SfiI2476 to HindIII3261) was used as a template. The product was 
isolated, purified and digested with BamHI and HindIII. pQE30 was cut similarly and 
dephosphorylated. Insert and vector were ligated and transformed in XL-1 blue cells. 
Recombinant DNA of the clones was sequenced and a correct one was used for 
transformation into BL21 cells. 
 
 
 
 
BamHI HindIII 
-6 3261
pQE30 
BamHI HindIII 
-6 3261
pQE30 
Start Start Stop 
502 1121 1 3258
primer  
sense 
primer  
antisense 
1 1121 
Stop 
3258
BglII BamHI 
BglII BglII 
Digestion BamHI/BglII 
BglII BamHI 
pQE30 
HindIII 
Stop 
__ 
BamHI BglII 
Transcription factor domain 
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Fig. 3.8: Cloning steps of the DNA-binding domain of Rv0386 in pQE30. Numbering 
corresponds to the nucleotide positions in the holoenzyme. 
 
 
3.6.3.6 Site-directed mutagenesis 
Mutation primers were used to introduce the desired changes. See appendix for DNA 
sequence with outlined restriction and mutation sites. 
 
3.6.3.6.1 Q57K and Q57A mutants 
In table 3.7 and figure 3.9 the primers and the strategy are delineated. PCR conditions: 
Ta= 60°C, 5 % DMSO, 40 cycles. The template was the construct of the AC domain in 
pQE30 vector. 
 
Mutant Fragment Primers Length of the PCR 
product (bp) 
1 myco0386/B-C-Hforw myco0386/Q57Krev 180 Q57K 
2 myco0386/Q57Kforw myco0386/B-C-Hrev 390 
1 myco0386/B-C-Hforw myco0386/Q57Arev 180 Q57A 
2 myco0386/Q57Aforw myco0386/B-C-Hrev 390 
 
Table 3.7: Primers used for the cloning of Q57K and Q57A  . 
 
∆EcoRV ∆EcoRV
SfiI HindIII 
Stop 
pBluescript 
2476 3261 3258 2980 
pQE30 
BamHI HindIII 
2980 3261 
sense primer antisense primer 
DNA-binding domain 
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Fragments 1 and 2 were purified, blunted, ligated with dephosphorylated pBluescript 
vector ∆EcoRV and transformed into XL-1 blue cells. Clones were verified through 
sequencing. Fragment 1 in pBluescript was digested with StuI and HindIII and 
dephosphorylated to serve as a vector. Fragment 2 was obtained by a StuI/HindIII 
digest. Vector and insert were ligated and transformed in XL-1 blue cells. Clones were 
controlled by a BamHI/HindIII digestion. Then the mutated catalytic domain was cut out 
of pBluescript, inserted in a dephosphorylated pQE30 vector ∆(BamHI/HindIII) and 
transformed into BL21 cells. 
 
  
 
 
 
 
   
 
 
  Fig. 3.9: Site-directed mutagenesis for cloning Q57K and Q57A in pQE30. A silent 
restriction site for StuI and the corresponding nucleotide changes for each mutation were 
inserted by PCR. Numbering is according to the holoenzyme. 
 
3.6.3.6.2 N106D and N106A mutants 
In table 3.8 and figure 3.10 the primers and the strategy are delineated. PCR conditions: 
Ta= 60°C, 5 % DMSO, 40 cycles. Template was the AC domain in pQE30. 
 
Mutant Fragment Primers Length of the PCR 
product (BP) 
1 myco0386/B-C-Hforw myco0386/N106Drev 339 N106D 
2 myco0386/N106Dforw myco0386/B-C-Hrev 234 
1 myco0386/B-C-Hforw myco0386/N106Arev 339 N106A 
2 myco0386/N106Aforw myco0386/B-C-Hrev 234 
 
Table 3.8: Primers used for cloning of N106D and N106A. 
 
AGGCCT XYZ 
BamHI StuI ClaI Stop 
HindIII 
-6 1 159 169 171 521 
Start 
pQE30 
534 
169CAG171 :  Q57 
169AAG171 :  Q57K 
169GCG171 :  Q57A 
Fragment 1 Fragment 2 
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Each fragment was purified, blunted, phosphorylated, ligated with a blunt 
dephosphorylated pBluescript ∆ApaI and transformed in XL-1 blue cells. Clones were 
verified through sequencing. Correct clones were digested with BamHI/ApaI and 
ApaI/HindIII to cut out fragments 1 and 2, respectively. Both fragments were ligated with 
dephosphorylated pQE30 ∆(BamHI/HindIII) and transformed in XL-1 cells. Clones were 
controlled by digestion with BamHI and HindIII and a correct one was transformed in 
BL21 cells. 
 
 
 
 
 
 
 
 
Fig. 3.10: Cloning of N106A and N106D in pQE30. Silent restriction site for ApaI and 
nucleotide changes for each mutant were inserted by PCR. Numbering is according to 
the holoenzyme. 
 
3.6.3.6.3 Q57K/N106D mutant  
Two PCR products were amplified with primers myco0386/B-C-Hforw and 
myco0386/QKNDrev for fragment 1, and myco0386/QKNDforw and myco0386/B-C-Hrev 
for fragment 2. PCR conditions: Ta= 56°C, 5 % DMSO and 20 cycles. Template for 
fragment 1 (258 bp) was the mutant Q57K in pQE30 vector and for fragment 2 (312 bp) 
mutant N106D in pQE30. 5’-BamHI and 3’-BglII sites for fragment 1 and 5’-BglII and 3’-
HindIII sites for fragment 2 were inserted. PCR products were purified, blunted, 
phosphorylated and ligated to a blunt dephosphorylated pBluescript SK(-) vector 
∆EcoRV. DNA of the clones was sequenced. Fragment 1 was cut from pBluescript with 
BamHI/BglII and fragment 2 with BglII/HindIII. Both fragments were simultaneously 
ligated into a dephosphorylated pQE30 vector ∆(BamHI/HindIII). The final construct was 
controlled by BamHI/Bgl II/HindIII digestion and transformed into BL21 cells (figure 
3.11).  
 
XYZ GGGCCC 
BamHI 
Start 
ApaI 
ClaI 
HindIII 
Stop 
-6 1 316 318 329 521 
pQE30 
534 
316AAC318 :  N106 
316GAC318 :  N106D 
316GCC318 :  N106A 
Fragment 1 
Fragment 2 
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Fig. 3.11: Cloning of Q57K/N106D in pQE30. Silent restriction site for BglII was inserted 
by PCR. Numbering is according to the holoenzyme. 
 
3.6.3.6.4 N106S mutant 
 
Mutant Fragment Primers Length of the PCR product (bp) 
1 myco0386/B-C-Hforw myco0386/N106Srev 342 N106S 
2 myco0386/N106Sforw myco0386/B-C-Hrev 228 
 
Table 3.9: Primers used for cloning of mutant N106S.  
 
PCR conditions: Ta= 58°C for fragment 1 and 54°C for fragment 2, 5 % DMSO and 30 
cycles. The AC domain in pQE30 was the template. Cloning strategy was similar as for 
mutant D300S of Rv1625c (see above). Products were purified, digested with 
BamHI/NdeI (fragment 1) or NdeI/HindIII (fragment 2), desalted and ligated into 
dephosphorylated pQE30 ∆(BamHI/HindIII) in a triple ligation. Recombinants were 
isolated from XL-1 blue cells and introduced into BL21 for expression with prior 
sequence confirmation.  
 
 
Q57K mutant 
HindIII 
Stop 
534 252 
BamHI 
Start 
pQE30 
-6 1 
primer 
sense 
primer 
antisense 
HindIII 
Stop 
534 
N106D mutant 
primer 
antisense 
BamHI 
Start 
pQE30 
-6 1 
primer 
sense 
220 
BamHI 
Start 
pQE30
-6 1 
HindIII 
BglII Stop 
534 234 
Q57K/N106D mutant 
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3.6.3.7 N-terminally elongated AC domain (with N-terminal His-tag) 
By comparison of Rv0386 with its homologue MT0399 from Mycobacterium tuberculosis 
CDC1551 (Fleischmann et al., 2002), an almost total identity was observed with the 
exception of 7 extra N-terminal amino acids in MT0399 (MRLSGAG). These amino acids 
are just ahead of the START codon of Rv0386. To determine the potential influence of 
this addition they were inserted through PCR. The original ‘gtg’ START of MT0399 was 
changed to ‘atg’.   
Primers CDC1551ac-forw and myco0386/B-C-Hrev were used. PCR conditions: Ta= 
58°C, 5% DMSO and 30 cycles. The AC domain in pQE30 was the template. The 564 
bp PCR product obtained was purified from agarose gel, digested with BamHI and 
HindIII and directly ligated with suitably prepared pQE30 vector. After transformation into 
XL-1 blue cells, it was controlled by sequencing. Finally, it was transformed into BL21 
cells for expression.  
 
3.6.3.8 N-terminally elongated AC domain (with C-terminal His-tag) 
The PCR product was amplified with primers CDC1551ac-forw and myco0386/cata/C-
His. PCR conditions: Ta= 58°C, 5 % DMSO, 30 cycles and AC domain in pQE30 as 
template. The product (564 bp) was purified, digested with BamHI and BglII and ligated 
into a dephosphorylated pQE60 vector ∆(BamHI/BglII). After transformation into XL-1 
blue cells clones were sequenced. Finally, it was transformed into BL21 cells for 
expression. 
 
3.6.3.9 C-terminally His-tagged AC catalytic domain of Rv0386 
With primers myco0386/B-C-Hforw and myco0386/cata/C-His the AC catalytic domain 
was amplified. PCR conditions: Ta= 58°C, 5% DMSO and 30 cycles. The AC domain in 
pQE30 was the template. The 543 bp PCR product was purified from agarose gel, 
digested with BamHI and BglII and directly ligated into suitably prepared pQE60. After 
transformation into XL-1 blue cells, it was controlled by sequencing. Finally, it was 
transformed into BL21 cells for expression. 
 
3.6.3.10 AC domain mutant R7G 
This mutant was unintentionally constructed due to a wrong nucleotide in the primer 
myco0386/B-C-Hforw. This changed nucleotide introduced a mutation by changing a C 
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in the codon CGG (codes for arginine) into a G forming the wrong codon GGG (codes 
for glycine). This mutant was cloned presuming that it was the catalytic domain wild type 
(see above). 
 
 
3.7 Protein chemistry methods 
3.7.1 Expression of proteins in E. coli 
Most proteins were expressed in E. coli BL21 (DE3) [pREP4]. Rv0386 holoenzyme and 
its transcription factor as well as its ATPase domain were also expressed in E. coli BL21 
STAR (DE3) [pREP4]. In E. coli Rosetta [pREP4] cells only the holoenzyme Rv0386 was 
expressed. 
 
3.7.1.1 Pre-cultures 
For expression in BL21 [pREP4], BL21 STAR [pREP4] and Rosetta [pREP4] cells, 5 ml 
of LB-broth with 50 µg/ml kanamycin and 100 µg/ml ampicillin were inoculated. With a 
sterile tip a small amount of the frozen glycerol stock culture was inoculated and 
incubated O/N at 37 °C (210-230 rpm).  
 
3.7.1.2 Expression 
All mammalian, protozoan and mycobacterial constructs were expressed in E. coli BL21 
[pREP4] from frozen stocks. Mycobacterial Rv0386 constructs were also expressed in E. 
coli BL21 STAR and ROSETTA. 5 ml pre-culture were inoculated and grown in 200 ml 
LB broth containing 100 µg/ml ampicillin and 50 µg/ml kanamycin (30°C, 220 rpm) to 
A600 0.4-0.6 (approx. after 1.5-3 h). Expression of the mammalian, protozoan and 
Rv1625c mycobacterial proteins was induced with 30 µM IPTG and Rv0386 proteins 
with 60 µM IPTG (22-25°C for BL21 or 12-16°C for STAR and ROSETTA, 220 rpm). 
Cells were harvested after 3-5 h for constructs in BL21 cells or after 16-18 h for 
constructs in BL21 STAR and ROSETTA cells (10 min, 5000 x g, 4°C). Supernatant was 
discarded and the pellet washed with 30 ml Pellet Wash Buffer and centrifuged again 
(6000 x g, 15-20 min, 4 °C). Cell pellets were then stored at –80°C.  
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3.7.2 Purification of soluble proteins from E. coli 
Frozen -80°C pellets were thawed on ice (10 min), suspended in 25 ml of Cell Lysis 
buffer and sonificated for lysis (microtip setting 4, on ice, 3 x 10 s). These suspensions 
were called cell homogenate. For mammalian ACs lysis buffer contained protease 
inhibitors (76 nM aprotinin, 62.5 µM TPCK, 59.6 µM TLCK, 126.3 µM PMSF and 0.16 
µM lima bean trypsin inhibitor).The cell homogenate was centrifuged (16,000 x g, 30 
min, 4°C). Occasionally, lysozyme (0.2 mg/ml, on ice, 30 min) and DNAse (0.02 mg/ml 
with 5 mM MgCl2, on ice, 30 min) were added prior to centrifugation. The supernatant 
and the pellet were separately tested for AC activity.  
Supernatants were mixed with 250 mM NaCl and 15 mM imidazole. Then 250 µl of pre-
equilibrated Ni2+-NTA-Agarose were added (rocking for at least 1 h on ice). Samples 
were centrifuged (5 min, 2500 x g). Supernatant was transferred into a 10 ml syringe 
with a Wizard mini-column attached. The solution was let through and the resin was then 
washed with 3 ml of each of Washing buffers A, B and C. Elution was performed with 
400 µl Elution Buffer.  
 
3.7.3 Purification of insoluble proteins from E. coli 
Frozen -80°C pellets were thawed on ice (10 min), suspended in 25 ml cell lysis buffer 
containing Complete® protease inhibitors (1/2 tablet) and passed twice through the 
french press for cell lysis (20,000 psi). The homogenate was centrifuged (4°C, 3000 x g, 
30 min). The pellet from this step was suspended in 500 µl lysis buffer to be analysed 
later. The supernatant was centrifuged (4°C, 100,000 x g, 1 h). Supernatant was 
discarded and the pellet was suspended in 25 ml of membrane suspension buffer 
containing 2 % CHAPS (or other detergent) and incubated on ice for 1 h with gentle 
agitation. The membrane suspension was centrifuged (4°C, 100,000 x g, 1 h). The pellet 
was suspended in 500 µl of membrane suspension buffer. Supernatant was mixed with 
15 mM imidazole pH 8.0 and incubated O/N with gentle agitation with 200 µl Ni-NTA-
agarose (pre-equilibrated with 2 % CHAPS). Ni-NTA bound protein was washed and 
eluted. Two washing steps were made, the first with 6 ml of High Saline Buffer and the 
second one with 6 ml of Low Saline Buffer. Finally, the protein was eluted with 400 µl of 
Elution Buffer. Each washing fraction was stored and analysed later.  
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3.7.4    Protein concentration 
3.7.4.1 Bio-Rad protein determination 
1 mg/ml of BSA was used as a standard. 1-10 µg of protein were pipetted to 800 µl 
distilled water and mixed. 200 µl of Dye Reagent Concentrate (5X) were added and 
mixed. Samples were measured at OD595. The presence of ≤ 2% of the detergent 
CHAPS did not interfere.  
 
3.7.4.2 Dialysis 
To eliminate imidazole from the eluate and change buffer samples were dialyzed 
(VISKING Dialysis Tubing, MWCO12000-14000). The DNA-binding domain of Rv0386 
(∼12000 Da) was dialyzed with a SPECTRAPOR membrane (MWCO 3500). Samples 
were dialyzed at least for 3 hours at 4°C. 
 
3.7.4.3 Sample Concentration 
To produce antibodies against the Rv0386 DNA-binding domain (made by BioGenes) 
and to carry out the crystallization experiments with the Rv0386 AC domain, 
concentration of proteins was required. Samples were centrifuged until the desirable 
protein concentration was achieved (4 °C, 2500-3500 x g, 2-4 h, CENTRICON 
Centrifugal Filter Devices MWCO 10000). For crystallization, samples were centrifuged 
with the Nanosep 10K Omega centrifugal devices MWCO 10000 (14,000 x g, 4°C, 10-30 
min). 
 
3.7.5 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
An electrophoresis apparatus from HOEFER was used. In Tables 3.10 a and b the 
recipe for polyacrylamide gels and the effective separation range of proteins are shown: 
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Resolving Gel (pH 8.8) 7.5 % 10 % 12.5 % 15 % 
Resolving Gel buffer 3 ml 3 ml 3 ml 3 ml 
H2O 6 ml 5 ml 4 ml 3 ml 
Acrylamide/Bisacrylamide 37.5 : 1 3 ml 4 ml 5 ml 6 ml 
TEMED 10 µl 10 µl 10 µl 10 µl 
APS 10 % 80 µl 80 µl 80 µl 80 µl 
Effective Separation Range (kDa) 45 - 200 20 - 200 14 - 70 5 - 70 
 
 
 
 
Stacking Gel (pH 6.8) 4 % 
Stacking Gel buffer 1 ml 
H2O 2.4 ml 
Acrylamide / Bisacrylamide 37.5 : 1 0.6 ml 
TEMED 10 µl 
APS 10 % 40 µl 
 
Table 3.10: (a) Components required for different concentrations (%) of resolving gels for 
SDS-PAGE; (b) components of the stacking gel. 
 
Soluble protein samples were mixed with 1X sample buffer and pellets and cell 
homogenates with 4X sample buffer. Usually, they were heated at 95 °C for 5 minutes 
before loading. Gels were run at a constant current: 20 mA, 200 V for 50-65 minutes. 
Gels were stained with Coomassie Blue for 30 min with gentle agitation. After destaining 
0.1 to 0.5 µg protein/band was detectable.  
Usually, SDS-PAGE was performed simultaneously with pellets and supernatants of E. 
coli containing an empty vector (pQE30) as a control. Protein Marker components (10 µl 
contained 1 µg of each protein) are listed below. 
 
 
a 
b 
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Protein Marker MW (kDa) peqGold Marker MW (kDa) 
Cytochrom C 12.5 Lysozyme 14.4 
Trypsin Inhibitor 20.1 β-Lactoglobulin 18.4 
Chymotrypsinogen A 25 RE Bsp981 25 
GAPDH 36 Lactate dehydrogenase 35 
Ovalbumin 45 Ovalbumin 45 
BSA 66 Bovine Serum Albumin 66 
  β-Galactosidase 116 
 
3.7.6 Anion exchange chromatography 
The holoenzyme Rv0386 and its catalytic domain were additionally purified with anion 
exchange chromatography with an ÄKTA FPLC at 4 °C. All buffers were made with 
MilliQ water, filtrated and degassed. Protein was measured at 280 nm. All fractions were 
tested for AC activity. About 1.4 mg (800 µl) catalytic domain protein or 0.3 mg (800 µl) 
holoenzyme diluted to 10 ml with respective “A” buffers (see Table 3.11), were applied 
through a 10 ml loop to a pre-equilibrated column (Mono Q).  
 
Protein pI Buffer A Buffer B 
Catalytic domain Rv0386 6.6 
50 mM Tris pH 8.0 
2 mM β-mercapto ethanol 
10 % glycerol 
Buffer A + 1 M NaCl 
Holoenzyme Rv0386 5.8 
50 mM Tris pH 7.0 
10 mM β-mercapto ethanol 
2 mM MgCl2 
20 % Glycerol 
 1 M NaCl 
 
Table 3.11: Compositions of buffer A and buffer B used for anion exchange 
chromatography of the catalytic domain and the holoenzyme Rv0386. pI= isoelectrical 
point.   
 
Columns were developed with a stepwise NaCl gradient. Flow rate was 1 ml/min. Elution 
began at 0% NaCl (only buffer A) for 3 fractions of 5 ml. After that fractions were 1 ml. 
After 10 fractions the NaCl concentration was increased (100, 200, 300, 400, 500 mM 
and 1 M NaCl steps). 70 fractions were collected.  
 
3.7.7 Cyclase enzyme tests 
They were carried out according to Salomon et al., 1974, and Steinlen, 1988.  
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3.7.7.1 Adenylyl cyclase test 
A standard test contained in 100 µl 75 µM [α-32P]-ATP (25 kBq, 30 °C, 10 min). 40 µl of 
protein sample including reagents like forskolin, inhibitors or detergents was mixed with 
50 µl of AC Test Cocktail. The assay was started with 10 µl of AC-Start solution. Final 
concentrations were: 50 mM buffer (Tris-HCl pH 7.5 or MOPS pH 7.5), 22 % glycerol, 2-
5 mM MnCl2 or 5-10 mM MgCl2, 2 mM [2,8-3H]-cAMP (100 Bq), 3 mM creatine 
phosphate and 1 U creatine kinase (the latter as an ATP-regenerating system when 
testing impure protein samples). [2,8-3H]-cAMP was used as an internal standard.  
The reaction was stopped by addition of 150 µl stop buffer. Water was added to 1 ml 
and the mixture was applied to a Dowex column (9 x 1 cm glass column with 1.2 g 
Dowex 50). After washing with 3 ml water the samples were eluted with 5 ml water on 
Al2O3 columns (10 x 0.5 cm plastic column with 1 g active, neutral Al2O3 90). Samples 
were immediately eluted with 4.5 mL 0.1 M Tris-HCl pH 7.5, mixed with 4 ml Ultima Gold 
XR Scintillator Solution and counted. Dowex columns were regenerated with 1 x 5 ml 
HCl (2N), 1 x 10 ml and 1 x 5 ml water, and Al2O3 columns with 2 x 5 ml Tris-HCl pH 7.5 
(0.1 M). Specific activity (A = pmol·mg-1·min-1) was calculated with the following formula:  
 
 
                Substrate (µM) x 100 µl                                  1000 
A =                                                           x     
                           Time (min)                                        Protein (µg) 
 
                           cpm [3H] total                          cpm [32P] sample – cpm [32P] blanc  
       x                                                        x   
            cpm [3H] sample – 3% [32P] sample                           cpm [32P] total 
 
 
The subtraction of 3 % of the phosphorous counts from the tritium value for each sample 
was made because of spillover of 32P into the tritium channel. For AC reconstitution 
assays where proteins were mixed at different concentrations the lowest one was used 
for calculations. Activities lower than double background (in cpm) were considered zero.  
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3.7.7.2 Guanylyl cyclase test 
Assays were carried out simultaneously with an AC test for comparison. The same 
protocol used for AC tests was used with [8-3H]-cGMP (100 Bq) contained in the GC 
Test Cocktail and 75 µM [α-32P]-GTP (25 kBq) as a substrate. The Dowex columns for 
GC test contained 4 g of this material, and the Al2O3 columns 0.8 g. The elution of the 
Dowex columns was with 2 ml water (after a washing step with 3 ml water) and of the 
Al2O3 columns with 4 ml 0.1 M Tris-HCl pH 7.5. Regeneration of the Dowex columns 
was with 1 x 5 ml 2 N HCl, 1 x 10 ml water and 1 x 5 ml with water, the Al2O3 columns 
were washed with 2 x 4 ml 0.1 M Tris-HCl pH 7.5. The calculation of the enzymatic 
activity was carried out as above.  
 
3.7.8 Production of specific antibodies 
Production of antibodies against the AC domain (KD0386) and the DNA-binding domain 
(DB0386) of Rv0386 was done by BioGenes (Berlin) using purified proteins dialyzed 
against 50 mM phosphate buffer (10 % glycerol, filtered). Specific IgG anti-KD0386 were 
delivered in Tris-Glycin-Buffer pH 7.5 containing 0.02% Thimerosal. Specific IgG anti 
DB0386 were delivered in Tris-Glycin-Buffer pH 7.5, 250 mM NaCl and 0.02% 
Thimerosal. The sensitivity and specificity of the antibodies were tested through Dot-Blot 
and Western-Blot, respectively. 
 
3.7.8.1 Dot Blot 
This was used to determine the optimal concentrations for subsequent binding assays. A 
set of serial dilutions of the purified protein (concentrations of 0.1 ng to 1 µg pro spot) 
were applied to a Protran nitrocellulose membrane.  The membrane was then incubated 
with different dilutions in M-TBS of the antibodies and developed as described for 
Western blotting. 
 
3.7.8.2 Western Blot 
Samples were separated by SDS-PAGE. The Semi-Dry-Electrotransfer method of 
Towbin et al. (1979) was used. At the end of the electrophoresis the gel was removed 
and attached to a PVDF membrane, which were soaked for 10 min in methanol, 10 min 
in water and 10 min in Towbin buffer. Gel and membrane were sandwiched between 
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pieces of Whatman 3 MM paper soaked in Towbin buffer. The sandwich was then 
placed between graphite plate electrodes with the transfer membrane on the anodic 
side. A current of 2-3 mA/cm2 of gel (20 V) was applied for 2-3 hours. The gel was 
stained with Coomassie Brilliant Blue. The transfer membrane was stained with 
Ponceau S for no longer than 5 minutes. When protein was visible the membrane was 
destained by washing with deionized water and the positions of proteins were marked 
with a pencil. The membrane was then incubated for 1 hour at RT in M-TBS blocking 
solution. The membrane was rinsed twice for 5 min with TBS-T buffer and then 
incubated for 1 h with the primary antibody solution (mouse monoclonal RGS⋅His 
antibodies, antibodies anti-KD0386 or antibodies anti-DB0386, in M-TBS diluted). The 
primary antibody was then discarded and the membrane rinsed once for 15 minutes and 
twice for 5 minutes with TBS-T. The membrane was incubated immediately with the 
secondary antibody solution (goat anti-mouse or goat anti-rabbit horseradish peroxidase 
conjugated antibodies, in M-TBS diluted). After 1 hour the secondary antibody was 
discarded and the membrane washed with TBS-T (see above). For chemiluminiscence a 
mixture of 2 ml solution A and 50 µl solution B of the ECL-Plus Western Blotting 
Detection Kit was prepared. The mixture was uniformly distributed over the whole 
surface of the membrane. After a 5 min reaction a film exposure with Hyperfilm-ECL was 
taken. Exposure periods varied from 10 seconds to 10 minutes.   
 
3.7.9 Crystallization 
Within the scope of this study conditions for crystallization and first attempts to optimize 
the obtained crystals of the Rv0386 catalytic domain were made. The hanging drop 
vapor diffusion technique (Figure 3.12) and the 24 well plates of Hampton Research 
were used. 
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Fig. 3.12: Scheme of the hanging drop method where drops are prepared on a 
siliconized microscope glass cover slip by mixing the protein sample and the precipitant 
solution. The cover slip is placed over a small well (reservoir) containing the precipitating 
solution. The drop and the liquid reservoir of reagent are placed in vapor equilibration.  
 
The reagent kits Crystal Screen, Crystal Screen 2 and Crystal Screen Lite of Hampton 
Research were used. For crystallization of Rv0386(1-175) with N-terminal His-tag the set 
of Crystal Screen buffers 4-6, 8-20, 22, 25, 27, 29-41, 43, 45, and 47-50 were used. The 
buffers 1-3, 6-11, 14, 16, 19, 22, 23, 28-30 and 39-46 of the set Crystal Screen 2 were 
also used. Finally the buffers 4-10, 13, 14, 16, 17, 19, 22, 23, 25-29, 31, 36, 41, 43, and 
47-50 of the set Crystal Screen Lite were utilized. In the case of Rv0386(1-175) with C-
terminal His-tag, all buffers of the three screening sets were examined with the protein 
dialyzed after Ni-NTA purification in glycerol dialysis buffer. All further optimization steps 
were performed only with the protein Rv0386(1-175) with N-terminal His-tag. 
The crystallization variables that were examined for optimization were: glycerol, buffer 
system in the sample solution and its pH, protein concentration, composition of the 
precipitant solution, temperature of incubation, proportions of the components in the 
drop mixture, protein sample purification steps and addition of substrates, inhibitors, 
cofactors and other substances. 
Protein sample solutions were dialyzed against glycerol dialysis buffer (10 and 20% 
glycerol) containing different buffer systems like MOPS, Tris-HCl and HEPES with pH’s 
7.5 and 8.5 and then stored at –20°C, 15°C, 4°C and RT. All these conditions were 
examined for stability tests by testing the AC activity. Conditions where the protein 
showed no aggregation and less lost of AC activity were examined in the crystallization 
screens. Protein samples were centrifuged by 14,000 rpm at 4°C for 30 min before 
setting the crystallization experiments to remove aggregates and amorphous debris. For 
the first screenings 1 µl of protein sample (protein concentration between 5 and 11 
µg/µl) was mixed with 1 µl of each screening buffer (drop mixture 1:1). In the reagent 
reservoir 0.5 ml of the precipitant solution were mixed with glycerol until obtaining a 
  50 
concentration of about 2-5% more than the glycerol present in the drop mixture. The 24 
well plates were incubated at 12 and 16°C and examined under a polarization 
microscope. 
After obtaining the first crystals the components of the successful precipitant solutions 
were varied to optimize form, amount and size of the crystals. The protein concentration 
of the sample was also varied (increased upto 30 µg/µl) and the composition of the drop 
mixture (proportions 2:1, 1:2, 3:1, 1:3 of protein:precipitant were examined). Ni-NTA 
purified protein further purified with anion exchange chromatography was also examined 
for crystal formation. Additions of Mn2+ or Mg2+, nucleotides like ATP (substrate), GTP 
(substrate) or CTP, P-site inhibitors, cGMP and cAMP analogs were examined for 
optimization.  
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4 Results  
 
4.1 Chimeras of M. tuberculosis Rv1625c mutants with 
mammalian adenylyl and Paramecium guanylyl cyclases   
4.1.1 Introductory remarks 
Biochemical and mutational studies showed that the mycobacterial AC Rv1625c forms a 
homodimer where two identical and equivalent catalytic sites are generated (Guo et al., 
2001). The possibility to make reconstitutions between mutated mycobacterial and 
mammalian cytosolic monomers as well as with Paramecium GC (ParaGC) monomers 
was examined (Fig. 4.1 and 4.2). From M. tuberculosis the mutants Rv1625c204-
443R376A and D300A from Dr. Guo and Rv1625c204-443N372A, N372T and D300S 
(generated here) were used. The mammalian cytosolic domains, the C2 region of 
ParaGC and its triple mutant ParaGC-C2 KWQ were from Hoffmann, 1999 (Table 4.1).  
 
Name Domain (function) Amino acid position Origin 
AC I C1 (C1) 304-519 Bovine 
AC II C2 (C2) 848-1114 Rat 
AC V C1 (C1) 403-647 Rabbit 
AC VII C1 (C1) 220-486 Bovine 
AC IX 
C1 (C1) 
C2 (C2) 
323-570 
1012-1355 
Mouse 
Rv1625c wild type 
D300A* 
D300S* 
R376A* 
N372A* 
N372T* 
C (C1+C2) 
C (C2) 
C (C2) 
C (C1) 
C (C1) 
C (C1) 
204-443 
 
M. tuberculosis 
ParaGC-C2 
ParaGC-C2-KWQ** 
C2 (C1) 
C2 (C1) 
2178-2415 Paramecium 
*Point mutants of M. tuberculosis Rv1625c AC domain. 
* *Triple mutant 2345LVR2347 to 2345KWQ2347 of Paramecium tetraurelia guanylyl cyclase. 
 
Table 4.1: Cytoplasmic domains used in this work (Hoffmann T.R., 1999; Guo et al., 2001). 
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Rv1625c    231 :IAERLKEPE----------RNIIADKYDEASVLFADIVGFTERASSTAPA 
IC1_BOV    304 :-----------------------------VSILFADIVGFTGLASQCTAQ 
VC1_RABBIT 451 :INAKQEDM---------MFHKIYIQKHDNVSILFADIEGFTSLASQCTAQ 
VIIC1_BOV  249 :IIERLKERGDRRYLPDNNFHNLYVKRHQNVSILYADIVGFTRLASDCSPK 
IXC1_MOU   368 :--NRKKKSSIQK--APIAFRPFKMQQIEEVSILFADIVGFTKMSANKSAH 
ParaGC-C2 2207 :---------LEEFFRPNEEKRVLREQADEVTLLFADIAGFTEYSSKVQPE 
                                                                   
                                                                   
                                                                   
Rv1625c    271 :DLVRFLDRLYSAFDELVDQHGLEKIKVSGDSYMVVS------GVPRPRPD 
IC1_BOV    325 :ELVKLLNELFGKFDELATENHCRRIKILGDCYYCVS------GLTQPKTD 
VC1_RABBIT 492 :ELVMTLNELFARFDKLAAENHCLRIKILGDCYYCVS------GLPEARAD 
VIIC1_BOV  299 :ELVVVLNELFGKFDQIAKANECMRIKILGDCYYCVS------GLPVSLPN 
IXC1_MOU   414 :ALVGLLNDLFGRFDRLCEQTKCEKISTLGDCYYCVA------GCPEPRAD 
ParaGC-C2 2248 :QVVNMLRNLFTEFDKNSLLHNVFKLYTIGDCYVVMGMVDYGKGIQRNPSQ 
                                                                   
                                                                   
                                                                   
Rv1625c    315 :HTQALADFALDMTNVAAQLKDPRGNP-VPLRVGLATGPVVAGVVGSRRFF 
IC1_BOV    369 :HAHCCVEMGLDMIDTITSVAEATEVD-LNMRVGLHTGRVLCGVLGLRKWQ 
VC1_RABBIT 536 :HAHCCVEMGMDMIEAISLVREVTGVN-VNMRVGIHSGRVHCGVLGLRKWQ 
VIIC1_BOV  343 :HARNCVKMGLDMCEAIKQVREATGVD-ISMRVGIHSGNVLCGVIGLRKWQ 
IXC1_MOU   458 :HAYCCIEMGLGMIKAIEQFCQEKKEM-VNMRVGVHTGTVLCGILGMRRFK 
ParaGC-C2 2298 :EAVNVVRMGFAMIDAIRRVRAHINHPTLDMRIGVHTGSIIGGVLGTELVR 
                                                                   
                                                                   
                                                                   
Rv1625c    364 :YDVWGDAVNVASRMESTDSVGQIQVPDEVYERLKDDFVLRERGHINVK-G 
IC1_BOV    418 :YDVWSNDVTLANVMEAAGLPGKVHITKTTLACLNGDYEV-EPGHGHER-- 
VC1_RABBIT 585 :FDVWSNDVTLANHMEAGGKAGRIHITKATLNYLNGDYEV-EPGCGGER-- 
VIIC1_BOV  392 :YDVWSHDVSLANRMEAAGVPGRVHITEATLKHLDKAYEV-EDGHGQQR-- 
IXC1_MOU   507 :FDVWSNDVNLANLMEQLGVAGKVHISEATAKYLDDRYEM-EDGRVIERLG 
ParaGC-C2 2348 :YDIYGPDVLIANKMESKGAKGFVQVSQETKDIIEREF------------- 
                                                                   
                                                                   
                                                                   
  
 
 
 
 
 
 
 
 
 
 
 
Me 
Me Pu 
Pu Ts Ts 
Fsk 
a
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Rv1625c    202 :-------LRDTA--RAEAVMEAEHDRSEALLANMLPASIAERLKEPE--- 
IIC2_RAT   825 :YYCRLDFLWKNKFKKEREEIETMENLNRVLLENVLPAHVAEHFLARSLKN 
IXC2_MOU  1012 :VEADLH----------RTKIQSMRDQADWLLRNIIPYHVAEQ-----LKV 
ParaGC-C1 1589 :LEV---FLGRINMNKENQIMSD-------ILSILLPQFIRDRINKAG--- 
                                                                   
                                                                   
                                                                   
Rv1625c    240 :RNIIADKYDEASVLFADIVGF----TERASSTAPADLVRFLDRLYSAFDE 
IIC2_RAT   875 :EELYHQSYDCVCVMFASIPDFKEFYTESDVNKEGLECLRLLNEIIADFDD 
IXC2_MOU  1047 :SQTYSKNHDSGGVIFASIVNFSEFYEEN--YEGGKECYRVLNELIGDFDE 
ParaGC-C1 1626 :QYDIQEDQGMVAVLFCDIIDFDQL-----IKNEQSNVVDILDKLFRRFD- 
                                                                   
                                                                   
                                                                   
Rv1625c    286 :LVDQ---HGLEKIKVSGDSYMVVSGVPRPRPD-----------HTQALAD 
IIC2_RAT   925 :LLSKPKFSGVEKIKTIGSTYMAATGLSAIPSQEHAQEPERQYMHIGTMVE 
IXC2_MOU  1095 :LLSKPDYNSIEKIKTIGATYMAASGLNTAQCQEGGHPQE----HLRILFE 
ParaGC-C1 1670 :LLCQQ--HEVQKIETVGKTYMAAAGLKIHVSQKSNP--------VNKVIS 
                                                                   
                                                                   
                                                                   
Rv1625c    222 :FALDMTNVAAQLKDPRGN-PVPLRVGLATGPVVAGVVGSRRFFYDVWGDA 
IIC2_RAT   975 :FAYALVGKLDAINKHSFN-DFKLRVGINHGPVIAGVIGAQKPQYDIWGNT 
IXC2_MOU  1141 :FAKEMMRVVDDFNNNMLWFNFKLRVGFNHGPLTAGVIGTTKLLYDIWGDT 
ParaGC-C1 1710 :LALDMKRYVMSNE------TFQIKIGIHYGNVIAGVIGHHKPQFSLIGDT 
                                                                   
                                                                   
                                                                   
Rv1625c    371 :VNVASRMESTDSVGQIQVPDEVYERLKD-DFVLRERGHINVKGKGVM--- 
IIC2_RAT  1024 :VNVASRMDSTGVLDKIQVTEETSLILQTLGYTCTCRGIINVKGKGDLKTY 
IXC2_MOU  1191 :VNIASRMDTTGVECRIQVSEESYRVLSKMGYDFDYRGTVNVKGKGQMKTY 
ParaGC-C1 1754 :INTASRICSTAESWDVAISEQAYRQTNKYELVYVQRDVVA-KGKGKLITY 
                                                                   
 
 
 
Fig 4.1: a) Alignment of the catalytic domain of Rv1625c with the cytosolic C1 loop from 
bovine AC type I (IC1), rabbit AC type V (VC1), bovine type VII (VIIC1), mouse type IX 
(IXC1) and with the cytosolic C2 loop from the Paramecium GC. b) Alignment of the 
catalytic domain of Rv1625c with the cytosolic C2 loops from rat AC type II (IIC2), mouse 
type IX (IXC2) and the C1 domain from the Paramecium GC. Me= metal-cofactor 
binding; Pu= purine-specifying; Ts= transition state stabilizing; Fsk= forskolin-binding. 
Conservation scale: inversed (80-100%), dark gray (60-80%), gray (40-60%). The top bar 
specifies the “arm region” (sequence between a conserved G and the downstream 
adenine-specifying residue in ACs). Boxed residues are the AC-specific dimer-formation 
stabilizing motif (KWQ) and its corresponding motif in Paramecium and Mycobacterium.  
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Fig. 4.2: (A) Graphic representation of the homodimeric catalytic center of the 
mycobacterial Rv1625c AC forming two catalytic sites (adapted from Guo et al., 2001). 
Residues D256, D300 and R376 are outlined; binding of the adenine ring A is indicated 
by dotted lines. (B) Heterodimer with only one catalytic site from the reconstitution of 
Rv1625c mutant monomers D300A with R376A. (C to F) Symbolized heterodimers 
between mycobacterial D300A and the C1 domain from canine type V; mycobacterial 
R376A reconstituted with C2 from rat type II; Paramecium GC C2 domain reconstituted 
with mycobaterial D300A and with the C2 domain from rat typ II. P= phosphate; Me= 
divalent metal cation. 
 
4.1.2 Expression and purification of mammalian, mycobacterial and 
Paramecium ACs 
The cytosolic domain constructs of the mammalian AC’s IC1, VC1, VIIC1, IXC1, IIC2 
and Paramecium GC (Hoffmann, 1999) as well as the mycobacterial Rv1625c cytosolic 
domain mutants D300A and R376A (Guo et al., 2001) were available as glycerol stock in 
BL21 cells. Total amount of protein obtained after purification based on 600 ml culture 
were: 200 µg of IC1, VC1 and IXC1; 300 µg of VIIC1, IIC2 and ParaGC-C2; 500 µg of 
ParaGC-C2 KWQ mutant; and 3 mg of D300A and R376A (Fig. 4.3).  
The mammalian monomers considerably lost activity after 3 days of storage with 50% 
glycerol. An example is the chimera VIIC1/IIC2 which had only a residual specific activity 
of 0.14 nmol⋅mg-1⋅min-1 (about 6%) [Table 4.2]. Therefore assays were carried out within 
hours after elution from the affinity resin. Mycobacterial mutants D300A and R376A were 
stable at –20°C with 50% glycerol. Paramecium ParaGC-C2 and ParaGC-C2-KWQ 
mutant also lost most of their activity after only 4 days of storage with 50% glycerol. The 
chimera ParaGC-C2/D300A retained only 11% from its activity after 4 days (6.5 
nmol⋅mg-1⋅min-1; Table 4.3). 
The three point mutants Rv1625c204-443N372T, N372A and D300S were expressed in 
BL21 cells. After Ni2+-NTA purification (addition of 20 µg/ml DnaseI after sonification was 
omitted) and dialysis with glycerol dialysis buffer (to remove excess imidazole) pure 
proteins were obtained. All mutants were expressed in good quantities, after purification 
about 1 mg protein was purified from 600 ml culture (Fig.  4.4).  
They were stable at -20°C with 20% glycerol. 
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Fig. 4.3: 15% SDS-PAGE analysis of the purified mammalian and Paramecium soluble 
cyclases (Coomassie blue staining). Applied were: about 7-9 µg of IIC2 (29kDa), 
ParaGC-C2 (29kDa) and ParaGC-C2-KWQ (29kDa); 12-16 µg of IXC2 (36kDa), IC1 
(27kDa), VC1 (27kDa), VIIC1 (29kDa) and IXC1 (29kDa). Molecular mass standards are 
on the left. The specific activities indicated below each lane were determined with 75 µM 
ATP at 4 µg IC1 (1.5 µM), 8 µg VC1, ParaGC-C2 and C2-KWQ (3 µM), 7 µg IIC2 and 
IXC2 (2.5 and 2 µM), 11 µg IXC1 (4 µM) and 15 µg VIIC1 (5 µM) protein/assay.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.4 : Purification and activity of all mutants of Mycobacterium Rv1625c204-443 used in 
this work (SDS-PAGE analysis, Coomassie blue staining). The catalytic domain wild type 
is also present on the gel. All proteins were Ni2+-NTA purified and dialyzed. About 1-2 µg 
of each protein were applied. Molecular weight marker is shown on the left. All mutants 
have a molecular weight of about 27 kDa like the wild type. The specific activities 
indicated below each lane were determined with 75 µM ATP (30°C, 10 min) at a protein 
concentration of 0.1 µg/assay (40 nM).  
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4.1.3 Mammalian/Mycobacterium chimeras 
The reconstitution of mammalian/mammalian monomers and of R376A with D300A 
(Guo et al., 2001) were used as a control. In most cases it was not possible to 
reconstitute robustly active heterodimeric catalytic complexes from mammalian 
monomers with the mycobacterial mutants. The low activities obtained were <<1% in 
comparison to that of the mycobacterial R376A/D300A chimera. Mutants D300S and 
N372T (generated to investigate the lack of forskolin stimulation of Rv1625c) in 
conjunction with mammalian monomers could not be stimulated by forskolin. Forskolin 
stimulation and cofactor dependence of chimera R376A/IIC2 were further investigated 
(not shown). Activity of this chimera was not detectable with Mg2+ as  a cofactor and an 
insignificant stimulation with forskolin was observed. 
  
Chimeras µM in the assay (µg) 
specific activity 
nmol ⋅ mg-1 ⋅ min-1  
(cpm) 
specific activity  
with forskolin  
nmol ⋅ mg-1 ⋅ min-1  
(cpm) 
IC1 / IIC2a 1.5 / 2.5 (4 / 7) 0.1 (629) 0.5 (2051) 
VC1 / IIC2c 3 / 2.5 (8 / 7) 0.1 (813) 0.5 (3500) 
VIIC1 / IIC2c 5 / 2.5 (15 / 7) 2.5 (12672) 2.7 (26731) 
IXC1 / IIC2a 3.7 / 3.7 (11 / 11) 0.04 (563) 0.03 (366) 
IC1 / D300A(C2)b 5 / 1.6 (13 / 4) 0.2 (1116) 
VC1 / D300A(C2)b 5 / 1.6 (14 / 4) 0.1 (526) 
VIIC1 / D300A(C2)b 5 / 1.6 (15 / 4) 0.1 (596) 
IXC1 / D300A(C2)b 3.8 / 1.6 (11 / 4) 0.8 (643) 
not done 
not done 
not done 
not done 
IC1 / D300S (C2)b 
VC1 / D300S (C2)b 
3 / 1.6 
3 / 1.6 
(9 / 4) 
(9 / 4) 
not detectable 
not detectable 
not detectable 
not detectable 
R376A(C1) / IIC2a 0.4 / 5 (1 / 14) 9.4 (14432) not done 
N372A (C1) / IIC2b 
N372A (C1) / IXC2b 
0.16 / 2.5 
0.16 / 1.9 
(0.4 / 7) 
(0.4 / 7) 
1.6 
2 
(711) 
(713) 
1.3 
1.6 
(538) 
(604) 
N372T (C1) / IIC2b 
N372T (C1) / IXC2b 
0.16 / 2.5 
0.16 / 1.9 
(0.4 / 7) 
(0.4 / 7) 
0.6 
0.5 
(311) 
(237) 
0.9 
1.2 
(423) 
(390) 
R376A / D300Aa 
(C1) / (C2) 0.4 / 1.6 (1 / 4) 351 (498939) not done 
Basal activities of R376A and N376A were 6.3 and 0.4 nmol⋅mg-1⋅min-1, respectively. Basal activities for 
IC1, VC1, IXC1, VIIC1 were 27, 20, 17 and 10 pmol/mg/min, respectively, and for the other monomers 
zero. DMSO (used for forskolin dilution) controls were not made. 
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Table 4.2: Reconstitution of mammalian/mammalian and mammalian/mycobacterial 
heterodimers. The functional analogies of the mutant mycobacterial catalytic loops to the 
C1 and C2 catalytic domains of mammalian AC’s are in parentheses. The reconstituted 
activity of the mycobacterial chimera R376A/D300A was used as control for the 
mycobacterial monomers. Assay conditions: 75 µM ATP, 30°C, 10 min, 2 mM MnCl2, 
forskolin 120 µM. Data are from single representative experiments (n=2a reproducible; 
n=1b and n=2c bad reproducible, experiments). The detection limit of the assays (double 
background) was 10 pmol·mg-1·min-1.  
 
4.1.4 Paramecium/Mycobacterium chimeras 
Reconstitution of AC activity by chimeras between Paramecium GC C1 monomer and 
mammalian C1- and C2-monomers (IC1, IIC2, VC1, VC2, VIIC1, VIIC2, IXC2) failed, all 
chimeras were inactive (Hoffmann, 1999). Therefore, in this work only ParaGC-C2 and 
C2-KWQ were used for reconstitution with IIC2 and this was used as a control for the 
reconstitution with D300A, N372T, N372A and D300S. The reconstitution of IIC2 with 
the mutant ParaGC-C2-KWQ was in this study 3-fold more active in comparison with 
ParaGC-C2/IIC2 (Table 4.3), as reported by Hoffmann, 1999. The chimeras ParaGC-
C2/D300A and ParaGC-C2-KWQ/D300A had comparable activity as ParaGC-C2/IIC2. 
Since in the mixtures of Paramecium monomers with N372A and N372T only C1 
domains were mixed, no significant reconstitution was observed, as expected.   
 
Chimera  µM in the assay (µg) specific activity nmol⋅mg-1⋅min-1 (cpm) 
ParaGC-C2 / IIC2b 5.1 / 3.7 (15 / 11) 50.3 (77741) 
ParaGC-C2KWQ / IIC2b 
C1 / C2 
9.2 / 3.7 
 
(27 / 11) 148.3 
 
(221496) 
ParaGC-C2 / D300Aa 5.1 / 1.6 (15 / 4.4) 57.5 (40617) 
ParaGC-C2KWQ / D300Aa 
C1 / C2 
9.2 / 1.6 
 
(27 / 4.4) 54.9 
 
(34137) 
ParaGC-C2 / D300Sb 
ParaGC-C2KWQ / D300Sb 
C1 / C2 
3.4 /1.6 
3.4 /1.6 
 
(10 / 4) 
(10 / 4) 
2.2 
2.6 
 
(7739) 
(9777) 
ParaGC-C2 / N372Tb 
ParaGC-C2KWQ / N372Tb 
C1 / C1 
3.4 / 0.16 
3.4 / 0.16 
 
(10 / 0.4) 
(10 / 0.4) 
0.4 
0.6 
 
(210) 
(290) 
ParaGC-C2 / N372Ab 
ParaGC-C2KWQ / N372Ab 
C1 / C1 
3.4 / 0.16 
3.4 / 0.16 
 
(10 / 0.4) 
(10 / 0.4) 
0.6 
0.7 
 
(274) 
(306) 
Basal activities of ParaGC-C2, ParaGC-C2-KWQ and N372A were 0.02, 0.03 and 0.4 
nmol/mg/min, respectively. Basal activities of the other monomers were zero.  
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Table 4.3: Reconstitution of C1-C2-like catalytic sites between IIC2, D300A and 
Paramecium GC-C2 and C2-KWQ. Assay  conditions: 75 µM ATP, 30°C, 10 min, 2 mM 
MnCl2. Data from a representative experiment are shown (n=2a; n=1b). Detection limit 
(double background) was 16 pmol·mg-1·min-1. 
 
4.1.4.1 Characterization of the chimera ParaGC-C2/D300A 
This chimera was 200-fold more active with Mn2+ compared to Mg2+ (Table 4.4). 
 
Protein(s) µM in the assay (µg) 
specific activity 
with 2 mM Mn2+ 
nmol⋅mg-1⋅min-1 
(cpm) 
specific activity  
with 5 mM Mg2+ 
nmol⋅mg-1⋅min-1 
(cpm) 
ParaGC-C2 3 (8.5) 0.01 (200) 0 (51) 
D300A 3 (8.5) 0.01 (170) 0 (52) 
ParaGC-C2 / D300A 3/3 (8.5/8.5) 6.77 (70000) 0.03 (279) 
 
Table 4.4: Cofactor dependence of the AC activity of the chimera ParaGC-C2/D300A. 
Test conditions: 75 µM ATP, 30°C, 10 min, Tris-HCl pH 7.5, 8.5 µg protein. Detection 
limit: 12 pmol·mg-1·min-1. Data from n=1 experiment are shown. 
 
ParaGC-C2 was titrated with increasing amounts of D300A to determine the Kd value 
(Fig. 4.5). Within the experimental conditions no saturation was observed, i.e. the Kd 
probably is rather high (>100 µM). 
 
Fig. 4.5: Titration of 155 nM ParaGC-C2 with D300A (0.144-63 µM). Assay was with 75 
µM ATP, 10 min, 30°C, 2 mM MnCl2. Circles show D300A alone.  
 
The kinetic characterization was carried out with 40 nM ParaGC-C2 and 9 µM D300A. 
Basal activities were zero for both monomers. By increasing ATP (10 µM to 1 mM) the 
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chimera showed a substrate dependence according to the Michaelis-Menten model. 
Lineweaver-Burk treatment yielded a KM of 201 µM and a Vmax of 29.5 nmol⋅mg-1⋅min-1  
(Fig.  4.6). 
 
 
 
Fig. 4.6: Substrate dependence of the chimera ParaGC-C2/D300A (30°C, 10 min, Tris-
HCl pH 7.5, 2 mM MnCl2). (a) Michaelis-Menten graphic; (b) Lineweaver-Burk graph 
(values of the two smallest ATP concentrations were not drawn for graph clarity but used 
for calculation of KM and Vmax). 
 
The effects of mammalian AC activators/inhibitors on the activity of ParaGC-C2/D300A 
were similar to those observed for Paramecium GC and Rv1625c separately (Table 4.5; 
Linder et al., 2000; Guo et al., 2001). 
 
Substance specific activity (nmol⋅mg-1⋅min-1) residual activity (%) 
Chimera alone 10.08 100% 
Forskolin (0.1 mM) 9.41 93.3 
2’d, 3’-AMP (1 mM) 8.28 82.1 
2’ d, 3’-GMP (1mM) 7.96 78.9 
GTPγs (1mM) 3.02 30 
 
Table 4.5: Influence of forskolin and P-site inhibitors on the chimera 860 nM ParaGC-C2/ 
9 µM D300A. Assay conditions were 75 µM ATP, 30°C, 10 min, Tris-HCl pH 7.5.  
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4.1.5 Mycobacterium/Mycobacterium chimeras 
Essentially inactive C1 and C2-like mutant monomers could reconstitute each other with 
Mn2+ as a cofactor (Table 4.6). Mg2+-mediated catalysis either was rather poor (0.3 nmol 
cAMP·mg-1·min-1 for N372T[0.2µM]/D300S[4µM] and 2.5 nmol·mg-1·min-1 for 
R376A[0.2µM]/D300S[4µM]) or was not detectable for other chimeras. 
 
Protein concentration  Specific activity 
40 nM 40 nM (nmol cAMP · mg-1 · min-1) 
R376A (C1)  
+ D300A (C2) 
  1.1 
24.8 
 + D300S (C2) 31.7 
N372A (C1)  
+ D300A (C2) 
   2.5 
 14.9 
 + D300S (C2)    4.2 
N372T (C1)  
+ D300A (C2) 
      0 
   5.3 
 + D300S (C2)    1.6 
 
Table 4.6: AC reconstitution in pairs from point-mutated Rv1625c monomers. The 
functional analogies to the C1 and C2 domains are in parentheses. Assay conditions: 75 
µM ATP, 30°C, 10 min, Tris-HCl pH 7.5, 2 mM MnCl2. Basal activities of monomers 
D300A and D300S were zero.  
 
Forskolin stimulation assays with the catalytic domain wild type and the chimera 
N372T/D300S were carried out. Since forskolin was diluted in DMSO, controls with 
addition of DMSO alone and DMSO/Forskolin were tested (Table 4.7). It was concluded 
that the stimulation observed with DMSO/Forskolin was due to DMSO.  
 
  Specific activity (nmol·mg-1·min-1) 
Protein (s) µM in the assay 
(µg protein) 
alone With 1 µl DMSO With 1 µl 50 µM 
Forskolin (0.5 µM 
in the assay) 
Rv1625c204-443 0.144  (0.4) 16.6 22.4 22.9 
N372T/D300S 1.6/1.6 (4.4/4.4) 3.7 4.1 4.0 
 
Table 4.7: DMSO stimulation in forskolin assays of Rv1625c204-443 and chimera 
N372T/D300S. Assay conditions: 75 µM ATP, 10 min, 30°C, 2 mM MnCl2, Tris-HCl pH 
7.5. 
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4.1.5.1 Titration of N372A, N372T and R376A with D300A or D300S 
For each chimera curves with 85 and 850 µM ATP were established to determine if the 
association of the monomers might be substrate-dependent. Mutants N372A, N372T 
and R376A (an inactive protein concentration was used) were titrated with increasing 
amounts of D300A and D300S (Fig. 4.7 to 4.12). The apparent Kd values were derived 
graphically. The high specific activities obtained were due to an unusual high radioactive 
substrate used (from ICN Biochemicals). 
 
 
Fig. 4.7: Reconstitution of AC activity of 45 nM N372A with increasing amounts of 
D300A. Assay conditions were 30 °C, Tris-HCl pH 7.5, 2 mM MnCl2 and (a) 85 µM ATP 
for 10 min; or (b) 850 µM ATP for 4 min. (a) Kd= 7 µM; (b) Kd= 6 µM.  
 
 
 
Fig. 4.8: Reconstitution of AC activity of 45 nM N372A with increasing amounts of 
D300S. Assay conditions were 30 °C, Tris-HCl pH 7.5, 2 mM MnCl2 and (a) 85 µM ATP 
for 10 min; or (b) 850 µM ATP for 4 min. (a) Kd= 14 µM; (b) Kd= 8 µM.  
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Fig. 4.9: Reconstitution of AC activity of 45 nM N372T with increasing amounts of 
D300A. Assay conditions were 30 °C, Tris-HCl pH 7.5, 2 mM MnCl2 and (a) 85 µM ATP 
for 10 min; or (b) 850 µM ATP for 4 min. (a) Kd= 12-14 µM; (b) Kd= 6-7 µM.  
 
 
 
Fig. 4.10: Reconstitution of AC activity of 45 nM N372T with increasing amounts of 
D300S. Assay conditions were 30 °C, Tris-HCl pH 7.5, 2 mM MnCl2 and (a) 85 µM ATP 
for 10 min; or (b) 850 µM ATP for 4 min. (a) and (b) Kd= not determinable.  
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Fig. 4.11: Reconstitution of AC activity of 45 nM R376A with increasing amounts of 
D300A. Assay conditions were 30 °C, Tris-HCl pH 7.5, 2 mM MnCl2 and (a) 85 µM ATP 
for 10 min; or (b) 850 µM ATP for 4 min. (a) Kd= 6-8 µM; (b) Kd not determinable. 
 
 
 
 
 
Fig. 4.12: Reconstitution of AC activity of 45 nM R376A with increasing amounts of 
D300S. Assay conditions were 30 °C, Tris-HCl pH 7.5, 2 mM MnCl2 and (a) 85 µM ATP 
for 10 min; or (b) 850 µM ATP for 4 min. (a) Kd= 6 µM; (b) Kd not determinable. 
 
The high activities reached for all chimeras could be explained by the formation of large 
amounts of productive heterodimers by the excess of D300A or D300S over N372A, 
N372T and R376A. Apparently, the association of the monomers of chimeras 
N372A/D300A, N372T/D300A and N372A/D300S was improved when using high ATP 
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concentration (850 µM) since their respective apparent Kd values decrease with respect 
of titration using 85 µM ATP. On the contrary, a Kd for chimeras R376A/D300A and 
R376A/D300S could not be determined by testing with 850 µM but with 85 µM ATP 
(possibly because of presence of limiting substrate concentrations). Affinity of the 
monomers of chimera N372T/D300S showed to be very low since no Kd value was 
determinable. These reconstitution assays with the new mutants are further evidence for 
the catalysis of the mycobacterial Rv1625c adenylyl cyclase through dimerization. The 
Kd values obtained for all chimeras is higher than the Kd of the wild type monomers (Guo 
et al., 2001), presumably indicating conformational changes due to mutations that had 
affected the dimerization process. 
 
 Expression and characterization of the adenylyl 
cyclase Rv0386 of Mycobacterium tuberculosis 
 Sequence features of Rv0386 
At the Sanger Institute Website, the M. tuberculosis gene product Rv0386 is annotated 
as a probable transcriptional regulator (LuxR/UhpA family) with some similarity to 
AFSR_STRCO P25941 regulatory protein afsr and many putative M. tuberculosis 
regulatory proteins. It has been reported to contain an ATP/GTP-binding motif A (P-loop) 
and a probable helix-turn-helix motif. AC Rv0386 was analyzed by several programs to 
collect information about sequence features and similarities to other proteins of M. 
tuberculosis and other organisms. Rv0386 was analyzed as entity as well as in 
separated domains (AC, ATPase-, DNA-binding and transcription factor) with the 
program Protein-Protein-BLAST (NCBI; Nov-26-2003; see 8.2 in appendix). Most 
similarities were found with M. tuberculosis hypothetical proteins Rv2488c and Rv0890c 
and with transcriptional regulators of Bradyrhizobium, Mesorhizobium and Streptomyces 
sp.. Analysis with the program DNA-STAR did not detect neither significant hydrophobic 
nor transmembrane segments in the sequence of Rv0386. Also with this program 
protein sequence alignments of Rv0386 with other ACs (e.g. Rv1625c, AC type II from 
rat), GCs (e.g. Paramecium GC), proteins containing the ATPase P-loop motif (e.g. AfsR 
and L6tr) and DNA-binding proteins (e.g. B. pertussis BVGA, S. coelicolor SCO3008 and 
M. tuberculosis Rv0890c) were made (see 8.3 in appendix). Additionally, an analysis 
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with the program PESTfind (Rechsteiner and Rogers, 1996) did not detect potential 
proteolytic signals in Rv0386.  
  
4.2.2   Expression and characterization of the Rv0386 adenylyl cyclase 
catalytic domain  
4.2.2.1   Expression and purification  
The protein was expressed for 4 h with 60 µM IPTG with a protein yield of approximately 
2.7 mg/600 ml culture after Ni2+-NTA-agarose purification. The protein was dialyzed with 
glycerol dialysis buffer (20%) and stored at –20°C. Pellet, supernatant and purified AC 
domain were analyzed by SDS-PAGE (20 kDa including N-terminal His-tag) and tested 
(Fig. 4.13). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 Fig. 4.13: 15% SDS-PAGE. Lanes A (control) and B (construct), pellets of pQE30 in 
BL21 cells. Lanes C and D, supernatants from A and B. Lane E, AC domain after Ni-NTA 
purification. Lane F, AC domain after dialysis. The specific activities indicated below each 
lane were determined for lanes A to E with 75 µM ATP (30°C, 2 mM MnCl2, buffer Tris-
HCl pH 7.5, 10 min assay) and 7, 26, 62, 5 and 9 µg protein, respectively. Specific 
activity in lane F was determined with 75 µM ATP (30°C, 5 mM MnCl2, MOPS pH 7,5, 10 
min assay)  and 4 µg protein (1.9 µM). Same protein amounts tested were 
correspondingly applied at each lane. 
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 4.2.2.2  Characterization of the AC activity  
4.2.2.2.1 Optimal temperature 
The temperature optimum was around 30-37°C (Fig. 4.14a). The activation energy of 
76.1 kJ/mol was derived by an Arrhenius plot (Fig. 4.14b). This value is within the range 
reported for other mycobacterial ACs (Guo et al., 2001; Linder et al., 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.14: a) Temperature dependence. Assay conditions: 75 µM ATP, 10 min, 11.6 µg 
protein (5.6 µM), MOPS pH 7.5. b) Arrhenius plot. An activation energy of 76.1 kJ/mol is 
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necessary for Rv0386 catalytic domain in order to convert ATP into cAMP. y = - 9149.16 
x + 30.03 
 
 
4.2.2.2.2 Mn2+/Mg2+ dependence 
ACs use predominantly Mn2+ as divalent cation although Mg2+ probably will be the 
physiologically more important divalent cation. In most class III ACs, Mg2+-supported 
activity is rather low (Kasahara et al., 1997; Hurley, 1999; Guo et al., 2001; Linder et al., 
2002). The in vitro activity of the Rv0386 catalytic domain is absolutely Mn2+ dependent 
(Fig. 4.15). 
 
 
 
 
 Fig. 4.15: Cofactor dependence of the AC activity. Mn2+ was tested from 0.7 mM 
to 4.7 mM and Mg2+ from 2.7 mM to 8.3 mM. Assay conditions: 75 µM ATP, 10 
min, 2.3 µM protein.  
 
4.2.2.2.3 pH dependence 
The activity of the catalytic domain was strongly affected by the pH and dependent on 
the buffer system. A pH range from 3.1 to 9.9 was tested using 10 different buffer 
systems (Fig. 4.16) pH 8.3 was the best for the activity corresponding to Tris/HCl pH 8.5. 
Because at this value Mn2+ is oxidized, pH 7.4 corresponding to MOPS pH 7.5 was used 
in assays. 
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 Fig. 4.16: pH dependence. Assay conditions: 75 µM ATP, 4.38 µM protein, 10 min.  
 
 
4.2.2.2.4 Effect of imidazole 
Elution buffer of Ni-NTA-agarose purification contains 150 mM imidazole. That 
corresponds to a maximal final concentration in the usual AC assay of 60 mM. On the 
other hand, imidazole was shown to inhibit Rv1625c (personal communication Dr. Guo). 
Therefore its effect on Rv0386 was examined (Fig. 4.17). Surprisingly, it was observed 
that at 60 mM AC activity is inhibited >>90%. Therefore the protein was always dialyzed 
after purification (glycerol dialysis buffer) to remove rest of the imidazole.  
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Fig. 4.17: Inhibition of the AC activity through imidazole (5-300 mM). Assay conditions 
were 75 µM ATP, 10 min, 30°C and 2.2 µM protein concentration.  
 
4.2.2.2.5 Effect of detergents 
A set of detergents used for purification of insoluble proteins was tested. A slight 
activation with Triton X-100, Polidocanol (dodecyl polyethylene glycolether) and Nonidet 
P-40 was observed. The addition of SDS (anionic detergent) ablated the activity 
completely. The detergent CHAPS (zwitterionic steroid detergent) reduced but did not 
completely abolished it (Table 4.8).  
 
Detergent % in test AC-activity (%) 
Triton X-100 1 124 
Polidocanol 1 130 
Nonidet P-40 1 144 
CHAPS 
1 
2 
3 
4 
33 
9 
6 
9 
SDS 1 1 
 
 Table 4.8: Influence of detergents on the AC activity. Assay conditions: 2.2 µM (4.5 µg) 
protein, 75 µM ATP, 3 mM Mn2+, 30°C, MOPS pH 7.5, 10 min.  
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4.2.2.2.6 Stability tests 
The best storage temperature was –20°C (with 20% glycerol). The best buffer system 
that maintained protein stability was Tris/HCl pH 7.5, which retained 90% of activity after 
1 month and 50% after 2.5 months. In Tris/HCl pH 8.5, the protein was fully active after 
2 weeks. At 4°C and 25°C a residual activity of 85% and 51% was present after 2 
weeks, respectively (data not shown). For crystallization purposes the stability of the 
protein with 10 % glycerol stored at –20°C was also tested. After one day full activity 
was retained in Tris/HCl pH 7.5, and after 2 weeks residual activity was 81%.  
 
4.2.2.2.7 Protein dependence 
From 46.5 to 465 nM protein specific activity increased 4.5-folds but further increments 
resulted in a slight decrement of activity (Fig. 4.18). These results suggested rapid 
formation of a homodimer with further formation of less active oligomers upon increasing 
protein concentrations. Half maximal activity was attained at 140 nM protein, indicating a 
high affinity of the catalytic domains for each other.  
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Fig. 4.18: Protein dependence of Rv0386 catalytic domain. Assay conditions were 850 
µM ATP, 5 mM Mn2+, MOPS buffer pH 7.5, 30 °C and 20 min. Protein concentrations 
tested were from 46.5 nM to 6.9 µM (96 ng to 14 µg).  
 
 
4.2.2.2.8 Enzyme kinetics 
The kinetic properties were analyzed using 5 mM Mn2+ and substrate concentrations 
from 10 µM to 2.3 mM. The KM for Mn-ATP was 417 µM, the Vmax was 14.4 pmol/min 
(4.8 nmol/mg/min). The KM value obtained is within the range of 30-400 µM observed for 
purified membrane-bound and soluble ACs (Tang and Hurley, 1998). Vmax is rather low 
compared with that of the catalytic domain of other ACs, e.g. Rv1625c (2.1 µmol·mg-
1·min-1; Guo et al., 2001), Rv1264 (1.25 µmol·mg-1·min-1; Linder et al., 2002) and cyaB1 
(309 nmol·mg-1·min-1; Kanacher et al., 2002). The Hill coefficient was 1.0 which indicated 
no cooperativity (Fig. 4.19a,b,c). 
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Fig. 4.19:  a) Michaelis-Menten kinetic of the catalytic domain. Assays were conducted at 
1.45 µM (3 µg) protein, MOPS pH 7.5, 30°C and 10 min; b) corresponding Lineweaver-
Burk linear fit; c) corresponding Hill-Plot (R2= 0.9835; y= 1.0148x - 3.0329). b and c) the 
two smallest values were not drawn for graph clarity but taken for KM and Vmax 
calculation. V= activity (pmol⋅min-1); [S]= ATP. 
 
 
4.2.2.2.9 Influence of inhibitors, substrate analogs and other substances 
Activity was tested in presence of forskolin, 2’-deoxy-3’-adenosine monophosphate 
(2’d3’-AMP) [P-site inhibitor], cyclic AMP (cAMP), guanosine 2’&3’-monophosphoric acid 
(2’3’ GMP; mixed isomers), guanosine 2’-monophosphoric acid (2’-GMP); 8-
bromoguanosine 3’,5’-cyclic monophosphate (8-Br-cGMP); O2-monobutyryl adenosine-
3’,5’-cyclic monophosphoric acid (monobutyryl cAMP); N6,O2’- dibutyryl adenosine 3’,5’-
cyclic monophosphoric acid (dibutyryl cAMP); 3’-deoxyadenosine 5’-triphosphate 
(Cordycepin 5’-triphosphate; ATP-analog); α,β-methylen adenosine diphosphate (αβ-
CH2-ADP; ADP-analog) and adenosine-5’-O-(1-thiotriphosphate), Rp-diastereomer (Rp-
ATP-α-S, ATP-analog).  
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Substance tested [mM] 
 % activity of 
corresponding 
basal 
Specific activity 
nmol·mg-1·min-1 
(control with no 
addition) 
Forskolin [0.1] 114 6.3 (5.5) 
2’d3’ AMP [1] 102 5.6 (5.5) 
2’3’ GMP [1] 119 6.6 (5.5) 
2’ GMP [1] 129 7.1 (5.5) 
8-Br-cGMP [1] 131 7.2 (5.5) 
cAMP [1] 103 6.4 (6.2) 
(Rp) ATP αS [1] 119 7.4 (6.2) 
Monobutyryl cAMP [1] 29 1.8 (6.2) 
Dibutyryl cAMP [1] 58 3.2 (5.5) 
αβ CH2 ADP [1] 13 0.8 (6.2) 
Cordycepin 5’ triphosphate [1] 23 1.4 (6.2) 
 
Table 4.9:  Effect of inhibitors, substrate analogs and other substances on AC activity. 
Assay conditions: 850 µM ATP, 30°C, 10 min, MOPS pH 7.5. Substances were tested in 
two separate assays.  
 
Only αβ-CH2-ADP, cordycepin and monobutyryl cAMP showed a significant inhibitory 
effect on Rv0386. Dibutyryl cAMP could be also considered as an inhibitor. Neither 
forskolin nor the P-site inhibitor did show considerable activation or inhibition, 
respectively. 
  
4.2.2.2.10 Influence of purine and pyrimidine nucleotides 
ITP and CTP had no significant effect (Fig. 4.20). The activation showed by addition of 
GTP and UTP may be explained as an allosteric effect. It is possible that GTP or UTP 
bound to one of the catalytic sites and activated the enzyme allosterically.  
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Fig. 4.20: Influence of nucleotides on the AC activity. Assay conditions were: 850 µM 
ATP, 30 °C, 5 mM MnCl2, MOPS pH 7.5, 10 min. Protein concentration tested was 465 
nM (0.96 µg) showing a specific activity of 6.2 nmol cAMP mg-1 min-1. 
 
4.2.2.3 Characterization of the GC activity 
The catalytic domain was tested for GC activity at a GTP concentration of 75 µM in 
MOPS buffer pH 7.5 at 30°C, 5 mM Mn2+. Simultaneously an AC assay was carried out 
for comparison. The catalytic domain has a GC activity of 30% of the AC activity. That 
resulted surprising since it is not reported about other ACs with any GC side activity. No 
GC activity was detectable with Mg2+ (Table 4.10).  
 
AC activity 
pmol · mg-1 · min-1 
GC activity 
pmol · mg-1 · min-1 Protein 
(µM) 5 mM 
Mn2+ 
10 mM 
Mg2+ 
5 mM 
Mn2+ 
10 mM 
Mg2+ 
 
 % GC to 
AC activity 
1.94 226 0 68 0 
2.15 308 0 85 0 
4.84 435 0 142 0 
30 
27.6 
32.6 
 
 Table 4.10: Determination of the guanylyl cyclase side activity of Rv0386.  
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The process of dimerization ocurred slower than with ATP as a substrate (see Fig. 4.19 
and 4.21 for comparison). The specific activity increased only 3-folds from 665 nM to 
14.5 µM protein. An EC50 value of 0.88 µM was derived graphically.  
 
 
 
 
Fig. 4.21: Protein dependence with GTP as a substrate. Assay conditions: 850 µM GTP, 
5 mM Mn2+, MOPS pH 7.5, 30 °C and 20 min.   
 
4.2.2.3.8 Enzyme kinetics 
The substrate dependency was assayed with 5 mM Mn2+ as a cofactor (Fig. 4.22a). The 
Km was 299 µM, the Vmax was 16.1 pmol/min. The Hill coefficient of 0.8 indicates no 
cooperativity. 
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Fig. 4.22:  a) Michaelis-Menten kinetic for GTP as a substrate. Assays were conducted 
at 4.85 µM of protein, MOPS pH 7.5, 30°C, 5 mM Mn2+ and 10 min; b) corresponding 
Lineweaver-Burk linear fit; c) corresponding Hill-Plot (R2= 0.9456; y= 0.7953x - 2.4837). 
b and c) the four smallest values were not drawn for graph clarity but taken for 
calculation of KM and Vmax. V= activity (pmol⋅min-1); [S]= GTP. 
 
 
UTP did not affect GC activity but other nucleotides did, presumably because of 
allosterical interactions or because they were used as substrates, e.g. ATP inhibited the 
GC activity as expected, since the enzyme uses it as a substrate (Fig. 4.23).  
 
 
Fig. 4.23: Influence of nucleotides on the GC activity. Assay conditions: 850 µM GTP, 30 
°C, 5 mM MnCl2, MOPS pH 7.5, 20 min, 4.6 µM (9.6 µg) protein.  
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4.2.2.4 Sensitivity of the antibodies anti-KD0386 
BioGenes GmbH Berlin produced antibodies against the catalytic domain (KD0386; see 
chapter 3). The immune reactivity of the antigen-affinity purified antibodies from two 
immunized rabbits was tested individually against different protein concentrations by Dot 
Blotting (Fig. 4.24). With an antibody dilution of 1:10 000 it was possible to detect 10 ng 
protein (rabbit 4555). Effect of addition of anti-KD0386 on the AC activity of the catalytic 
domain was tested (Table 4.11). Inhibition of the enzyme activity results obvious since 
antibody bound to the protein brings it to precipitation. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.24: Control of the KD0386 antibodies by Dot Blot. 5 different antibody dilutions 
(1:2000 to 1:500,000) as well as protein concentrations were used (rabbits 4554: animal 
1; and 4555: animal 2). Protein concentrations were 1 µg (A), 100 ng (B), 10 ng (C), 1 ng 
(D) and 0.1 ng (E).  
 
 
Anti-KD0386 [µg] specific activity (nmol·mg-1·min-1) % residual activity 
No addition 5.2 100 
0.8 4.5 86 
1.6 4.5 86 
2.4 4.1 77 
3.2 3.7 71 
5 1 20 
 
Table 4.11: Inhibition of the AC activity by addition of antibody anti-KD0386. Assay 
conditions: 500 µM ATP, 30°C, 20 min, 5 mM Mn2+, MOPS pH 7.5, 8.5 µg (4.1 µM) 
protein. 
A    B    C   D   E    a     b    c    d    e 
Animal 1     Animal 2 
1:2000
1:10 000
1:100 000
1:200 000
1:500 000
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4.2.2.5 Multimerization of the catalytic domain 
On a Coomassie-stained SDS-PAGE the Ni2+-NTA purified protein was visible as a 
single band (Fig. 4.13). Using 3 µg protein/lane it was tested whether multimerization 
could be detected in a Western blot (Fig. 4.25). The protein sample (3 µg, 1.45 µmol, 
purified, dialyzed, 20% glycerol, at –20°C for about 2 months) was blotted from a 15% 
SDS-PAGE gel following the standard Western Blot method described in chapter 3. AC 
and GC activities of the sample were 3.7 and 1.1 nmol/mg/min, respectively (tested with 
500 µM ATP or GTP; 10 min; MOPS pH 7.5; 5 mM Mn2+). The formation of oligomers 
presumed from the protein dependence curve (Fig. 4.21) was proved as well as the 
difference in sensitivity between anti-KD0386 and Coomassie blue. 
 
Fig. 4.25: Western blot analysis of the AC domain. Primary antibody diluted 1:200 000 
and secondary antibody (Goat anti-rabbit antibodies conjugated with horseradish 
peroxidase) 1:5000. Exposure time was 15 s.  
 
 
4.2.2.6 Determination of cross-reactivity between anti-KD0386 and other ACs  
The 15 mycobacterial ACs (present work; Guo et al., 2001; Linder et al., 2002; Wetterer, 
Hammer, Motaal, Zeibig, Weber, Luban unpublished data) were analyzed with the 
specific antibodies anti-KD0386 for determination of possible cross-reactivity (see Table 
4.12 and Fig. 4.26 a to d). At a dilution of 1:10000 of the antibodies all ACs with 
exception of Rv3645c, Rv1318c, Rv1319c and Rv1320 showed crossreactivity after a 15 
s exposure. Based on these results, this antibody will not be a suitable tool for 
immunodetection studies of Rv0386.  
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Adenylyl 
cyclase 
Construct Sample type Molecular 
weight (kDa) 
Protein amount 
applied (µg) 
Rv1625c Holoenzyme Purified 47 2 
Rv2435c Catalytic domain Purified 26 4 
Rv1264 Holoenzyme Purified 43 5 
Rv2212 Holoenzyme Purified 40 3 
Rv1900 (LipJ) Holoenzyme Purified 51 6 
Rv0891 Holoenzyme Cell homogenate 33 16 
Rv1647 Holoenzyme Cell homogenate 37 30 
Rv1358 Catalytic domain Cell homogenate 29 16 
Rv1359 Holoenzyme Cell homogenate 28 22 
Rv2488 Catalytic domain Cell homogenate 29 16 
Rv3645c Holoenzyme Cell homogenate 60 19 
Rv1318c Holoenzyme Cell homogenate 60 17 
Rv1319c Holoenzyme Cell homogenate 60 20 
Rv1320c Holoenzyme Cell homogenate 60 20 
 
Table 4.12: Samples of the mycobacterial ACs used for a Western blot with antibodies 
anti-KD0386. 
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Fig. 4.26 a to d: Western blot of the 15 ACs of M. tuberculosis with antibodies anti-
KD0386. According to the molecular weight of each protein (see table 4.21), only ACs of 
figure d did not show cross-reactivity with anti-KD0386. 
 
 
4.2.2.7 Expression, purification and characterization of mutants Q57K, Q57A, 
N106D, N106A and Q57K/N106D 
These mutants were generated to study the importance of residues Q57 and N106 for the 
AC activity of Rv0386 on the basis of the alignment with mammalian cyclases and with 
Rv1625c (Fig. 4.27).  
                                                                    
                                                                    
                                                                    
Rv1625c     259 :DELVDQ---HGLEKIKVSGDSYMVVSGVPRPRPD-----------HTQAL 
AC2_C2_RAT  923 :DDLLSKPKFSGVEKIKTIGSTYMAATGLSAIPSQEHAQEPERQYMHIGTM 
ParaGC_C1  1669 :D-LLCQQ--HEVQKIETVGKTYMAAAGLKIHVSQKSNP--------VNKV 
Rv0386       46 :IAAHDG---V-RPVEQGEGDSFVLAF------------------------ 
                                                                    
                                                                                  
Rv1625c     295 :ADFALDMTNVAAQLKDPRGN-P-VPLRVGLATGPVVAGVVGSRRFFYDVW 
AC2_C2_RAT  973 :VEFAYALVGKLDAINKHSFN-D-FKLRVGINHGPVIAGVIGAQKPQYDIW 
ParaGC_C1  1708 :ISLALDMKRYVMSNE------T-FQIKIGIHYGNVIAGVIGHHKPQFSLI 
Rv0386       68 :--ACASDAVAAALDLQRARL-APIRLRIGVHTGEVALRDEG------NYA 
                                                                    
 
Fig. 4.27: Alignment of Rv0386 AC domain with the cytosolic domains of mammalian AC 
type 2, Paramecium GC and Rv1625c. Marked in boxes: purine-specifying residues. 
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All mutants were expressed in BL21 cells (60 µM IPTG, RT, 4 h). They were purified 
with Ni-NTA-agarose and dialyzed (20% glycerol; Fig. 4.28a,b,c). Mutants Q57K, N106A 
and Q57K/N106D were well purified. From 400 ml culture the recoveries of Q57K and 
N106A were 3 and 0.7 mg protein, respectively. From 600 ml culture the recovery of 
Q57K/N106D was 0.8 mg protein. Purification of mutants N106D and Q57A was 
incomplete. The presence of a 25 kDa protein after purification and dialysis could not be 
avoided. From 600 ml culture the recovery of N106D was only 80 µg protein. Recovery 
of mutant Q57A was 0.1 mg protein from 400 ml culture. No further purification was 
attempted with these proteins. Western blot analysis with antibodies anti-KD0386 was 
more sensitive than Coomasie blue showing dimerization of all mutants and degradation 
of N106D (Fig. 4.28d). 
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Fig. 4.28: 15% SDS-PAGE analysis of five mutants in pellet and supernatant fractions 
and after Ni-NTA purification with further dialysis (Coomassie staining). About 20 µg 
protein were applied in each lane from the pellets (a) and supernatants (b). Purified and 
dialyzed proteins (c) were applied in amounts of about 1-1.5 µg.  Controls of vector 
pQE30 also in pellet, supernatant and purification’s eluate are shown. Note proteins of 
the vector control that could also bind to Ni-NTA-agarose (c). (d) Western blot from 15% 
SDS-PAGE of 2 µg/lane of each mutant. Antibodies anti-KD0386 were used (5 s 
exposure time). 
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4.2.2.7.1 AC activity of the mutants 
Substrate specificity in class III ACs is determined by a lysine and aspartic acid residues 
(e.g. K296 and D365 in Rv1625c), in Rv0386, these residues are glutamine and 
asparagine. Therefore, it was already surprising, that Rv0386 had AC activity at all. Now 
I investigated by a mutational approach the importance of the substrate-defining amino 
acids for catalysis in Rv0386. In all mutants, activity was below 10% of the wild-type 
level (Table 4.13) indicating the critical role of Q57 and N106 for substrate recognition in 
Rv0386 which could not be improved or replaced when mutating to the canonical 
corresponding amino acids. 
  
Mutant [µM] cpm 
Specific activity 
(pmol·mg-1·min-1) 
(%) activity of 
corresponding 
basal 
[ATP] in 
assay (µM) 
Q57K 
2 
5 
9.5 
182 
294 
562 
18 
16 
16 
(363) 
(289) 
(433) 
5 75 
Q57A 
3.9 
5.8 
145 
120 
66 
35 
(3905) 
(3281) 
1.4 1000 
N106D 
1.9 
4.9 
9.7 
62 
68 
76 
0 
0 
0 
(569) 
(538) 
(381) 
0 75 
N106A 
1.9 
4.9 
9.7 
125 
121 
245 
13 
5 
6.4 
(569) 
(538) 
(381) 
1.5 75 
Q57K/N106D 
2.4 
4.8 
290 
397 
136 
95 
(1830) 
(2080) 
6 500 
 
 Table 4.13: AC activities of the five mutants. Specific activities in parenthesis correspond 
to the catalytic domain wild type under the same assay conditions (MOPS pH7.5, 10 min, 
30°C, 5 mM Mn2+). Detection limit was 5 pmol·mg-1·min-1. 
 
4.2.2.7.2 pH dependence  
Each mutant was tested with different buffer systems from pH 3 to 9 (Fig. 4.29 a and b). 
Activity was strongly affected by the pH. Optimal buffers were: for Q57K and N106A 
Glycin/NaOH buffer pH 8.4 and for N106D and Q57K/N106D Glycin/NaOH pH 9.1. 
  87 
Q57A did not show activity under these assay conditions. Activity of Q57A was actually 
only detectable with Tris/HCl pH 8.3 and MOPS pH 7.5 when testing at higher ATP 
concentrations (Tables 4.13 and 4.14). Since activities of Q57A and N106D are rather 
low it resulted not clear if they show a large buffer effect or the observations are due 
only to the substrate concentration in the different assays (see Tables 4.13 and 4.14, 
Fig. 4.29a and b for comparison). A slight displacement of the pH optimum compared 
with the catalytic domain wild type was observed only for N106D and Q57K/N106D (Fig. 
4.17 and 4.29). 
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Fig. 4.29: Dependence on pH of the mutants. Assay conditions: 500 µM ATP, 10 min, 
30°C, 5 mM Mn2+, 6 µM Q57K, 4 µM Q57A, 5 µM Q57K/N106D (a), 3 µM N106D and 9 
µM N106A (b). 
 
 
Mutant [µM] cpm Specific activity (pmol·mg-1·min-1) 
% activity of 
corresponding 
basal  
ATP in 
assay 
[µM] 
pH 
Q57K 1.9 634 512 (7787) 6.5 850 8.4 
Q57A 1.9 290 182 (4577) 4 850 8.3 
N106D 3.9 155 45 (1872) 2.4 850 9.1 
N106A 2.4 176 161 (3168) 5 500 8.4 
Q57K/N106D 2.9 648 399 (6437) 6 850 9.1 
  
Table 4.14: AC activities of the mutants measured at their pH optimum. The pH values 
correspond to the final pH measured after mixing all components of the AC-test mixture. 
Assays conditions: 30°C, 20 min, 5 mM Mn2+. Data are from separate tests. Specific 
activities in parentheses correspond to the catalytic domain wild type under the same 
assay conditions. 
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4.2.2.7.3 Protein dependence  
Mutants Q57K, Q57A and Q57K/N106D showed a notable decrease in activity at 
increasing protein concentration (Fig. 4.30a,b,d). The Kd values could not be calculated 
because at lower concentrations AC activity was reliably unmeasurable. It is possible 
that the mutants have a Kd similar or lower than that calculated for the wild type (0.14 
µM) and that less active multimers are formed upon increasing protein concentrations. 
Activity of N106A was relatively constant at increasing protein concentrations (Fig. 
4.30c). For mutant N106D it was impossible to determine protein dependency because 
of its lack of activity at concentrations lower than 1.9 µM, and its low recovery after 
purification made it impossible to test it at concentrations higher than 5 µM (Fig. 4.30e).  
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Fig. 4.30: Protein dependence of the Rv0386 catalytic domain mutants. For the curves of 
Q57K (a), Q57A (b), Q57K/N106D (d) and N106D (e) conditions were 850 µM ATP, 5 mM 
Mn2+, 30°C, 20 min. Assay conditions for N106A (c) were 500 µM ATP, 5 mM  Mn2+, 30°C, 
10 min. Each mutant was tested at the optimal pH. Data are from a single representative 
experiment (n=2 with similar results). 
  
4.2.2.7.4 GC activity of the mutants 
Direct comparison of AC and GC activities of the mutants showed a considerably 
attenuation in the substrate discrimination for mutants Q57K/N106D and N106A (Table 
4.15). Mutant Q57K discriminate the substrate in the same proportion that the wild type 
did (30% residual activity). No GC activity was detectable for mutants N106D and Q57A. 
Activity of lower or higher protein concentrations of these mutants was impossible to be 
detected. It is possible that residues Q57 and N106D in conjunction are responsible for 
preferring ATP as a substrate.  
 
Mutant 
µM 
Protein 
(µg)  
AC activity 
pmol · mg-1 · min-1 
(cpm) 
GC activity  
pmol · mg-1 · min-1 
(cpm) 
% GC 
residual 
activity 
GTP  in 
assay 
[µM] 
Q57K 1.9   (4) 512 (634) 154 (245) 30 850 
Q57A 1.9   (4) 182 (290) 0 (184) 0 850 
N106D 3.9   (8) 45.1 (155) 0 (161) 0 850 
N106A 2.4   (5) 161 (176) 109 (176) 67.7 500 
Q57K/N106D 4.4   (9) 357 (918) 331 (801) 92.7 850 
 
Table 4.15: GC activities of the mutants of the catalytic domain. Assay conditions: 30°C, 
20 min for Q57A, Q57K, N106D and Q57K/N106D and 10 min for N106A. Each mutant 
was tested at its pH. 
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4.2.2.8 Expression and characterization of the mutant N106S 
Mutant N106S was generated to turn the substrate specificity of the catalytic domain 
toward GTP, according to the alignment of the sequences of the AC domain of Rv0386 
and the C1 domain of the Paramecium GC (Fig. 4.31). It was assumed that residue E56 
(next neighbor to Q57) in Rv0386 could bind the purine corresponding to E1681 in 
ParaGC. Therefore only N106 was mutated to S. 
 
 
 
 
 
 ParaGC_C1  1677 :VQKIETVGKTYMAA   ParaGC_C1  1733 :GNVIAGVIGHHKPQFSLI 
 Rv0386       53 :RPVEQGEGDSFVLA   Rv0386       97 :GEVALRDEG------NYA 
 
 
 
Fig. 4.31: Short alignment of Rv0386 with Paramecium GC showing their corresponding 
purine-specifying residues. Residues E1681 and S1748 confer ParaGC its GTP-specificity 
(Linder et al., 2000). 
 
 
N106S was expressed in BL21 cells (5 h, 60 µM IPTG, RT), purified and dialyzed as 
usual and stored at –20°C with 20% glycerol. From 3 x 600 ml bacterial culture approx. 
1 mg of purified and dialyzed protein was obtained. Expression and purification grade of 
N106S were analyzed by SDS-PAGE (Fig. 4.32a). Dimerization of the mutant was 
shown with a Western blot with anti-KD0386 (Fig. 4.32b). 
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 Fig. 4.32: a) 15% SDS-PAGE analysis of N106S. Lanes 1 and 2 correspond to the pellet 
(20 µg) and supernatant (8 µg) of empty pQE30 vector in BL21 cells. Lanes 3 and 4 
correspond to pellet (20 µg) and supernatant (20 µg) of N106S. Lane 5 corresponds to 
the purified mutant (3 µg). b) Western blot from 15 % SDS-PAGE of 2 µg dialyzed 
N106S analyzed with antibodies anti-KD0386. Time of exposure was 5 s. 
 
N106S showed an AC residual activity of 43% with respect of the wild type. The GC 
activity corresponded to 8% of its AC activity (Table 4.16).  
 
Protein 
[µM] 
AC activity 
nmol · mg-1 · min-1 
(wild type) 
% activity of 
the wild type 
GC specific activity 
(nmol · mg-1 · min-1) 
% GC vs. 
AC activity 
2.4 2.1       (5.4) 38.9 0.2  9.5 
3.8 1.7       (3.7) 46 0.1  5.9 
 
Table 4.16: AC and GC activities of N106S. Wild-type AC activity at the same assay 
conditions are in parentheses. Assay conditions were: 850 µM ATP or GTP, 20 min, 
30°C, buffer MOPS pH 7.5.  
 
Protein and substrate dependence of N106S were investigated. Like wild type, the 
mutant N106S AC activity increased with increasing protein concentrations (figure 4.33). 
That indicates dimerization already observed in Western blot (see above). The 
graphically derived apparent Kd value is 0.3 µM (2-fold wild type). The enzyme kinetics 
of N106S showed a Km value of 337 µM and Vmax of 9.3 pmol/min (figure 4.34). The Hill 
coefficient of 0.9 indicated no cooperativity. 
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Fig. 4.33: Protein dependence of N106S with ATP as a substrate. Assay conditions: 850 
µM ATP, 5 mM Mn2+, MOPS pH 7.5, 30 °C, 20 min. Protein concentrations were from 
136 nM to 5.5 µM. An EC50 value of 0.34 µM could be derived from a graphical analysis.  
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Fig. 4.34:  a) Michaelis-Menten kinetic for ATP as a substrate. Assays were conducted at 
1.4 µM of protein, MOPS pH 7.5, 30°C, 5 mM Mn2+ and 10 min; b) corresponding 
Lineweaver-Burk linear fit; c) corresponding Hill-Plot (R2= 0.9229; y= 0.92213x - 
2.42055). b and c) the two smallest values were not drawn for graph clarity but taken for 
KM and Vmax calculation. V= activity (pmol⋅min-1); [S]= ATP. 
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4.2.2.9 Expression and characterization of an N-terminally elongated AC domain 
This protein corresponds to the Rv0386 AC domain elongated at the N-terminus with 7 
amino acids (MRLSGAG) and is also called AC domain MT0399 (see 3.6.3.7 and 
3.6.3.8 on chapter 3 for details). Purpose of its characterization was to determine its 
utility for crystallization experiments. Protein was expressed with N-terminal as well as 
with C-terminal His-tag in BL21 cells (5 h, 60 µM IPTG, RT), purified and dialyzed as 
usual. Recoveries of 0.6 mg of N-terminally His-tagged protein (from 3 x 600 ml culture) 
and 0.3 mg of C-terminally His-tagged protein (from 400 ml culture) were obtained. 
Expression and purification steps were controlled by SDS-PAGE (Fig. 4.35). 
Both proteins showed an AC activity of 30% of the wild type. The GC activities 
correspond to 27% of the AC activity for N-His tag MT0399 and 21% of the AC activity 
for C-His tag MT0399 (Table 4.17). The proportion AC/GC activity of both proteins is 
similar to that of wild type indicating no change in the substrate discrimination. 
Nevertheless the low activities point to a critical role of the N-terminus of the protein for 
catalysis in Rv0386. Both proteins were used for crystallization experiments but without 
success. 
 
 
 
 
 
Fig. 4.35: 15% SDS-PAGE analysis of the N-terminally elongated AC domain (equivalent 
to MT0399 AC domain). a) Protein with N-terminal His-tag and b) with C-terminal His-tag. 
Empty vectors pQE30 and pQE60 were also expressed as controls. 20 µg of pellets and 
10-15 µg of supernatants were applied. 1-2 µg of purified and dialyzed protein were 
applied. 
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Protein  [µM] 
AC activity 
nmol · mg-1 · min-1 
(wild type) 
% AC 
activity of 
the wild type 
GC activity 
nmol · mg-1 · min-1 
% GC vs. 
AC 
activity 
N-His tag 
MT0399 
1.4 
2.4 
3.8 
5.2 
2.3      (6.7) 
1.4      (5.4) 
1.2      (3.7) 
1.2      (4.1) 
34.3 
25.9 
32.4 
29.2 
n.d. 
0.4  
0.3  
n.d. 
- 
28.6 
25 
- 
C-His tag 
MT0399 
1.9 
3.9 
0.9      (4.2) 
1      (3.4) 
21.4 
29.4 
0.2  
0.2  
22 
20 
 
Table 4.17: AC and GC activities of MT0399 AC domain with N-terminal and C-terminal 
His-tag. Activities of both proteins were examined in separated assays (AC domain wild 
type at same assay conditions in parentheses). Assay conditions: 850 µM ATP or GTP, 
20 min, 30°C, buffer MOPS pH 7.5. n.d.= not determined.  
 
Protein and substrate dependence of MT0399 with N-His tag were investigated. No 
apparent Kd value could be determined (Fig. 4.36). Probably the dimerization of the 
protein occurred at protein concentrations <214 nM. That could not be further 
investigated due to the detection limit. The enzyme kinetics of this protein showed a Km 
value of 2.3 mM and Vmax of 13.6 pmol/min (Fig. 4.37). The Hill coefficient of 0.9 pointed 
to no cooperativity. Such characterizations were not made for MT0399 with C-terminal 
His-tag. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.36: Protein dependence of MT0399 (N-His tag) with ATP as a substrate. Assay 
conditions: 850 µM ATP, 5 mM Mn2+, MOPS pH 7.5, 30 °C, 20 min. Protein 
concentrations tested were from 214 nM to 10.2 µM.  
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Fig. 4.37:  a) Michaelis-Menten kinetic for ATP as substrate. Assays were conducted at 
1.5 µM protein, MOPS pH 7.5, 30°C, 5 mM Mn2+ and 10 min; b) corresponding 
Lineweaver-Burk linear fit; c) corresponding Hill-Plot (R2= 0.9540; y= 0.90744x – 
3.11893). b and c) the smallest value were not drawn for graph clarity but taken for KM 
and Vmax calculation. V= activity (pmol⋅min-1); [S]= ATP. 
 
 
4.2.2.10 Expression and characterization of the C-terminally His-tagged AC domain  
The C-terminally His-tagged AC domain of Rv0386 was expressed in BL21 cells (5 h, 60 
µM IPTG, RT) with a protein recovery of 0.7 mg pro 400 ml culture after Ni2+-NTA-
agarose purification (Fig. 4.38). The protein was dialyzed (20% glycerol) and stored at –
20°C. The calculated molecular weight was 20 kDa including the C-terminal His-tag. 
This protein showed 81% of the AC activity of the N-terminally His-tagged AC domain. 
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Fig. 4.38: 15% SDS-PAGE of the C-terminally His-tagged AC domain. An empty vector 
control was carried in parallel. 20 µg of pellet proteins were applied. From supernatants, 
5 µg of pQE60 and 20 µg of AC domain were applied. After purification and dialysis 2 µg 
of protein were applied.  
 
Protein and substrate dependence of the C-terminally His-tagged AC domain were 
examined. A considerably slowdown of the dimerization process of this protein was 
observed. The graphically derived apparent Kd value was 1.5 µM (Fig. 4.39). 
Surprisingly up to 15 µg protein no reduction in the activity was observed. After kinetic 
characterization the Km value was 454 µM and Vmax was 34.8 pmol of cAMP/min (3.9 
nmol of cAMP⋅mg-1⋅min-1). The Hill coefficient of 0.9 indicated no cooperativity. A slight 
inhibition of the activity upon 2 mM ATP was observed (Fig. 4.40).  
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Fig. 4.39: Protein dependence of the AC domain with an C-terminal His-tag. Assay 
conditions: 850 µM ATP, 5 mM Mn2+, MOPS pH 7.5, 30°C, 20 min. Protein 
concentrations tested were from 175 nM to 7.5 µM. An EC50 value of 1.5 µM could be 
derived graphically.  
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Fig. 4.40: a) Michaelis-Menten kinetic of AC domain with C-terminal His-tag. Assay was 
conducted at 4.3 µM of protein, MOPS pH 7.5, 30°C, 5 mM Mn2+ and 10 min; b) 
corresponding Lineweaver-Burk linear fit; c) corresponding Hill-Plot (R2= 0.8225; y= 
0.9085x – 2.3927). b) the two smallest values were not drawn for graph clarity but taken 
for KM and Vmax calculation. V= activity (pmol⋅min-1). 
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4.2.2.11 Expression and AC assay of mutant R7G  
This mutant was generated due to a cloning error (see 3.6.3.10 for details). It was 
expressed in BL21 cells (60 µM IPTG, 4 h, RT), pellet and supernatant were separated, 
analyzed by SDS-PAGE and tested (Fig. 4.41). AC assay conditions were 75 µM ATP, 
37°C, 2 mM Mn2+, 10 min, Tris-HCl pH 7.5. Activity of the supernatant fraction (0.6 pmol 
min-1) was identical to an empty vector control (0.5 pmol min-1). Activity of the pellet was 
0.3 pmol min-1 (control pellet 0.1 pmol min-1). After Ni-NTA-agarose purification the 
specific activity was 26 pmol mg-1 min-1 (4 µM protein, 30°C, 75 µM ATP, 10 min, Tris 
pH 7.5).  Under identical conditions the wild type AC showed a specific activity of 460 
pmol mg-1 min-1. Since the activity of this mutant was rather low it is possible that this N-
terminally positioned arginine residue in Rv0386 AC domain is critical for catalysis. For 
Rv1625c it is reported a significant loss of the activity when two N-terminally located 
arginine residues i.e. R43 and R44 were mutated to alanine and glycine, respectively 
(Reddy et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.41: 15% SDS-PAGE analysis of the mutant R7G in pellet and supernatant and in 
eluate after Ni-NTA purification. Applied were about 40 µg protein of pellets and about 20 
µg protein of supernatants. About 5 µg of purified R7G were applied.  
 
 
4.2.2.12 Crystallization of the AC domain 
First crystals were obtained with the N-terminally His-tag construct with buffers CS#22 
and CS2#1 (Hampton Research kit). Variations of these conditions and of the protein 
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solution components and concentration were made to optimize size and quality of the 
crystals (Table 4.18). With the C-terminally His-tagged construct four different conditions 
corresponding to buffers CS#6, CS2#30, CSL#22 and CSL#25 were found (Table 4.19). 
See appendix for pictures of the best crystals obtained.  
 
Protein: N-terminally His-tagged Rv0386(1-175) 
Buffer components Protein solution components 
Protein 
concentration Crystal form Remarks 
30% PEG 4000, 0.1 M Tris 
HCl pH 8.5, 0.2 M sodium 
acetate (CS#22*) 
Needles 
(clusters) 
After 3 
weeks at 
12 °C. 
10% PEG 6000, 2 M NaCl 
(CS2#1*) 
50 mM Tris HCl 
pH 8.5, 20% 
glycerol, 10 mM 
NaCl, 2 mM β-
mercaptoethanol 
9 mg/ml 
Cubes 
(very small) 
after 8 
days at 
12°C 
 
 
 
Optimization based on buffer CS2#1* 
16 mg/ml Rectangles 40 x 25 µm 
after 6 
days at 
12°C 
30 mg/ml Rectangles 115 x 30 µm 10% PEG 6000, 2 M NaCl 
22 mg/ml + 
1.7 mM α,β-
CH2 ADP 
Rectangles 
150 x 35 µm 
10% PEG 6000, 2 M NaCl, 
1 mM Dibutyryl cAMP 22 mg/ml 
Rectangles 
200 x 75 µm 
after 2 
weeks at 
12°C 
12% PEG 6000, 2 M NaCl 30 mg/ml Rectangles 115 x 30 µm 
after 2 
weeks at 
12°C 
10% PEG 5000, 2 M NaCl Rectangles 50 x 20 µm 
10% PEG 4000, 2 M NaCl Rectangles 200 x 175 µm 
10% PEG 3350, 2 M NaCl 
50 mM Tris HCl 
pH 8.5, 10% 
glycerol, 10 mM 
NaCl, 2 mM β-
mercaptoethanol 
 
16 mg/ml 
Rectangles 
200 x 175 µm 
after 8 
days at 
12°C 
 
 
Table 4.18: Summary of conditions in which crystals of N-terminally His-tagged Rv0386(1-
175) were grown. * Name according to the Crystal Screen Buffer Kit of Hampton Research 
(CS= crystal screen, CS2= crystal screen 2, CSL= crystal screen lite). 
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Protein: C-terminally His-tagged Rv0386(1-175) 
Buffer 
name 
Buffer components Protein solution 
components 
Protein 
conc. 
Crystal 
form 
Remarks 
CS#6* 
30% PEG 4000,  
0.1 M Tris HCl pH 
8.5, 0.2 M MgCl2 
Needles 
(clusters) 
CS2#30 
10 % PEG 6000,  
0.1 M Hepes pH 
7.5, 5% MPD 
Needles 
40 x 5 µm 
after 10 
days at 16 
°C 
CSL#22 
15% PEG 4000, 
 0.1 M Tris HCl pH 
8.5, 0.2 M sodium 
acetate 
Half-moon 
shaped 
50 x 50 µm 
CSL#25 
0.5 M sodium 
acetate, 0.1 M 
imidazole pH 6.5 
50 mM Tris HCl pH 
8.5,  
5 % glycerol,  
2 mM β-
mercaptoethanol,  
10 mM NaCl, 
incubated 12-14 h at 
0°C with 1 mM ATP 
9 mg/ml 
Needles** 
40 x 5 µm 
after 24 h 
at 16 °C 
 
Table 4.19: Summary of conditions in which crystals of N-terminally His-tagged Rv0386(1-
175) were grown. * Name according to the Crystal Screen Buffer Kit of Hampton Research 
(CS= crystal screen, CS2= crystal screen 2, CSL= crystal screen lite). ** Diffraction-
quality crystals; see preliminary data in appendix. 
 
4.2.3      Expression of Rv0386 holoenzyme 
4.2.3.1  Expression in BL21 (DE3) [pREP4] cells 
After expression (60 µM IPTG, 5 h, RT) cells were sonificated, pellet and supernatant 
were separated (14000 x g; 30 min; 4°C) and tested for AC activity. BL21 with empty 
vector served as a control (Fig. 4.42a). The expected MW including His-tag was 117 
kDa. The holoenzyme was in the pellet (presumably inclusion bodies). For better lysis a 
French Press was used (20,000 psi). Pellet and supernatant were separated as usual, 
protein purified with Ni-NTA-agarose (Fig. 4.42b) and tested. Only degradation products 
(because AC activity was detectable) were found in the eluate after purification. 
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Fig. 4.42: 12.5% SDS-PAGE of the holoenzyme Rv0386 using (a) sonification and (b) 
French Press for lysis. (a) Applied were: about 1.5 µg protein of supernatants, 4 µg of 
pQE30 pellet and 7 µg of holoenzyme pellet. Activities correspond to: 5 µg protein of 
supernatants, 32 µg of pQE30 pellet and 55 µg of holoenzyme pellet. (b) Applied were: 8 
µg of pellet, 5 µg of supernatant and 1 µg of purified protein. Activities correspond to 10.8 
µg protein. Specific activity of the purified protein (0.9 µM) was 254 pmol cAMP·mg-1·min-
1 (assay conditions: 75 µM ATP, 10 min, 30°C, 2 mM Mn2+, Tris-HCl pH 7.5).   
 
Incubation with DNAse (30 min, 0°C, 20 µg/ml) direct after cell lysis with French Press 
was performed in case that the holoenzyme bound to the DNA. Pellet and supernatant 
were as usual separated and the supernatant was further purified with Ni-NTA-agarose 
(Fig. 4.43). An increment of soluble holoenzyme in the supernatant was not observed. 
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Fig. 4.43: 12.5% SDS-PAGE analysis. Applied were : 24 µg of pellet proteins, 5 µg of 
supernatant and 1 µg of eluate. AC activities correspond to 2 µg pQE30 supernatant, 54 
µg pQE30 pellet, 72 µg holoenzyme pellet, 40 µg holoenzyme supernatant and 4 µg (0.3 
µM) of eluate. Specific activity of the purified protein is 181 pmol cAMP·mg-1·min-1. Assay 
conditions: 75 µM ATP, 10 min, 2 mM Mn2+, Tris/HCl pH 7.5, 30°C, 60 mM imidazole 
(from purified samples). 
 
Furthermore protease inhibitors (Complete tablets) with and without EDTA (1 mM) were 
added to the lysis buffer before French Press lysis. Pellets and supernatants were 
separated and analyzed by SDS-PAGE together with the eluates after protein 
purification (Fig. 4.44). In both cases intact holoenzyme could be recovered in the 
eluates.  
 
 
 
 
 
 
 
 
 
 
 
   
 
 
Fig. 4.44: 12.5% SDS-PAGE analysis after addition of (a) protease inhibitors only or (b) 
together with EDTA. Applied were 20 µg pellets, 15 µg supernatants and 1.5 µg eluates. 
AC activities are from (a) 50 µg pellet proteins, 35 µg supernatant, 4.8 µg eluate (0.4 µM; 
235 pmol cAMP·mg-1·min-1) and (b) 90 µg pellet proteins, 52 µg supernatant, 6.8 µg 
eluate (0.6 µM; 262 pmol cAMP·mg-1·min-1). Assay conditions: 75 µM ATP, 30°C, 2 mM 
Mn2+, Tris/HCl pH 7.5, 10 min, 60 mM imidazole (from purified samples). 
 
Expression of the holoenzyme with and without IPTG induction (60 µM, 3 h, RT) was 
investigated. Cell lysis was with addition of protease inhibitors and French Press, pellet 
and supernatant were separated as usual and the holoenzyme was further purified with 
Ni-NTA-agarose (Fig. 4.45). The majority of the expressed holoenzyme was found in the 
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pellet. From the expression without IPTG a little more soluble protein could be purified, 
but presumably IPTG induction is not directly responsible for the formation of inclusion 
bodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.45: 12.5 % SDS-PAGE of the holoenzyme expression with and without IPTG 
induction. Applied were: about 4 µg of pellet and supernatant proteins together with 0.5 
µg of eluates. AC activities were from 80 µg supernatants, 54 µg pellet –IPTG, 90 µg 
pellet +IPTG, 3.2 µg eluate –IPTG (0.3 µM; 443 pmol·mg-1·min-1) and 0.8 µg eluate 
+IPTG (68 nM; 174 pmol·mg-1·min-1). Assay conditions: 100 µM ATP, 30°C, 10 min, 2 
mM Mn2+, MOPS pH 7.5, 60 mM imidazole (from purified samples). 
 
4.2.3.2  Membrane preparations and attempts of solubilization 
A methodology normally used for solubilizing membrane proteins by addition of 
detergents was used for the holoenzyme (see chapter 3, purification of insoluble 
proteins). Detergents polidocanol (1%; Table 4.20; Fig. 4.46) and CHAPS (2%; Fig. 4.47 
and 4.48) solubilized good quantities of intact holoenzyme. Other detergents like SDS 
and Nonidet P-40 were of no use for the solubilization (Fig. 4.47). Degradation products 
were present in all cases.  
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SDS-PAGE AC-TEST 
SAMPLE µg protein µg protein 
Activity 
 (pmol min-1) 
A Pellet after centrifugation at 3000 g 100 412 185 
B Supernatant after centrifugation at 3000 g - 74 7.4 
C Supernatant after centrifug. At 100,000 g 14 54 0.7 
D Pellet after incubation with detergent 12 49 15.3 
E Supernatant after 2nd centrifug.100,000 g 12 48 0.6 
F Pellet after 2nd centrifug, at 100.000 g 62 249 113.5 
G Wash fraction of Ni-NTA purification 4 16 0 
H Eluate after Ni-NTA purification 3 16 4.3 
 
Table 4.20: Solubilization and purification of the holoenzyme using 1% Polidocanol. 
Samples of each step of the process were analyzed by SDS-PAGE and AC-test. Assay 
conditions: 75 µM ATP, 30°C, 10 min, MOPS pH 7.5. Eluate after purification showed a 
specific activity of 274 pmol·mg-1·min-1 for 16 µg protein (7.6 µM).  
 
 
 
 
 
 
 
 
 
Fig. 4.46: 12.5% SDS-PAGE analysis of the solubilization with 1 % Polidocanol. Sample 
and protein amounts applied on each lane are specified above in table 4.17.   
 
To investigate the solubilization with 2% CHAPS, 1% TRITON X-100, 1% SDS and 1% 
NONIDET P-40, pellets before incubation with the detergent and the Ni-NTA-purification 
eluates were analyzed by Western blot (antibodies anti-RGS-His4). For CHAPS and 
TRITON, the presence of more degradation products in the eluates than in the pellets 
was noticeable. With SDS it was impossible to purify detectable amounts of protein.  
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Fig. 4.47: a) Western blot analysis of the pellets (33,000 x g) before incubation with 
detergent (lanes A, C, E and G each about 4 µg of protein) and of the Ni-NTA-purification 
eluates (lanes B, D, F and H each 0.2-1 µg of protein). Samples were analyzed with 
antibodies anti-RGS-His4 diluted 1:2000. Time of exposure: 5 s. b) AC-test of the blotted 
samples: 75 µM ATP, MOPS pH 7.5, 30 °C, 10 min, with ATP-regenerating system. 
Specific activities of the eluates were: 555 (CHAPS), 1871 (Triton), 0 (SDS) and 311 
(Nonidet) pmol mg-1 min-1. 
 
 
Solubilization with CHAPS (2%) was examined in detail. Cell pellets were processed as 
usual. 8-15 µl of each step were analyzed by Western blot (no determination of protein 
concentration was made; Fig. 4.48). Degradation products of the holoenzyme were 
detected in most of the samples with exception of the supernatant after the second 
centrifugation step at 33,000 x g. A protein concentration of 80 ng was calculated for it 
by Western blot through a calibration curve (catalytic domain as a standard, anti-RGS-
His4). An AC-test using 320 ng protein showed an activity of 0.9 pmol min-1 (assay 
conditions: 500 µM ATP, MOPS pH 7.5, 30 °C, 4 min, with ATP-regenerating system). It 
corresponds to a specific activity of 2.9 nmol mg-1 min-1.  
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Fig. 4.48: Western blot analysis of the solubilization with 2% CHAPS. Antibodies anti-
RGS-His4 were used. Time of exposure was 60 s. 8 µl of pellet samples as well as 15 µl 
of supernatant and eluate samples were applied.  
 
4.2.3.3 Expression in BL21 STAR and ROSETTA cells 
4.2.3.3.1 Expression in BL21 STAR (DE3) [pREP4] cells 
Expression was performed with and without IPTG induction (30 µM, O/N, 15°C). Cells 
were sonificated in presence of protease inhibitors, lysates were incubated with 
lysozyme and DNAse, pellets and supernatants were separated as usual and protein 
was purified with Ni-NTA agarose (Fig. 4.49). From 3 x 600 ml of uninduced culture, 20 
µg purified protein were obtained and from an induced culture 12 µg protein. AC 
activities of pellets, supernatants and eluates were measured (Table 4.21). Differences 
between holoenzyme expression with or without induction with IPTG were not observed. 
In both cases eluates after purification showed degradation products.  
 
 
                                    
 
 
 
 
 
 
Fig. 4.49: 12.5% SDS-PAGE analysis of the expression in BL21 STAR cells. a) Cells 
were not induced; applied: 20 µg pellet, 15 µg supernatant and 1 µg eluate. b) Cells 
induced with 30 µM IPTG; applied: 20 µg pellet, 9 µg supernatant and 0.6 µg eluate.  
 
Lane            Sample 
A:     French Press homogenate 
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F:      Suspension after 1 h with     
detergent 
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Sample Protein (µg) 
Activity 
 (pmol·min-1) 
Specific activity 
(nmol·mg-1·min-1) 
Pellet  40.3 59 1.4 
Supernatant         uninduced 14.8 0.7 0.05 
Eluate  2 7.3 3.7 
Pellet  35.6 77 2.2 
Supernatant     +30 µM IPTG 8.6 0.2 0.02 
Eluate  1.2 6.7 5.6 
 
Table 4.21: AC activities of pellets, supernatants and eluates of expression in BL21 
STAR cells. Specific activites of eluates: 3.7 nmol·mg-1·min-1 without induction and 5.6 
nmol·mg-1·min-1 with induction (30 µM IPTG). Assay conditions: 500 µM ATP, 10 min, 
30°C, 5 mM Mn2+ and MOPS pH 7.5. Detection limit was 20 pmol·mg-1·min-1. 
 
An expression was carried out (60 µM IPTG, 16°C, 21 h). Cells were lysed with French 
Press with prior addition of protease inhibitors (Complete EDTA-free), and the cell 
homogenate was incubated with lysozyme and DNAse. Pellet and supernatant were 
separated as usual and protein was purified from with Ni-NTA-agarose (19 h binding). 
From 3 x 600 ml culture 0.4 mg protein could be purified. Analysis by SDS-PAGE (Fig. 
4.50), AC assay (Table 4.22) and Western blot of the pellet, supernatant and eluate 
were performed (Fig. 4.51). 
 
Sample Activity    (pmol·min-1) 
Specific activity 
(nmol·mg-1·min-1) 
Pellet 21 4.3 
Supernatant 1.1 0.2 
Eluate 31 6.3 
 
Table 4.22: AC activities from expression in BL21 STAR cells. Protein amount tested of 
each sample was 5 µg. Specific activity of the purified protein: 6.3 nmol·mg-1·min-1. Assay 
conditions: 500 µM ATP, 10 min, 30 °C, 5 mM Mn2+ and MOPS pH 7.5.  
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Fig. 4.50: 12.5% SDS-PAGE analysis of (a) expression of holoenzyme in BL21 STAR 
cells; applied were: 20 µg protein of pellet and supernatant and 3.2 µg of eluate and (b) 
expression of empty vector pQE30; applied were: 10 µg of pellet and supernatant. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.51: Western Blot analysis of the expression in BL21 STAR cells. Lanes A and B 
correspond to the proteins of the pellet (5 µg) and eluate (1.4 µg) respectively, analyzed with 
anti-KD0386. Lane C corresponds to the eluate analyzed with anti-DB0386 (antibodies 
against the DNA-binding domain). Time of exposure: 15 s. Molecular weight of the signals 
were calculated with the marker peqGold. 
 
After SDS-PAGE and Western blot analysis a band of approximately 25 kDa was 
identified as the main degradation product of the holoenzyme after purification. A 
considerable amount of non-degraded protein could be purified after expression in 
STAR cells when cell lysis was performed with sonification, but with the unavoidable 
presence of degradation products. 
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4.2.3.3.2 Expression in BL21 ROSETTA [pREP4] cells 
Expression was carried out (12 h, 12°C, 60 µM IPTG), cells were lysed with French 
Press with prior addition of protease inhibitors (Complete EDTA free), cell homogenate 
was incubated with lysozyme and DNAse, pellet and supernatant were separated as 
usual and the protein was purified with Ni-NTA agarose (19 h binding). SDS-PAGE 
analysis (Fig. 4.52), AC assay (Table 4.23) and Western blot (Fig. 4.53) were performed.  
 
 
 
 
 
 
 
 
 
 
                                    
Fig. 4.52: 12.5% SDS-PAGE analysis of expression in BL21 ROSETTA cells of (a) the 
holoenzyme; applied were: 20 µg protein of pellet and supernatant and 3.8 µg of eluate 
and (b) the empty vector pQE30; applied were: 10 µg protein of pellet and supernatant. 
 
 
Sample Activity (pmol·min-1) 
Pellet 13.2 
Supernatant   0.8 
Eluate 23.8 
 
Table 4.23: AC activity of the holoenzyme expressed in BL21 ROSETTA cells. Protein 
amount tested was 5 µg of each sample. Specific activity of the purified protein: 4.8 
nmol·mg-1·min-1. Assay conditions: 500 µM ATP, 10 min, 30 °C, MOPS pH 7.5.  
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Fig. 4.53: Western Blot of the holoenzyme expressed in ROSETTA cells. Lanes A and B: 
pellet (5 µg) and eluate (1.2 µg) analyzed with anti-KD0386. Lane C correspond to the 
eluate analyzed with anti-DB0386 (antibodies against the DNA-binding domain, see 
below). Time of exposure: 15s.  
 
4.2.3.4 Anion exchange chromatography of the purified holoenzyme 
The holoenzyme was expressed in BL21 STAR cells (1.2 L culture, 12°C, 15 h, 60 µM 
IPTG). Cell lysis was with protease inhibitors (Complete tablets, EDTA free) and French 
Press, lysates were incubated with lysozyme and DNAse, after centrifugation (33,000 x 
g, 1 h) protein purification was carried out as usual, 20% glycerol was added. Sample for 
chromatography was 800 µl of Ni-NTA eluate (about 280 µg protein; Fig. 4.54a). 
Chromatography was described in chapter 3 more exact. A 40 µL sample of fractions 
with UV absorption was tested. An SDS-PAGE analysis and Western Blot (Fig. 4.55) 
were performed only for those fractions which showed AC activity. 
                   
 
 
 
 
                              
 
 
 
 
 
 
Fig. 4.54: a) 12.5% SDS-PAGE analysis of the Ni-NTA eluate sample applied for 
chromatography; b and c) fractions collected with 100mM NaCl (6 to10), 200 mM NaCl 
(14 to16) and 300 mM NaCl (25 and 26). Activities in AC-test (850 µM ATP, 30 °C, 
MOPS pH 7.5, 5 mM MnCl2, 20 min) are shown below. 
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Fig. 4.55: Western blot analysis of the fractions analyzed in figure 4.54. Antibodies anti-
KD0386 diluted 1:10000 were used. Time of exposure was 60 s.  
 
All fractions which showed AC activity contained a degradation product of approximately 
25 kDa containing the AC catalytic domain of Rv0386. Another degradation product of 
about 60 kDa contained also the catalytic domain but had low activity presumably 
because of the high NaCl concentrations (fractions 25 and 26, 300 mM NaCl). 
 
4.2.3.6 Determination of Rv0386 orthologs in M. bovis BCG and M.  smegmatis 
Mycobacterium bovis and Mycobacterium smegmatis cell cultures (about 3 days old) 
were obtained from Priv. Doz. Dr. Peter Sander (Institut für Medizinische Mikrobiologie, 
Universität Zürich). 50 ml cultures were centrifuged (5,000 x g, 10 min). Pellets were 
frozen with liquid nitrogen, then suspended in 3 ml of 50 mM Tris-HCl pH 7.5 and lysed 
with French Press. Cell homogenates (1 ml) were centrifuged (20,000 x g, 30 min), 
supernatants were separated from pellets, and pellets were suspended in 100 µl of 50 
mM Tris-HCl pH 7.5. Samples were analyzed by Western blot with specific antibodies 
anti-KD0386 and anti-DB0386. The presence of an ortholog of Rv0386 was shown for 
M. bovis (detected in the soluble fraction only) but not in M. smegmatis (Fig. 4.56). 
These results are in line with genomic data which indicate the presence of a Rv0386 
ortholog in M. bovis, but not in M. smegmatis. With anti-KD0386 additionally to the ~116 
kDa band detected, other more intense protein signals could be detected, maybe 
corresponding to other cyclases which cross-reacted with the antibodies. With the 
antibodies anti-DB0386 only a protein of about 64 kDa was detected, possibly another 
protein of M. bovis with a similar DNA-binding domain.  
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Fig. 4.56: Western blot analysis of the supernatant proteins found in M. bovis BCG with 
specific antibodies anti-KD0386 (a) and anti-DB0386 (b). 11 and 7 µg protein were 
applied in a and b respectively. Antibodies anti-KD0386 were diluted 1:10000 and the 
anti-DB0386 1:5000. Time of exposure was 60 s (a) and 90 s (b). Molecular weight of the 
proteins detected were calculated with the help of the protein marker peqGold. 
 
 
4.2.4 Expression of the putative ATPase domain of Rv0386 
This domain (351 aa, 39 kDa) was expressed in BL21 cells (30 µM IPTG, 25°C, 3 h). 
Cells were sonificated, pellet and supernatant were separated and analyzed by SDS-
PAGE (Fig. 4.57a). After Ni-NTA purification the yield of protein was 0.1 mg protein from 
400 ml culture. Most of the protein was found in the pellet and after Ni-NTA purification 
the protein could be detected only by Western blot (Fig. 4.57b). Molecular weight of this 
protein is about 39 kDa (including N-terminal His-tag). 
  
 
 
 
 
                        
 
 
 
 
 
Fig. 4.57: a) 15% SDS-PAGE analysis of empty vector pQE30 and ATPase domain 
expressed in BL21 cells (Coomassie staining). Applied were: 20 µg of pellets and pQE30 
supernatant and 8 µg of ATPase supernatant. b) Western blot of pellet, supernatant and 
eluate from Ni2+-NTA of the ATPase domain with anti-RGS-His4. Applied were: 2 µg of 
pellet and supernatant and 1 µg of purified protein. Time of exposure: 5 seconds. 
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The ATPase domain was also expressed in BL21 STAR cells (6 µM IPTG, 20°C, 3 h). 
Cells were sonificated, pellet and supernatant were separated and analyzed by SDS-
PAGE (Fig. 4.58a). For protein purification and Western blot analysis a second 
expression was carried out (30 µM IPTG, 22°C, 3.5 h). A sample of pellet and 
supernatant was separated and the rest of the supernatant was purified as usual. From 
600 ml culture it was impossible to determine protein with BIORAD in the Ni-NTA eluate. 
All samples were analyzed by Western blot (Fig. 4.58b). Since only small amounts of 
ATPase domain were soluble, no ATPase tests were attempted.  
 
 
 
 
 
 
 
                                                    
 
 
 
 
Fig. 4.58: a) 12.5% SDS-PAGE analysis of the ATPase domain in BL21 STAR cells. 
About 20 µg protein of both pellet and supernatant were applied. b) Western blot 
analysis. Pellet (1.2 µg), supernatant (0.5 µg) and 15 µl eluate after Ni-NTA purification 
were analyzed with anti-RGS-His4. Time of exposure: 15 s. 
 
4.2.5 Expression of the putative transcription factor domain of Rv0386 
This domain (929 aa, 100 kDa including His-tag) was expressed in BL21 and BL21 
STAR cells (60 µM IPTG, 23 °C, 3 h) and analyzed by SDS-PAGE (Fig. 4.59). Only the 
pellet of BL21 STAR cells showed an overexpressed protein compared with the control.  
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Fig. 4.59: 12.5% SDS-PAGE analysis of a) empty pQE30 and transcription factor (TF) 
domain expressed in BL21 and BL21 STAR cells. Applied were: 15-20 µg of pQE30 
pellet (BL21), pQE30 supernatant (STAR) and TF supernatants (BL21 and STAR); 8-12 
µg of pQE30 and TF pellets (STAR), pQE30 supernatant and TF pellet (BL21). b) TF 
domain purified with Ni-NTA-agarose after expression in STAR cells. 15 µl of the eluate 
were applied. P=pellets and S=supernatants.  
 
For Western blot analysis expression was carried out again (30 µM IPTG, 3 h, 22 °C). 
Cells were sonificated (with protease inhibitors and lysozyme). Pellet, supernatant and 
eluate after Ni-NTA-agarose purification were analyzed by Western blot. The presence 
of degradation products in pellets and eluates was observed.  
 
 
 
 
 
             
 
 
 
 
 
 
Fig. 4.60: Western blot of the transcription factor domain expressed in BL21 and BL21 
STAR cells. Applied were: about 1 µg of pellets, 0.5 µg of supernatants and 15 µl of the Ni-
NTA-agarose eluate. Antibodies anti-RGS-His4 were used. Time of exposure: 15 s. 
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4.2.6   Expression of the putative DNA-binding domain of Rv0386 
This domain (103 aa, 12 kDa including His-tag)) was expressed in BL21 cells (4 h, 25°C, 
60 µM IPTG). Pellet, supernatant and eluate after Ni-NTA purification were analyzed by 
SDS-PAGE and Western blot (Fig. 4.61 a, b, c). This protein tended to dimerize and 
multimerize. 
 
 
 
 
 
 
 
 
           
 
 
 
 
Fig.4.61: (a)15% SDS-PAGE analysis of the DNA-binding domain (DB) expressed in 
BL21 cells (pQE30 empty vector as a control). (b) Western blot of 0.3 µg of pellet and 
eluate from Ni-NTA analyzed with anti-RGS-His4 antibodies. Time of exposure: 15 
seconds. (c) Western blot of the purified DB domain (1 µg) after dialysis with phosphate 
buffer and concentration. Time of exposure: 30 s. Protein of lane b2 was purified without 
DNAse and that of lane c with addition of it. 
 
 
4.2.6.7 Sensitivity and specificity of the antibodies anti-DB0386 
A protein sample with a concentration of 1-2 µg/µl (Fig. 4.62a) was used by BioGenes to 
produce affinity purified antibodies against the DNA-binding domain of Rv0386 (see 
chapter 3). The reactivity of the antibodies from two immunized rabbits was tested 
against different concentrations of DNA-binding domain by Dot Blot (Fig. 4.62b). With an 
antibody dilution of 1:10 000 it was possible to detect 10 ng protein (rabbit 5081).  
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Fig. 4.62: (a) 15% SDS-PAGE analysis of the protein used for production of anti-
DB0386. 2 µg protein were applied. (b) Dot Blot. 5 different antibody dilutions (1:2000 to 
1:500,000) as well as protein concentrations were used for testing purified antibodies 
from rabbit 5081. Protein concentrations were: 300 ng (A), 100 ng (B), 10 ng (C), 1 ng 
(D) and 0.1 ng (E). Time of exposure: 30 s. 
 
 
With anti-DB0386 it was possible to detect cross-reactivity with proteins of the three E. 
coli strains used for expression within this work (Fig. 4.63). These proteins have a MW 
(derived from standards on the blotted membrane) of 68 and 25 kDa and presumably 
contain a DNA-binding domain very similar to that of Rv0386. Based on these results, 
this antibody seems to recognize many DNA-binding proteins of E. coli and probably 
also of M. tuberculosis. Its utility for immunodetection of Rv0386 might be only possible 
simultaneously with antibody anti-KD0386. 
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Fig. 4.63: (a) Western blot of the expressed DNA-binding domain and empty vector 
pQE30 in BL21 cells. Antibodies anti-DB0386 1:5000 were used. Time of exposure: 30 s. 
Molecular weights were calculated with a marker. Applied were: 20 µg of DB 
supernatant, pellet and pQE30 pellet. From pQE30 and DB purified, 3 and 1 µg 
respectively were applied. (b) Western blot of expression of empty vector pQE30 in 
BL21, STAR and ROSETTA cells analyzed with antibodies anti-DB0386 (diluted 
1:10000). 10 µg protein were applied in each lane. Time of exposure was 60 s.  
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5 Discussion 
5.1 Chimeras of mycobacterial Rv1625c mutants with soluble 
mammalian and Paramecium cyclases 
As a complementary study to the already published data regarding the expression and 
characterization of Rv1625c (Guo et al., 2001), additional point mutants N372A, N372T 
and D300S were generated here. The idea was to check a) whether a threonine might 
be able to take over the function of an asparagine in transition state stabilization and b) 
whether a serine might substitute for aspartate in substrate definition. This was not the 
case. The mutants were essentially inactive. This was further proof that the six canonical 
amino acids identified in mammalian ACs as critical for catalysis and conserved in 
Rv1625c, are also absolutely essential in the latter.  
Since soluble mammalian AC domains C1 and C2 from different isoforms have shown a 
restored catalytic activity when mixed i.e. IC1/IIC2 (Tang and Gilman, 1995; Whisnant et 
al., 1996; Yan et al., 1996), VC1/IIC2 (Désaubry et al., 1996; Dessauer et al., 1997; 
Sunahara et al., 1997; Tesmer et al., 1997) and IXC1/IIC2 (Hoffmann, 1999), the 
possibility to get active chimeras by mixing mycobacterial soluble catalytic domains with 
mammalian ones was enticing. The mycobacterial Rv1625c inactive mutant D300A 
lacking its metal binding function and consequently their mammalian-like C1-domain 
function, were barely able to reconstitute enzymatic activity when mixed with mammalian 
IC1, VC1, VIIC1 or IXC1 domains. Similarly inactive mutants R376A, N372T and N372A 
having no mammalian-like C2-function were not really capable to complement inactive 
mammalian IIC2 and IXC2 domains.  
The observed specific AC activity of these chimeras was very small, actually tiny 
compared to Rv1625 wild type. This fact indicates that although the substrate binding 
and some catalysis may have taken place, no complementation of the C1/C2 domains 
occurred. One explanation could be the differences of dimerization epitopes between 
Rv1625c and mammalian ACs, e.g. the “arm region” (proposed in Linder et al., 2002) 
where the motif KWQ is replaced by RFF in Rv1625c. This KWQ motif is invariant in 
ACs I-VIII and specially the residue Q (Q584 in AC type V from rabbit) was identified as 
crucial on the dimerization interface (Zhang et al., 1997; Sunahara et al., 1998; Tucker 
et al., 1998). Although recent studies showed that in the chimera VC1a/IIC2 the KWQ 
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motif is not involved in substrate binding (Tesmer et al., 1999), it could be possible that 
its direct participation depends on the cyclase isoform. The lack of the KWQ motif in 
Rv1625c and also the conformational changes due to the mutations in the mycobacterial 
monomers could explain the lack of a robust reconstitution.  
Surprisingly, the C2-positioned domain from the Paramecium GC and its triple mutant 
ParaGC-C2KWQ reconstituted a soluble AC when mixed with mammalian IIC2 domain 
(Linder et al., 2000) and with the mycobacterial mutant D300A. The topological inversion 
of the cytosolic domains in the Paramecium GC and the fact that the KWQ motif is an 
AC-specific stabilizing motif of the dimerization between C1 and C2, was in agreement 
with Linder et al. (2000). The C2-positioned Paramecium GC domain contributed the 
metal binding function while IIC2 or D300A contributed the substrate specificity function 
upon mixing. Additionally, the mutant ParaGC-C2KWQ stabilized and/or enhanced the 
interaction of the C1 and C2 equivalent domains since the specific activity of ParaGC-
C2KWQ/IIC2 was about 3-fold higher than ParaGC-C2/IIC2. That was not the case with 
the chimera ParaGC-C2KWQ/D300A which was equally active as  the ParaGC-
C2/D300A dimer. Dimerization of the chimera ParaGC-C2/D300A was substrate 
dependent, no activity with Mg2+ was supported, the diterpene forskolin did not stimulate 
and P-site inhibitors did not inhibit. It seems that the individual catalysis and regulation 
properties possess enough structural complementarity to allow formation of a functional 
chimera. Kinetic characterization of ParaGC-C2/D300A showed an ATP affinity (Km= 
201 µM) similar to that of Rv1625c AC domain (Km= 150 µM; Guo et al., 2001) with 
about a 70-fold reduced Vmax (29.5 nmol cAMP·mg-1·min-1).  
An open question concerning the Rv1625c AC was why was it not stimulated by  
forskolin, a character shared among all but type IX of the mammalian ACs. The 
alignments in chapter 4 (Fig. 4.1 a, b) clearly indicate the amino acid differences which 
may be responsible for this lack of a forskolin effect on Rv1625c. While in mammalian 
ACs the binding of forskolin is shared between C1 and C2 domains (the C1 domain 
provides a threonine and C2 a serine, e.g., T426 in ACI-C1 and S927 in ACII-C2), in the 
mycobacterial AC Rv1625c those residues are substituted by an asparagine (N372) and 
an aspartate (D300), respectively, both directly implicated in catalysis. Rv1625c acts as 
a homodimer with two ATP binding sites in contrast to the mammalian ACs in which one 
site has evolved to bind forskolin instead of ATP. Therefore, it was speculated that the 
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mutants N372T and D300S may reconstitute an active heterodimer with a single ATP-
binding site and a forskolin-binding site. 
Somewhat surprisingly mutants N372T and D300S subserving C1 and C2 functions, 
respectively, did complement each other quite well to form an active enzyme (Table 4.6, 
Fig. 4.10). A forskolin stimulation, however, was not observed. This is evidence that 
those two amino acids implicated in forskolin stimulation are required but not sufficient to 
confer diterpene sensitivity. Obviously, the binding pocket for forskolin at the C1/C2 
interface is more elaborate and probably requires additional structural features absent in 
Rv1625c. Similarly, chimeras N372T/IIC2 and N372T/IXC2 were not activated by 
addition of forskolin. The observed weak effects were solely due to the solvent DMSO. 
Reconstitution experiments with the mutants N372T, N372A and D300S were carried 
out. Chimeras of these mutants did not show Mg2+ supported activity in agreement with 
the observations for the wild type (Guo et al., 2001). By titration of N372T, N372A and 
R376A with increasing amounts of D300A or D300S it was determined that they folded 
correctly and are capable of forming productive heterodimeric complexes in analogy to a 
mammalian C1-C2 arrangement. Nevertheless, the apparent dissociation constants 
derived from the titration curves showed lower affinity of the monomers to each other in 
comparison with the wild type (Guo et al., 2001). Conformational changes due to 
mutations may explain this effect on the dimerization of these chimeras.  
 
5.2 Adenylyl cyclase catalytic domain of Rv0386 
The gene product of Rv0386 was not originally predicted as an AC but denoted as a 
transcriptional regulator containing an ATP/GTP-binding site motif A, a luxR family 
signature and an helix-turn-helix motif.  After a functional classification of nucleotide 
cyclase superfamilies in M. tuberculosis through computational methods and 
phylogenetic analysis, the cyclase homology domain (CHD) of Rv0386 was described as 
a cytoplasmic class III AC with similarity to CHDs detected in other Gram-positive 
bacteria, e.g. in Streptomyces (McCue et al., 2000). Following subclassification of class 
III ACs, Rv0386 was assigned to class IIIc ACs in which the frequency of substitutions in 
the six canonical catalytic residues is remarkably high (Linder and Schultz, 2003). In the 
CHD of Rv0386 a substrate-defining glutamine and an asparagine instead of the 
canonical lysine and aspartate were found. Since enzymatic activities have been 
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demonstrated for unorthodox cyclases having variations in the canonical residues and 
since all known subclass IIIc enzymes appear to function as homodimers (Linder and 
Schultz, 2003), two major questions were addressed: Has AC Rv0386 an AC activity in 
spite of the changes of both amino acids involved in defining the substrate specificity? 
And if active, is AC Rv0386 functioning as a homodimer like mammalian-type AC 
Rv1625c? 
The recombinant CHD Rv0386(1-175) was used for answering these questions. This AC 
was capable of converting ATP to cAMP, using Mn2+ as a cofactor. Yet it displayed a 
rather low activity (4.8 nmol of cAMP⋅mg-1⋅min-1), corresponding to only 1/400 to 1/250 of 
AC activities characterized in other mycobacterial ACs, e.g. Rv1625c (Guo et al., 2001) 
and Rv1264 (Linder et al., 2002). Most surprisingly, Rv0386(1-175) had also a 30% GC 
side activity strictly dependent on Mn2+ as divalent cation cofactor. No AC nor GC 
activities were detectable with Mg2+ as a cofactor. A preference for Mn2+ was also shown 
for Rv1625c and Rv1264 (Guo et al., 2001, Linder et al., 2002). It was reported that 
macrophages are able to import Mn2+ providing a suitable environment for resident M. 
tuberculosis. The mycobacterial gene product Rv0924c was recently reported to be a 
homologue of the macrophage Nramp Mn2+ transporter protein (Agranoff et al., 1999; 
Reddy et al., 2001). The kinetic properties of Rv0386(1-175) such as temperature optimum 
of 30-37°C, activation energy of 76 kJ/mol and pH optimum of 8.3 were within the usual 
range reported for the mammalian AC catalysts. No activation by forskolin and no 
inhibition by the P-site inhibitor 2’d3’-AMP were observed, as expected. Substances like 
α,β-CH2-ADP (ADP-analog) and cordycepin 5’-triphosphate (ATP-analog) inhibited AC 
activity as did cAMP derivates like monobutyryl cAMP and dibutyryl cAMP. Dimerization 
of the catalytic domain of Rv0386 was demonstrated by the fact that AC specific activity 
increased almost 5-fold by increasing protein concentration and an apparent association 
constant of 0.1 µM was derived indicating a high affinity of the monomers to each other. 
That was further substantiated by western blotting, where with the specific antibody anti-
KD0386, the presence of monomers, dimers, tetramers together with higher multimers 
was observed. Using GTP as a substrate, the specific activity increased only 3-fold upon 
increasing protein concentration and the calculated apparent association constant was 
0.9 µM. The fact that the dimerization process occurs slower with GTP than with ATP 
points to an important role played by the substrate during the formation of the 
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homodimeric catalytic complex. AC kinetic parameters were Km= 417 µM and Vmax= 4.8 
nmol of cAMP⋅mg-1⋅min-1. For GC activity Km and Vmax values of 299 µM and 1.6 nmol of 
cAMP⋅mg-1⋅min-1 were obtained.  
To determine if the amino acid residues Q57 and N106 which deviate from the canonical K 
and D, are critical for catalysis in Rv0386, they were mutated to A. Residual AC specific 
activities of less than 2% for mutants Q57A and N106A demonstrated the important role 
played by Q and N when recognizing ATP as a substrate. GC residual activities of these 
mutants were also lower showing that the same residues are involved in recognizing 
GTP as a substrate. Whether the AC activity of Rv0386 is so low because of the 
substituted canonical K and D residues was examined with the mutants Q57K, N106D 
and Q57K/N106D. A reduction of more than 90% of the AC activity was observed by 
these three mutants. The GC activity was also affected as expected. Interestingly, 
comparison of the AC and GC activities of the mutants showed a significant reduction in 
the substrate discrimination for mutants Q57K/N106D and N106A. These results 
strongly argue that completely different substrate-specifying mechanisms exist in 
Rv0386 in comparison with canonical class III ACs.  
Through an alignment of the sequences of the AC domain of Rv0386 and the 
Paramecium GC (see appendix and alignment in section 4.2.2.8, chapter 4) the 
substitution of Q57 and N106 (Rv0386) by E1681 and S1748 (in ParaGC) was identified. 
Assuming that E56 (Rv0386) might functionally correspond to E1681 of ParaGC,  the 
mutation of N106 to S was examined for its substrate specificity. This mutant had no 
increased GC activity, on the contrary it was reduced >80%. The AC activity of N106S 
was also reduced but to a lesser extent. Considering that the AC activity of Rv0386 is 
lower in comparison with the mycobacterial AC’s Rv1625c and Rv1264, its low but 
detectable GC activity points to a certain plasticity of the substrate-defining mechanism. 
A hypothetical substrate binding mechanism for AC Rv0386 is shown in figure 5.1. This 
way of binding of ATP or GTP is drawn according to the mode of binding of cAMP or 
cGMP within the phosphodiesterase (PDE) superfamily based on the X-ray structure of 
the catalytic domain of PDE 4B2B (Xu et al., 2000).  
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Fig. 5.1: Hypothetical substrate recognition mechanism proposed for Rv0386 as adenylyl 
cyclase (left) and as guanylyl cyclase (right). See explanation in the text.  
 
According to the model of cAMP binding in PDE4, the side chain of a glutamine residue 
present in the active site forms hydrogen bonds with the N1 and N6 groups of adenine, 
but this glutamine could also accommodate the N1 and O6 groups of guanine in cGMP-
binding by rotation of its amide group by 180° (Xu et al., 2000). Compared with that, in 
Rv0386 Q57 could be responsible for the dual specificity and N106 could form a hydrogen 
bond with Q57 affecting the correct orientation of the substrate towards the transition 
state. In PDE4 this role is taken by a tyrosine side chain. Unfortunately, the low AC and 
GC activities of mutants Q57K, Q57A, N106D, N106A and Q57K/N106D did not permit 
kinetic studies to determine if their diminished turnover was due to reduced substrate-
affinity, conformational changes affecting the transition state or both. However, the 
kinetic parameters obtained for N106S using ATP as a substrate somewhat support the 
hypothetical substrate-binding mechanism proposed above. Since N106S showed a 
reduced Vmax but not reduced Km in comparison with the catalytic domain of the wild 
type, it is clear that N106 is less important for coupling the substrate than for positioning 
it. Such an argument was previously made for the Anabaena AC cyaB1, where a 
threonine functionally replaced the substrate-specifying aspartate and its mutation to 
alanine resulted also in a Vmax- but not a Km-change (Kanacher et al., 2002). 
Unfortunately, it was not possible to make a kinetic study for N106S to determine its 
specificity for GTP as a substrate because of its low GC activity. Finally, when the 
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differences in length of the respective side chains between Q and K, and N and D are 
considered, the variation in length of the “arm region” or “dimerization region” in Rv0386 
(see chapter 1 for explanation and alignments in appendix) compared with this 
sequence segment in mammalian ACs (8 vs. 14 residues, respectively) could be also 
responsible for the changes in the fine structure of the purine-binding pocket in Rv0386 
as a result of a conformational adjustment and compensation. Within this arm region, the 
triad KWQ (in mammalian ACs) or LVR (in Paramecium GC) is found. Particularly, the Q 
of this triad was claimed to assist K and D in adenine binding (Tesmer et al., 1997; 
Sunahara et al., 1998) while its correspondent R in the Paramecium GC is supposed to 
assist the E and S in guanine binding (Linder and Schultz, 2002; see fig. 4.1 for 
sequence alignments). On the contrary, structural data concerning substrate binding of 
the AC VC1a/IIC2 chimera showed that the KWQ motif appeared uninvolved (Tesmer et 
al., 1999). In any case this motif stabilizes AC-specifically the dimerization and its 
residues are absent in the shortened arm region of Rv0386. The unexpected reduction 
in the GC activity upon mutation of N106 to S highlights again the different substrate-
specifying mechanism in Rv0386. 
The effect on the catalytic properties of Rv0386(1-175) by modifications of its N-terminal 
region was also remarkable. Mutant R7G showed only 6% residual activity and the 
Rv0386 catalytic domain-equivalent of MT0399 (with 7 amino acid residues elongation 
before the M1 of Rv0386) showed only 30% residual activity. Kinetic parameters of R7G 
were not investigated but the N-terminally elongated catalytic domain showed a 5-fold 
reduction in ATP-affinity (Km= 2.3 mM) in comparison with Rv0386(1-175) (Km= 417 µM). 
Notably, small C-terminal modifications of Rv0386(1-175) like changing the His-tag to the 
C-terminal position were well tolerated and did not modify the substrate affinity (Km= 454 
µM) and caused only an insignificant reduction (20%) in the specific activity, but 
compromising significantly the dimerization process. 
It can be concluded that amino acid additions or charge changes in the N-terminal end 
of Rv0386 considerably affected the substrate binding and/or catalysis, maybe because 
of important conformational changes. These results together with the mutational studies 
show how important the determination of the three-dimensional structure of the 
unorthodox catalytic domain of Rv0386 might be to establish the individual architecture 
of its purine-binding pocket. Within the scope of this study, crystals of the AC catalytic 
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domain of Rv0386 were obtained. N-terminal as well as C-terminal His-tagged Rv0386(1-
175) were successfully used for these purposes. Using the vapor diffusion method, a wide 
variety of crystallization conditions and crystal forms were found for these proteins. Until 
now diffraction-quality crystals were obtained only with the C-terminal His-tagged 
catalytic domain. Since Rv0386(1-175) has a high crystallization potential, optimization 
experiments are continuing in collaboration with the Biochemie-Zentrum in Heidelberg. 
 
5.3 Holoenzyme Rv0386  
Rv0386 seems to be a very interesting enzyme in terms of its multi-domain composition, 
the possible evolutionary origin of its modular architecture and, of course, its 
demonstrated unorthodox activity as an AC. In Rv0386, the N-terminally located cyclase 
homology domain is succeeded by a putative transcription factor domain comprising an 
ATPase domain and a HTH-DNA-binding domain.  
The Rv0386 holoenzyme could be expressed in three different E. coli strains (BL21, 
BL21 STAR and BL21 ROSETTA all with pREP4 plasmid), but it ended up mostly in 
inclusion bodies. Small amounts of full length protein remained in the soluble fraction 
and could be purified using Ni-NTA-agarose including all kinds of degradation products, 
possibly originating during the purification process. It is likely that the protein was 
degraded instead of prematurely terminated, since the full length protein was still 
present in the insoluble material (inclusion bodies). It was attempted to optimize 
expression varying external conditions (time, temperature, concentration of the inducer) 
or using special host strains for improvement of mRNA stability (STAR cells) or 
enhancing the expression of proteins containing rare codons (ROSETTA cells). The use 
of protease inhibitors and detergents for protein solubilization after cell lysis were also 
tried. DNAse was added after cell disruption in case that protein was bound to DNA 
through its DNA-binding domain. These steps did not improve recovery of the 
holoenzyme. The conditions found to be best for obtaining more soluble protein and less 
degradation products were expression in BL21 STAR cells without induction with IPTG 
(expression at 15°C for 16 h) and addition of lysozyme and DNAse after cell disruption. 
The protein obtained under these conditions showed an AC activity of 3.7 nmol of 
cAMP⋅mg-1⋅min-1. Unfortunately, the eluate contained at least five additional main 
degradation products which, if containing AC catalytic domain, could also contribute to 
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the AC activity observed. Therefore, it is impossible to make any conclusions or 
comparisons between the AC activity of the holoenzyme and the AC domain. 
With the antibodies anti-KD0386 and anti-DB0386 it was possible to identify the principal 
degradation products of Rv0386. Identified with anti-KD0386 were products of 25-28 
kDa, 40-45 kDa and 60-70 kDa as main bands. With anti-DB0386, a main product of 
about 25 kDa was detected. There were also degradation products observed on the 
SDS-PAGE gels that were not detected either with anti-KD0386 nor with anti-DB0386, 
probably corresponding to holoenzyme fragments that did not contain the AC catalytic 
domain nor the DNA-binding domain. It could be speculated that the folding of the 
holoenzyme Rv0386 was defective and that the most probable sites for rupture were 
interdomain, mainly after the AC catalytic domain. Until now for most studied 
transcription factor proteins, binding of their cognate signals destabilized them for 
proteolysis (sometimes autoproteolysis) (Little et al., 1980; Becker et al., 1999), but 
recently it was also reported that the transcription factor TraR of Agrobacterium 
tumefaciens must bind its inducing ligand (N-3-oxooctanoyl-L-homoserine lactone) to 
acquire its native conformation and protease resistance when expressing in E. coli cells. 
This TraR signaling ligand is critical for the folding of nascent protein into its mature 
tertiary structure (Zhu and Winans, 2001). Both aspects could be the reason why 
Rv0386 full length protein was found mainly degraded. Either an E. coli signaling 
molecule is inducing proteolysis of Rv0386 in some manner or a particular ligand for 
Rv0386 could exist in M. tuberculosis and not in E. coli expression cells, which could be 
responsible for attaining the Rv0386 native conformation and conferring resistance to 
cellular proteolysis only when synthesized in the presence of this signal molecule.  
The in vivo expression of Rv0386 was shown using Mycobacterium bovis cell 
cultures (BCG strain), which is reported to contain a homologous protein denoted as 
Mb0393 (Garnier et al., 2003). A very slight signal of the holoenzyme could be detected 
with the help of antibodies anti-KD0386 in the soluble cellular fraction. Since the 
antibodies anti-KD0386 were able to recognize 10 of the other 14 class III AC’s present 
in M. tuberculosis (probably because of the high conformation similarity between their 
cyclase homology domains), the detection of two additional stronger signals (about 55 
and 38 kDa) with these antibodies in the soluble fraction of M. bovis cells could be 
explained as the recognition of other cyclases. It is possible to suggest that Rv0386 as a 
  132
transcription factor could show variable expression levels and was expressed in very low 
amounts when the M. bovis cells were disrupted for analysis. With the antibodies anti-
DB0386 only a signal of about 64 kDa could be detected, maybe because of the 
recognition of other transcription factors with similar HTH-DNA-binding domains. 
Nevertheless, the possibility that Rv0386 could also suffer interdomain proteolysis in 
vivo should not be neglected. 
The putative transcription factor-, ATPase and DNA-binding domains of Rv0386 
could also be expressed in E. coli as individual proteins. The purification of reasonable 
amounts of the transcription factor domain was however impossible. The ATPase 
domain was found in its majority in the insoluble fraction and only a very low amount 
could be purified. That is the reason why no further experiments were made. On the 
contrary, the DNA-binding domain could be purified in sufficient amounts to produce 
specific antibodies. Through Western blot it was possible to determine the high tendency 
of dimerization of this domain. However, antibodies anti-DB0386 were also capable of 
detecting E. coli proteins (28 and 68 kDa, approximately), probably transcription factors 
with a similar conformation to the DNA-binding domain as Rv0386.  
The role that could be played by Rv0386 as a transcription factor in M. 
tuberculosis remains unclear. The consequences and advantages gained by joining an 
adenylyl cyclase domain with a transcription factor containing an ATPase motif 
responsible for ATP binding and hydrolysis remain unexplained. Certainly, the vast 
regulation possibilities of Rv0386 as an AC and as a transcription regulator in vivo must 
be the reason why this multimeric signaling unit could evolutionarily arise.  
 
5.4 Remaining questions 
Since Rv0386 has evolved to use specific variant residues in an altered catalytic 
mechanism and of unsuspected regulation possibilities by joining this AC domain with a 
transcriptional regulator, two main questions remain open after this work: Is it possible to 
elucidate the structure of the AC domain for an understanding of its catalytic properties 
observed until now through biochemical analysis? And what is the role that Rv0386 
plays in vivo as a transcription factor? Anyhow, the first of these questions is hopefully 
going to be answered soon, since the first crystallization attempts of the Rv0386 AC 
domain were started successfully.  
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6 Summary 
I report on two class III ACs of Mycobacterium tuberculosis which possess very different 
structural as well as catalytic characteristics: the mammalian-like membrane-anchored 
Rv1625c and the transcription-factor-attached Rv0386. As a complementary study to 
published data (Guo et al., 2001), additional point mutations were made which 
demonstrated the essential role of the six canonical amino acids for catalysis in 
Rv1625c. The cytosolic mutants of Rv1625c N372A, N372T and D300S were used to 
investigate dimerization with mammalian AC catalytic units. Rv1625c engineered to 
contain forskolin binding amino acids cannot be stimulated by the diterpene. The 
similarities in conformation and mechanisms of catalysis between ACs and GCs was 
confirmed through the formation of functional chimeras between Mycobacterium 
Rv1625c and a guanylyl cyclase of Paramecium. The versatility of the class III cyclase 
homology domains concerning their modular architectures and mechanisms of catalysis 
was demonstrated with the biochemical characterization of Rv0386. This enzyme has a 
substrate-defining mechanism distinctly different of that of mammalian ACs. In addition 
by using ATP as well as GTP as a substrate it is a unique AC isoform unknown so far. 
Mutational studies of the Rv0386 AC domain proved the essential role that is played by 
a glutamine and an asparagine instead of the canonical lysine and aspartate for 
recognition of ATP and GTP as substrates. Diffraction-quality crystals of this AC domain 
were obtained as a first step to decipher the molecular and structural particularities of its 
catalytic function. Sequence comparisons identified an ATPase, a HTH DNA-binding 
and a transcription factor domain in Rv0386. How these domains affect AC activity in a 
concerted regulatory mechanism remains a pressing question for future studies. 
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7 Zusammenfassung  
Im Rahmen der vorliegenden Arbeit wurden zwei Klasse III ACn aus Mycobacterium 
tuberculosis mit unterschiedlicher strukturellen und katalytischen Eigenschaften 
untersucht: die Mammalia-ähnliche Rv1625c und die an einen Transkriptionsfaktor 
gebundene Rv0386. Als ergänzende Studien zu bereits publizierten Daten (Guo et al., 
2001), wurden zur Überprüfung der wesentlichen Rolle der sechs kanonischen 
Aminosäuren, die bei Mammalia-ACn in der Katalyse beteiligt sind und die in Rv1625c 
konserviert und auch katalytisch relevant sind, zusätzliche Punktmutationen 
durchgeführt und getestet. Die Rv1625c Mutanten N372A, N372T und D300S, die 
einzeln inaktiv sind, wurden für Rekonstitutionsversuchen benutzt wobei die Bildung 
katalytisch aktiver Homodimere in Rv1625c nachgewiesen wurde. Punktmutationen in 
Rv1625c, die Forskolin-bindende Aminosäuren in Säugercyclasen betreffen, erfahren 
dennoch keine Stimulierbarkeit durch das Diterpen. Die Ähnlichkeiten in Struktur und 
katalytischem Mechanismus zwischen ACn und GCn wurden hier bestätigt, da 
Chimären zwischen Mycobacterium Rv1625c und einer Guanylatcyclase aus 
Paramecium aktive katalytische Zentren gebildet haben. Die Vielseitigkeit der Klasse-III 
Cyclase Homologie Domänen hinsichtlich ihres modularen Aufbaus und ihres 
katalytischen Mechanismus wurde hier durch die biochemische Charakterisierung von 
Rv0386 nachgewiesen. Dieses Enzym zeigte einen Mechanismus zur Erkennung des 
Substrates, der sich von dem der Mammalia-ACn deutlich unterscheidet. Dieser 
ermöglicht die Erkennung sowohl von ATP als auch GTP als Substrat und ist eine 
Eigenschaft, die bis jetzt in keiner anderen AC Isoform beobachtet wurde. Mutationen 
der AC Domäne beweisen die essentielle Rolle, die Glutamin und Asparagine statt dem 
kanonischen Lysin und Aspartat bei der Erkennung der Substrate ATP und GTP in 
Rv0386 spielen. Der Erhalt der ersten diffraktionsfähigen Kristalle der AC Domäne 
innerhalb dieser Arbeit ist ein erster Schritt zur Erkenntnis der Besonderheiten ihrer 
katalytischen Funktion. Die Suche nach Sequenz Ähnlichkeiten zeigte, dass Rv0386 
zusätzlich zu der AC Domäne aus ATPase-, HTH DNA-bindungs- und 
Transkriptionsfaktor-Domänen besteht. Noch zu beantworten bleibt die Frage, wie die 
regulatorische Verbindung zwischen der AC Domäne und dem Transkriptionsregulator 
AC Aktivität und weitere unbekannte Regulationsmechanismen beeinflusst.  
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8 Appendix 
 
8.1 DNA and protein sequences of Rv0386 
DNA and protein sequences of Rv0386 (Sanger Institute MTV036.21 or Swiss-
Prot/TrEMBL accession number O53720). 
         
                bp      aa 
ATG AGC AAG TTG CTG CCA CGG GGC ACA GTG ACA TTG CTG TTG GCC  45 
 M   S   K   L   L   P   R   G   T   V   T   L   L   L   A    15 
GAC GTC GAG GGA TCC ACC TGG CTG TGG GAG ACC CAT CCA GAC GAC  90 
 D   V   E   G   S   T   W   L   W   E   T   H   P   D   D    30 
ATG GGT GCT GCC GTG GCG CGC CTC GAC AAA GCC GTG TCT GGT GTG  135 
 M   G   A   A   V   A   R   L   D   K   A   V   S   G   V    45 
ATT GCC GCC CAT GAC GGC GTA CGC CCA GTC GAG CAG GGT GAG GGT  180 
 I   A   A   H   D   G   V   R   P   V   E   Q   G   E   G    60 
GAT AGC TTT GTC CTC GCG TTC GCC TGC GCG TCG GAT GCC GTG GCC  225 
 D   S   F   V   L   A   F   A   C   A   S   D   A   V   A    75 
GCC GCG TTG GAC TTG CAG CGA GCG CGG CTC GCA CCG ATC CGG TTG  270 
 A   A   L   D   L   Q   R   A   R   L   A   P   I   R   L    90 
CGC ATA GGC GTG CAC ACC GGG GAG GTC GCG CTC CGC GAC GAA GGC  315 
 R   I   G   V   H   T   G   E   V   A   L   R   D   E   G    105 
AAC TAT GCC GGT CCG ACC ATC AAC CGG ACC GCG CGC CTG CGT GAC  360 
 N   Y   A   G   P   T   I   N   R   T   A   R   L   R   D    120 
TTG GCG CAT GGG GGC CAG ACG GTG CTC TCG GGC GTG ACC GAA AGC  405 
 L   A   H   G   G   Q   T   V   L   S   G   V   T   E   S    135 
CTG GTC ATC GAT CGC CTC CCG GAC AAA GCA TGG CTG GTT GAC CTG  450 
 L   V   I   D   R   L   P   D   K   A   W   L   V   D   L    150 
GGG ACG CAC GCG CTG CGG GAT CTG TCG CGT CCG GAG CGG GTA ATG  495 
 G   T   H   A   L   R   D   L   S   R   P   E   R   V   M    165 
CAG CTG TGT CAT CCC GAA TTG CGT ATC GAT TTC CCG CCG CTG CGG  540 
 Q   L   C   H   P   E   L   R   I   D   F   P   P   L   R    180 
GTG GCC AAT GAC GAT GTG GCC CAT GGT CTT CCG GTG CAC CTG ACG  585 
 V   A   N   D   D   V   A   H   G   L   P   V   H   L   T    195 
CGT TTT GTG GGG CGC GGC GCG CAG ATC ACC GAG GTG CAC CGG TTG  630 
 R   F   V   G   R   G   A   Q   I   T   E   V   H   R   L    210 
GTG ACC GAT AAC CGG TTG GTG ACC CTG ACC GGC GCC GGC GGC GTG  675 
 V   T   D   N   R   L   V   T   L   T   G   A   G   G   V    225 
GGC AAG ACA CGG CTG GCG GCG CAG CTC GCG GCG CAG ATC GCC GGT  720 
 G   K   T   R   L   A   A   Q   L   A   A   Q   I   A   G    240 
GAG TTC GGT CGC GCG TGG TTC GTG GAT CTG GCG CCG ATC ACG GAC  765 
 E   F   G   R   A   W   F   V   D   L   A   P   I   T   D    255 
CCC GAC TTG GTG CCG GTC ACG GTG GCG GGC GCG CTG GGA CTG CAC  810 
 P   D   L   V   P   V   T   V   A   G   A   L   G   L   H    270 
GAC CAG CCG GGC CGC TCC ACG ACG GAC ACC GTG CTG CGC TTT CTT  855 
 D   Q   P   G   R   S   T   T   D   T   V   L   R   F   L    285  
GGC GGG CGT CCA GCC CTG GTG GTG CTG GAT AAC TGC GAG CAC CTG  900 
 G   G   R   P   A   L   V   V   L   D   N   C   E   H   L    300 
CTG GAT GCG ACG GCG GCC TTG GTG TTA GCG CTG GTG AAA GCG TGC  945 
 L   D   A   T   A   A   L   V   L   A   L   V   K   A   C    315 
CGG GGG GTG AGG TTG CTG GCA ACT TGT CGT GAG CCG CTC CGG GTC  990 
 R   G   V   R   L   L   A   T   C   R   E   P   L   R   V    330 
GAG GGT GAG GTG AGC TAC CGG GTG CCG TCG CTG TCA CTG AGC GAT  1035 
 E   G   E   V   S   Y   R   V   P   S   L   S   L   S   D    345 
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GAA GCC GTT GAG ATG TTT TGC TAC CGG GCT CAG CGA GTC CGG CCG  1080 
 E   A   V   E   M   F   C   Y   R   A   Q   R   V   R   P    360 
GAC TTT CGC CTC ACC GAC GAC AAC TCC GCC GCA GTG ACC GAG ATC  1125 
 D   F   R   L   T   D   D   N   S   A   A   V   T   E   I     375 
TGC AAA CGG CTG GAC GGT TTG CCG CTG GCG ATC GAG CTG GCG GCT  1170 
 C   K   R   L   D   G   L   P   L   A   I   E   L   A   A    390 
GCG CGG CTG CGG TCG ATG ACG CTT GAC GAG ATC ATC GAT GGC TTG  1215 
 A   R   L   R   S   M   T   L   D   E   I   I   D   G   L    405 
CGT GAC CGG TTC GCG CTG TTG ACC GGC GGT GCG CGC ACG GCC GCG  1260 
 R   D   R   F   A   L   L   T   G   G   A   R   T   A   A    420 
CAC CGG CAG CAG ACG CTG TGG GCC TCG GTG GAT TGG TCG TAC ACG  1305 
 H   R   Q   Q   T   L   W   A   S   V   D   W   S   Y   T    435 
CTA TTG ACC GAG CCG GAA CGT ACC TTG TTT CGC CGG CTT GCG GTG  1350 
 L   L   T   E   P   E   R   T   L   F   R   R   L   A   V    450 
TTT GTG GGT TGC TTT TTT GTC GAC GAC GCA CAG GCG GTT GCC TGC  1395 
 F   V   G   C   F   F   V   D   D   A   Q   A   V   A   C    465 
AGC GGC GAT GTG CAG CGC TAC CAG GTC CTT GAC GAG ATC ACC CTG  1440 
 S   G   D   V   Q   R   Y   Q   V   L   D   E   I   T   L    480 
CTG GTC GAC AAG TCA CTG GTG ATG GCC GAC GAC AAC AGC GGC CGG  1485 
 L   V   D   K   S   L   V   M   A   D   D   N   S   G   R    495 
ACG TGC TAT CGG TTA TGC GAG ACG ATG CGC CAC TAC GCG TTG GAA  1530 
 T   C   Y   R   L   C   E   T   M   R   H   Y   A   L   E    510 
AAA CTC TCC GAG GCT GGC GAG GTG GAC GCC GTG TTT GCG CGG CAC  1575 
 K   L   S   E   A   G   E   V   D   A   V   F   A   R   H    525 
CGT GAC TAC TAC ACG GCG CTG GCT GCC AGG GTC GAC AAT CCC GGA  1620 
 R   D   Y   Y   T   A   L   A   A   R   V   D   N   P   G    540 
CCC TCC GAT TAT TCG CAC TGC CTC GAC CAA GCC GAA ACC GAG ATC  1665 
 P   S   D   Y   S   H   C   L   D   Q   A   E   T   E   I    555 
GAC AAC CTA CGT GCC GCC TTT GTG TGG AAC CGG GAA AAT TCC GAC  1710 
 D   N   L   R   A   A   F   V   W   N   R   E   N   S   D    570 
ACC GAG GGC GCC TTG GCG CTG GCG TCC TCC CTG TTG CGG GTA TGG  1755 
 T   E   G   A   L   A   L   A   S   S   L   L   R   V   W    585 
ATG ACG CGG GGG CGC ATC CAG GAG GGG CGC GCC TGG TTT GAC AGC  1800 
 M   T   R   G   R   I   Q   E   G   R   A   W   F   D   S    600  
ATT CTT GCC GAC GAG AAT GCG CGT CAT CTC GAG GTG GCG GCC GCG  1845 
 I   L   A   D   E   N   A   R   H   L   E   V   A   A   A    615 
GTG CGC GCC CGG GCA TTG GCC GAC AAG GCC CTG CTC GAC ATC TTC  1890 
 V   R   A   R   A   L   A   D   K   A   L   L   D   I   F    630 
GTC GAC GCC GCC GCC GGT ATG GAG CAG GCC CAA CAG GCT TTG GTG  1935 
 V   D   A   A   A   G   M   E   Q   A   Q   Q   A   L   V     645 
ATC GCG CGC GAG GTC GAT GAA CCG GCG CTG CTG TCC CGG GCG CTC  1980 
 I   A   R   E   V   D   E   P   A   L   L   S   R   A   L     660 
ACG GCC TGC GGC TTG ATC GCG GTA GCG GTA GCT CGC GCC GAT GCG  2025 
 T   A   C   G   L   I   A   V   A   V   A   R   A   D   A    675  
GCC GCG TCT TAT TTC GCC GAG GCG ATC GAC CTG GCA CGA GCG GTA  2070 
 A   A   S   Y   F   A   E   A   I   D   L   A   R   A   V     690 
GAC GAC CGG TGG AGG CTG GCC CAG ATC CTT ACC TTT CAG GCG GTC  2115 
 D   D   R   W   R   L   A   Q   I   L   T   F   Q   A   V     705 
GAT GCG GTC GTG GCG GGT GAC CCG GTC GCG GCA CGC CCG GCC GCC  2160  
 D   A   V   V   A   G   D   P   V   A   A   R   P   A   A     720 
CAA GAG GCA CGC GAG CTG GCT GCC GCG ATC GGT GAC CAC TCC AAT  2205 
 Q   E   A   R   E   L   A   A   A   I   G   D   H   S   N     735 
GCG CTG TGG TGC CGC TGG TGT CTC GGC TAC GCC CAG CTG ATG CGG  2250 
 A   L   W   C   R   W   C   L   G   Y   A   Q   L   M   R     750 
GGG GAG CTG GCC GCG GCC GCC GCC CAA TTC GGC GAG GTG GTG GAC  2295 
 G   E   L   A   A   A   A   A   Q   F   G   E   V   V   D     765 
GAG GCC GAG GCG TCT CAG GAA GTG CTG CAC AAG GCC AAC AGC CTG  2340 
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 E   A   E   A   S   Q   E   V   L   H   K   A   N   S   L     780 
CAG GGC CTG GCC TTC GCG CTC GCC TAC CAG GGT GAA TTG AGT GCG  2385 
 Q   G   L   A   F   A   L   A   Y   Q   G   E   L   S   A     795 
GCT AGG GCG GCG GCC GAC GCC GCT CTC GAG GCC GCC GAG CTG GGC  2430 
 A   R   A   A   A   D   A   A   L   E   A   A   E   L   G         810 
GAG TAC TTC GCG GGT ATG GGC TAC TCG GCG TTG ACC ACG GCC GCG  2475 
 E   Y   F   A   G   M   G   Y   S   A   L   T   T   A   A     825 
TTG GCC GCC GGC GAC GTG CAG ACG GCT CAA CAT GCC AGC GAG GCG  2520 
 L   A   A   G   D   V   Q   T   A   Q   H   A   S   E   A     840 
GCC TGG CGG AAC TTG AGT TTG GCG CTG CCC CTC TCG GCA GCG GTG  2565  
 A   W   R   N   L   S   L   A   L   P   L   S   A   A   V     855 
CAG CGC GCG TTC AAT GCC CAG GCT GCA CTG GCT GGT GGT GAC CTT  2610 
 Q   R   A   F   N   A   Q   A   A   L   A   G   G   D   L     870 
AGC GCA GCG CGT CGT TGG TGT GAC GAT GCC GTG CAG TCA ATG ACC  2655 
 S   A   A   R   R   W   C   D   D   A   V   Q   S   M   T     885 
GGC CAT CAT CTG GCG ATG GCG CTG GCG ACT CGC GCC AGG ATC GCG  2700 
 G   H   H   L   A   M   A   L   A   T   R   A   R   I   A     900 
GTC GCC GAG GGC AAG CGG GAA GAA GCC GAA CGC GAC GCG CAT AAG  2745 
 V   A   E   G   K   R   E   E   A   E   R   D   A   H   K     915 
GCG CTC GCG TGC GCG GCC GAG AGC GGG GCA CAC CTG GAT CTC CCC  2790 
 A   L   A   C   A   A   E   S   G   A   H   L   D   L   P    930 
GAC GTG CTC GAA TGC CTT GCC GGC CTG GCC AGC GAC GCC GGC ACC  2835  
 D   V   L   E   C   L   A   G   L   A   S   D   A   G   T     945 
CAC CAT GCG GCG GCA CGA CTC TTC GGC GCC GCC GAG GCT ATC CGA  2880 
 H   H   A   A   A   R   L   F   G   A   A   E   A   I   R     960 
CAG CAG ATC GGC TCG GTC CGC TTC GCG ATT TAC CGT TCG GAC TAT  2925 
 Q   Q   I   G   S   V   R   F   A   I   Y   R   S   D   Y     975 
GTG CAG TCG GTG ACG GCT CTG CGA GAT GCG ATG GGG GAG AAA GAC  2970 
 V   Q   S   V   T   A   L   R   D   A   M   G   E   K   D     990 
TTC GAC GCT GCA TGG GCC GAA GGT GCC GCG TTG TCG ATC AAG GAG  3015 
 F   D   A   A   W   A   E   G   A   A   L   S   I   K   E     1005 
ACG ATC GCC TAT GCG CAA CGT GGC CAC TCC TGG CGC AAA CGA CCG  3060 
 T   I   A   Y   A   Q   R   G   H   S   W   R   K   R   P     1020 
GCC ACC GGT TGG GAA TCG CTT ACT CCG ACC GAG ATT GAC GTC GTG  3105 
 A   T   G   W   E   S   L   T   P   T   E   I   D   V   V     1035 
CGA CTG GTT GGC GAG GGA CTG GCC AAC AAG GAC ATC GCG ACG CGG  3150 
 R   L   V   G   E   G   L   A   N   K   D   I   A   T   R     1050 
CTT TTC GTC TCA CCG CGA ACA GTG CAA ACG CAC CTG ACG CAC GTC  3195 
 L   F   V   S   P   R   T   V   Q   T   H   L   T   H   V     1065 
TAC ACC AAA CTC GGC TTC ACC TCG CGA CTG CAA CTC GCT CAA GCG  3240 
 Y   T   K   L   G   F   T   S   R   L   Q   L   A   Q   A     1080 
GCC GCC CGC CGT ACC TGA                                      3258 
 A   A   R   R   T   .                                       1085 
 
8.2 Results of the Protein-Protein BLAST Search  
At NCBI a Protein-Protein BLAST search (blastp) with the full length Rv0386 and its AC, 
ATPase, Transcription factor and DNA-binding domains was made (Nov-26-2003; 
http://www.ncbi.nlm.nih.gov/BLAST/; Altschul et al., 1997). The 5 best hits are here 
reported.  
Database: All non-redundant GenBank CDS translations+PDB+SwissProt+PIR+PRF 
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8.2.1 Blastp of the full length Rv0386 
                                                                  Score    E 
Sequences producing significant alignments:                      (bits) Value 
gi|15609625|ref|NP_217004.1|  hypothetical protein Rv2488c [...   890   0.0    
gi|31792554|ref|NP_855047.1|  PROBABLE TRANSCRIPTIONAL REGUL...   759   0.0    
gi|15840308|ref|NP_335345.1|  transcriptional regulator, Lux...   688   0.0    
gi|15840309|ref|NP_335346.1|  hypothetical protein [Mycobact...   223   2e-56  
gi|29832482|ref|NP_827116.1|  putative multi-domain regulato...   219   2e-55  
  
8.2.2 Blastp of the adenylyl cyclase domain 
                                                                  Score    E 
Sequences producing significant alignments:                      (bits) Value 
gi|31791563|ref|NP_854056.1|  PROBABLE TRANSCRIPTIONAL REGUL...   300   9e-81  
gi|15607527|ref|NP_214900.1|  hypothetical protein Rv0386 [M...   300   1e-80  
gi|15839770|ref|NP_334807.1|  transcriptional regulator, Lux...   299   1e-80  
gi|15840309|ref|NP_335346.1|  hypothetical protein [Mycobact...   191   5e-48  
gi|15842015|ref|NP_337052.1|  transcriptional regulator, Lux...   178   4e-44  
 
 
8.2.3 Blastp of the ATPase domain 
                                                                  Score    E 
Sequences producing significant alignments:                      (bits) Value 
 
gi|15609625|ref|NP_217004.1|  hypothetical protein Rv2488c [...   228   8e-59  
gi|31792554|ref|NP_855047.1|  PROBABLE TRANSCRIPTIONAL REGUL...   219   3e-56  
gi|15840814|ref|NP_335851.1|  transcriptional regulator, Lux...   217   1e-55  
gi|15608030|ref|NP_215405.1|  hypothetical protein Rv0890c [...   197   1e-49  
gi|15840308|ref|NP_335345.1|  transcriptional regulator, Lux...   197   1e-49  
 
 
8.2.4 Blastp of the transcription factor domain 
                                                                 Score    E 
Sequences producing significant alignments:                      (bits) Value 
 
gi|15839770|ref|NP_334807.1|  transcriptional regulator, Lux...  1428   0.0    
gi|15607527|ref|NP_214900.1|  hypothetical protein Rv0386 [M...  1428   0.0    
gi|31791563|ref|NP_854056.1|  PROBABLE TRANSCRIPTIONAL REGUL...  1411   0.0    
gi|15842015|ref|NP_337052.1|  transcriptional regulator, Lux...   728   0.0    
gi|15609625|ref|NP_217004.1|  hypothetical protein Rv2488c [...   727   0.0    
 
8.2.5 Blastp of the DNA-binding domain 
                                                                  Score    E 
Sequences producing significant alignments:                      (bits) Value 
 
gi|15839770|ref|NP_334807.1|  transcriptional regulator, Lux...   162   1e-39  
gi|15607527|ref|NP_214900.1|  hypothetical protein Rv0386 [M...   162   1e-39  
gi|31791563|ref|NP_854056.1|  PROBABLE TRANSCRIPTIONAL REGUL...   148   2e-35  
gi|15840308|ref|NP_335345.1|  transcriptional regulator, Lux...   127   4e-29  
gi|15608030|ref|NP_215405.1|  hypothetical protein Rv0890c [...   127   5e-29  
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8.3 Sequence alignments of Rv0386 
The sequence of the AC domain of Rv0386 was aligned with mammalian AC’s, 
mycobacterial Rv1625c and Paramecium GC sequences for identification of variations in 
amino acids that are critical for AC and GC catalysis and for presence or absence of 
other features like the “arm region”. The sequences of the other individual domains of 
Rv0386 were aligned with those proteins who showed the highest similarity after BLAST 
Search. 
                                                                
                                                                    
Rv1625c     202 :-------LRDTA--RAEAVMEAEHDRSEALLANMLPASIAERLKEPE--- 
AC2_C2_RAT  825 :YYCRLDFLWKNKFKKEREEIETMENLNRVLLENVLPAHVAEHFLARSLKN 
ParaGC_C1  1589 :LEV---FLGRINMNKENQIMSD-------ILSILLPQFIRDRINKAG--- 
Rv0386        1 :------------------------------MSKLLPR------------- 
                                                                    
                                                                    
                                                                    
Rv1625c     240 :RNIIADKYDEASVLFADIVGF----TERASSTAPAD--LVRFLDRLYSAF 
AC2_C2_RAT  875 :EELYHQSYDCVCVMFASIPDFKEFYTESDVNKEGLE--CLRLLNEIIADF 
ParaGC_C1  1626 :QYDIQEDQGMVAVLFCDIIDFDQL-----IKNEQSN--VVDILDKLFRRF 
Rv0386        8 :--------GTVTLLLADVEGS----TWLWETHPDDMGAAVARLDKAVSGV 
                                                                    
                                                                    
                                                                    
Rv1625c     284 :DELVDQ---HGLEKIKVSGDSYMVVSGVPRPRPD-----------HTQAL 
AC2_C2_RAT  923 :DDLLSKPKFSGVEKIKTIGSTYMAATGLSAIPSQEHAQEPERQYMHIGTM 
ParaGC_C1  1669 :D-LLCQQ--HEVQKIETVGKTYMAAAGLKIHVSQKSNP--------VNKV 
Rv0386       46 :IAAHDG---V-RPVEQGEGDSFVLAF------------------------ 
                                                                    
                                                                    
                                                                    
Rv1625c     320 :ADFALDMTNVAAQLKDPRGN-P-VPLRVGLATGPVVAGVVGSRRFFYDVW 
AC2_C2_RAT  973 :VEFAYALVGKLDAINKHSFN-D-FKLRVGINHGPVIAGVIGAQKPQYDIW 
ParaGC_C1  1708 :ISLALDMKRYVMSNE------T-FQIKIGIHYGNVIAGVIGHHKPQFSLI 
Rv0386       68 :--ACASDAVAAALDLQRARL-APIRLRIGVHTGEVALRDEG------NYA 
                                                                    
                                                                    
                                                                    
Rv1625c     368 :GDAVNVASRMESTDSVGQIQVPDEVYERLKD-DFVLRERGH----INVKG 
AC2_C2_RAT 1021 :GNTVNVASRMDSTGVLDKIQVTEETSLILQTLGYTCTCRGI----INVKG 
ParaGC_C1  1751 :GDTINTASRICSTAESWDVAISEQAYRQTNKYELVYVQRDV----VA-KG 
Rv0386      109 :GPTINRTARLRDLAHGGQTVLSGVTESLVID-RLPDKAWLVDLGTHALRD 
  
 
Fig. 8.1: Complete alignment of the AC domain of Rv0386 with the mycobacterial 
Rv1625c AC domain, the mammalian C2 cytosolic domain (rat) and the C1 region of the 
Paramecium GC. Shown are the purine-binding sites (Pu), the transition state-stabilizing 
sites (Ts), the γ-phosphate-binding site (Pγ), the metal binding sites (Me) and the “arm or 
dimerization region” (represented with a top bar).  
Me 
Me Pu 
Pu Pγ 
Ts Ts 
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Rv0386 179 : -LRVANDDVAHGLPVHLTRFVGRGAQITEVHRL---VTDNR----LVTLT 
AfsR   258 : PGRAPSDGRKGNIRPRLTTFVGREPELDALRSE---LPGAR----LVTLT 
Apaf-1 109 : --YVRTVLCEGGVPQRPVVFVTRKKLVNAIQQKLSKLKGEP---GWVTIH 
I2C-1  153 : ---KQETRTPSTSLVDDSGIFGRKNEIENLVGRLLSMDTKRKNLAVVPIV 
L6tr   220 : --DIWSHISKENLILETDELVGIDDHITAVLEK-LSLDSEN--VTMVGLY 
RPM1   156 : ---WVNNISESSLFFSENSLVGIDAPKGKLIGRLLSPEPQR---IVVAVV 
                                                                
                                                                
                                                                
Rv0386 221 : GAGGVGKTRLAAQLAAQ--IAGEFGRAWFVDLAPITDPDLVPVTVAGALG 
AfsR   301 : GPGGSGKTRLAEEAAAG--LD----QAWLVELAPLDRPEAVPGAIVNALG 
Apaf-1 154 : GMAGCGKSVLAAEAVRDHSLLEGCFPGGVHWVSVGKQDKSGLLMKLQNLC 
I2C-1  200 : GMGGMGKTTLAKAVYNDERVQKHFGLTAWFCVSEAYDAFRITKGLLQEIG 
L6tr   265 : GMGGIGKTTTAKAVYN--KISSCFDCCCFIDNIRETQEKDGVVVLQKKLV 
RPM1   200 : GMGGSGKTTLSANIFKSQSVRRHFESYAWVTISKSYVIEDVFRTMIKEF- 
                                                                
                                                                
                                                                
Rv0386 269 : ---LHD-----------QPGR---STTDTVLRFLGGRPALVVLDNCEHLL 
AfsR   345 : ---LRETV----LLTGDRPAGQ-DDPVALLVEYCAPRSQLLVLDNCEHVI 
Apaf-1 204 : TRLDQDESFSQRLPLNIEEAKD----RLRILMLRKHPRSLLILDDVWDSW 
I2C-1  250 : STDLKADDNLNQLQVKLKADDNLNQLQVKLKEKLNGKRFLVVLDDVWNDN 
L6tr   313 : SEILRIDS--GSVGFNNDSGG-----RKTIKERVSRFKILVVLDDVDEKF 
RPM1   249 : ---YKEAD--TQIPAELYSLG-YRELVEKLVEYLQSKRYIVVLDDVWTTG 
                                                                
                                                                
                                                                
Rv0386 302 : D-ATAALVLALVKACRGVRLLATCREPLRVEGE------VSYRVPSLSLS 
AfsR   387 : G-AAARLVETLLTRCPGLTVLATSREPLGVPGE------SVRPVEPLTQ- 
Apaf-1 250 : ---------VLKAFDSQCQILLTTRD-KSVTDSVMGPKYVVPVESSLGK- 
I2C-1  300 : YPEWDDLRNLFLQGDIGSKIIVTTRK-ESVALM---MDSGAIYMGILSS- 
L6tr   356 : --KFEDMLGSPKDFISQSRFIITSRS-MRVLGTLNENQCKLYEVGSMSK- 
RPM1   293 : --LWREISIALPDGIYGSRVMMTTRD-MNVASFPYGIGSTKHEIELLKE- 
                                                                
                                                                
                                                                
Rv0386 345 : DEAVEMFCYRAQRVRPDFRLTDDNSAAVTEICKRLDGLPLAIELAAARLR 
AfsR   429 : EQAQRLFTARAGAVRPDADAVLRDEEAVAEICRRLDGLPLAIELAAARLR 
Apaf-1 289 : EKGLEILSLFVNMKK------ADLPEQAHSIIKECKGSPLVVSLIGALL- 
I2C-1  345 : EDSWALFKRHSLEHK-DPKEHPEFEEVGKQIADKCKGLPLALKALAGMLR 
L6tr   402 : PRSLELFSKHAFKKN---TPPSYYETLANDVVDTTAGLPLTLKVIGSLL- 
RPM1   339 : DEAWVLFSNKAFPASLEQCRTQNLEPIARKLVERCQGLPLAIASLGSMMS 
 
Fig. 8.2 : Alignment of the ATPase domain of Rv0386 with representative proteins 
containing also an ATP/GTP-binding motif A (P-loop or Walker A box with a consensus 
sequence [AG]-x(4)-G-K-[ST]; represented here through black triangles) and disease 
resistance genes signatures (represented with top bars). Aligned were: AfsR (P25941), 
Apaf-1 (O14727), I2C-1 (O24015), L6tr (Q40254) and RPM1 (Q39214). The Swiss-
Prot/TrEMBL accession numbers are in parentheses.  
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BVGA_BORPER  149 :LSNRELTVLQLLAQGMSNKDIADSMFLSNKTVSTYKTRLLQKLNATSLVE 
FIMZ_ECOLI   150 :LSNREVTILRYLVSGLSNKEIADKLLLSNKTVSAHKSNIYGKLGLHSIVE 
FIMZ_SALTY   150 :LSNREVTVLRYLANGMSNKEIAEQLLLSNKTISAHKANIFSKLGLHSIVE 
NARP_HAEIN   149 :LTDREMGVLRQIATGLSNKQIAAQLFISEETVKVHIRNLLRKLNVHSRVA 
YXJL_BACSU   157 :FTKRELEVLQQMAYGLRNEDIAEKLFVSESTVKTHVHRILQKCNAQDRTQ 
SCO3008      189 :LTDRELEVLKLVATGMNNRDIAKELFISENTVKNHVRNILEKLQLHSRME 
Rv0890c      821 :LTPTERDVVRLVSEGLSNKDIAKRLFVSPRTVQTHLTHVYAKLGLPSRVQ 
Rv0386      1027 :LTPTEIDVVRLVGEGLANKDIATRLFVSPRTVQTHLTHVYTKLGFTSRLQ 
                                                                     
 
                                                                
                                                                
narL      1 :SNQEPATILLIDDHPMLRTGVKQLISMAPDITVVGEASNGE-------QG 
uhpA      1 :----MITVALIDDHLIVRSGFAQLLGLEPDLQVVAEFGSGR-------EA 
Rv0386  867 :GGDLSAARRWCDDAVQSMTGHHLAMALATRARIAVAEGKREEAERDAHKA 
                                                                
                                                                
                                                                
narL     44 :IELAESLDPDLILLDLNMPGMNGLETLDKLREKSLSGRIVVFSVSNHEED 
uhpA     40 :LAGLPGRGVQVCICDISMPDISGLELLSQLP-KGMA--TIVLSVHDSPAL 
Rv0386  917 :LACAAESGAHLDLPDV-LECLAGLASDAGTHHAAARLFGAAEAIRQQIGS 
                                                                
                                                                
                                                                
narL     94 :VVTALKRGADGYLLKDMEPEDLLKALHQAAAGEMVLSEALTPVLAASLRA 
uhpA     87 :VEQALNAGARGFLSKRCSPDELIAAVHTVATGGCYL----TPDIAVKLAA 
Rv0386  966 :VRFAIYRSDYVQSVTALRDAMGEKDFDAAWAEGAALSIKETIAYAQRGHS 
                                                                
                                                                
                                                                
narL    144 :NRATTERDVNQLTPRERDILKLIAQGLPNKMIARRLDITESTVKVHVKHM 
uhpA    133 :GRQ--D----PLTKRERQVAEKLAQGMAVKEIAAELGLSPKTVHVHRANL 
Rv0386 1016 :WRKRPATGWESLTPTEIDVVRLVGEGLANKDIATRLFVSPRTVQTHLTHV 
                                                                
                                    
                                    
narL    194 :LKKMKLKSRVEAAVWVHQERIF 
uhpA    177 :LEKLGVSNDVELAHRMFDGW-- 
Rv0386 1066 :YTKLGFTSRLQLAQAAARRT-- 
 
Fig. 8.3: a) Alignment of the DNA-binding domain of Rv0386 with representative proteins 
containing a Helix-Turn-Helix DNA-binding signature (top bar). The consensus sequence 
of this signature is represented here with black triangles. Aligned were: BVGA (P16574), 
FIMZ (P26319), NarP from Haemophilus influenza, YXJL from Bacillus subtilis, SCO3008 
from Streptomyces coelicolor  and Rv0890c from M. tuberculosis. b) Detailed alignment 
with narL (P10957) and uhpA (P27667) showing the DNA-binding motif and other 
conserved regions. Swiss-Prot/TrEMBL accession numbers are in parentheses. 
 
a 
b 
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8.4 Crystal pictures 
Representative pictures of some of the crystals obtained with the catalytic domain of 
Rv0386 within this work. First diffraction-data obtained is also shown.  
 
8.4.1 Crystals of the AC domain of Rv0386 with N-terminal His-tag 
 
 
 
 
 
 
 
 
a b 
c d 
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Fig. 8.4: Crystals obtained with the N-terminal His-tagged AC domain dialyzed after Ni-
NTA-purification in 50 mM Tris-HCl pH 8.5, 10 mM NaCl, 2 mM β-mercaptoethanol and 
10% glycerol. Precipitant solution was 10 % PEG 6000 + 2 M NaCl (a,b,e and f); 12 % 
PEG 6000 + 2 M NaCl (c) and 10 % PEG 4000 + 2 M NaCl (d). Incubation temperatures 
were: 16 °C (a and d) and 12 °C (b,c,e and f). Protein concentrations used were: a) 16 
µg/µl; b) 25 µg/µl; c) 20 µg/µl ; d) 12 µg/µl ; e and f) 22 µg/µl. Approximate size of the 
crystals: a) 15x17 µm and 50x50 µm; b) 50x20 µm; c) 25x75 µm and 90x30 µm; d) 
175x125 µm; e) 150x75 µm and f) 150x50 µm.  
 
 
8.4.2 Crystals of the AC domain of Rv0386 with C-terminal His-tag 
 
 
e f 
a b 
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Fig. 8.5: Crystals obtained with the C-terminal His-tagged AC domain dialyzed after Ni-
NTA-purification in 50 mM Tris-HCl pH 8.5, 10 mM NaCl, 2 mM β-mercaptoethanol and 
5% glycerol. Protein concentration was 9.8 µg/µl. Protein was 14 h incubated with 1 mM 
ATP at 0 °C. Incubation temperature was 16 °C. Precipitant solutions were: a) 15 % PEG 
4000 + 0.1 M Tris HCl pH 8.5 + 0.2 M sodium acetate; b) 10 % PEG 6000 + 0.1 M Hepes 
pH 7.5 + 5 % MPD; c) 30 % PEG 4000 + 0.1 M Tris HCl pH 8.5 + 0.2 M magnesium 
chloride; d) 0.5 M sodium acetate + 0.1 M imidazole pH 6.5. First diffraction data could be 
obtained with the crystals of picture d (see data below). 
 
Shell Lower Upper Average      Average     Norm. Linear Square 
   limit    Angstrom       I   error   stat. Chi**2  R-fac  R-fac 
        25.00  15.81    37.3     6.6     3.1  1.000  0.105  0.078 
        15.81  13.13    38.2     7.6     3.9  1.000  0.138  0.122 
        13.13  11.66    53.9    11.0     6.7  1.000  0.117  0.106 
        11.66  10.69    79.9    11.6     8.9  0.999  0.096  0.087 
        10.69   9.97    63.4     9.9     7.1  1.000  0.109  0.110 
         9.97   9.42    58.7     8.7     6.0  1.000  0.120  0.106 
         9.42   8.97    49.3    13.8     8.7  1.001  0.160  0.148 
         8.97   8.59    50.3    15.1    10.2  1.000  0.197  0.196 
         8.59   8.28    32.3    11.3     6.9  1.000  0.226  0.174 
         8.28   8.00    22.5    16.8    10.3  1.001  0.382  0.335 
    All reflections     49.0    11.3     7.2  1.000  0.146  0.128 
  finishing up after  8 cycles - overall R 14.6 percent - crystal q2-1 
  calculating ... 
  ======================================================== 
   dataset: q2-1.tru   logfile: q2-1.truncate-log 
  ======================================================== 
   unit cell:    82.941 82.941 277.636 90.000 90.000 90.000 
   space group                             =            75 
   starting resolution                     =         24.77 
   finishing resolution                    =          8.00 
   number of amino acids in AU             =           1600 
   fraction of unit cell occupied by atoms =         53.1% 
   solvent content                         =         46.9% 
  ======================================================== 
 
Fig. 8.6: Preliminar diffraction data of the crystals of figure 8.5 d collected on the ID13 
Micro Focus Beam Line (ESRF-Grenoble, France). Dr. Ivo Tews and Dr. Felix Findeisen 
from Biochemie Zentrum Heidelberg made the measurements.  
c d 
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